WO2022127807A1 - 一种芳基磷氧化物类衍生物自由碱的晶型及其制备方法和应用 - Google Patents
一种芳基磷氧化物类衍生物自由碱的晶型及其制备方法和应用 Download PDFInfo
- Publication number
- WO2022127807A1 WO2022127807A1 PCT/CN2021/138219 CN2021138219W WO2022127807A1 WO 2022127807 A1 WO2022127807 A1 WO 2022127807A1 CN 2021138219 W CN2021138219 W CN 2021138219W WO 2022127807 A1 WO2022127807 A1 WO 2022127807A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- places
- amino
- crystal form
- diffraction peak
- diffraction
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 157
- -1 aryl phosphorus oxide derivative Chemical class 0.000 title claims abstract description 147
- 239000013078 crystal Substances 0.000 title claims abstract description 138
- 239000012458 free base Substances 0.000 title claims abstract description 33
- 150000001875 compounds Chemical class 0.000 claims abstract description 122
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 22
- 239000003814 drug Substances 0.000 claims abstract description 20
- 229940079593 drug Drugs 0.000 claims abstract description 18
- 229940121647 egfr inhibitor Drugs 0.000 claims abstract description 10
- 201000011510 cancer Diseases 0.000 claims abstract description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
- 201000010099 disease Diseases 0.000 claims abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 5
- 238000007254 oxidation reaction Methods 0.000 claims description 113
- 230000003647 oxidation Effects 0.000 claims description 112
- YOTZYFSGUCFUKA-UHFFFAOYSA-N dimethylphosphine Chemical compound CPC YOTZYFSGUCFUKA-UHFFFAOYSA-N 0.000 claims description 93
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 76
- 125000000217 alkyl group Chemical group 0.000 claims description 69
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 61
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 60
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 55
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 53
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims description 50
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 47
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 46
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 36
- 125000000623 heterocyclic group Chemical group 0.000 claims description 34
- 125000003545 alkoxy group Chemical group 0.000 claims description 32
- 229910052739 hydrogen Inorganic materials 0.000 claims description 32
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 30
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 30
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 30
- 229910052736 halogen Inorganic materials 0.000 claims description 30
- 150000002367 halogens Chemical class 0.000 claims description 30
- 239000001257 hydrogen Substances 0.000 claims description 30
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 26
- 229910052805 deuterium Inorganic materials 0.000 claims description 26
- 150000002431 hydrogen Chemical class 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 25
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 25
- 125000003118 aryl group Chemical group 0.000 claims description 23
- 125000001072 heteroaryl group Chemical group 0.000 claims description 23
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 22
- 125000004432 carbon atom Chemical group C* 0.000 claims description 22
- 239000002904 solvent Substances 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 21
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 20
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 18
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 16
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical group CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 16
- 125000000304 alkynyl group Chemical group 0.000 claims description 15
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims description 15
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 13
- 239000007787 solid Substances 0.000 claims description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 12
- 239000000725 suspension Substances 0.000 claims description 12
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 10
- KBPLFHHGFOOTCA-UHFFFAOYSA-N caprylic alcohol Natural products CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 claims description 10
- 239000000460 chlorine Substances 0.000 claims description 10
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 claims description 10
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 claims description 10
- JYVLIDXNZAXMDK-UHFFFAOYSA-N pentan-2-ol Chemical compound CCCC(C)O JYVLIDXNZAXMDK-UHFFFAOYSA-N 0.000 claims description 10
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 claims description 10
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 10
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 9
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 9
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 9
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 9
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 9
- 229910020008 S(O) Inorganic materials 0.000 claims description 9
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 9
- 229910052794 bromium Inorganic materials 0.000 claims description 9
- 229910052801 chlorine Inorganic materials 0.000 claims description 9
- 229910052731 fluorine Inorganic materials 0.000 claims description 9
- 239000011737 fluorine Substances 0.000 claims description 9
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 9
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 8
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 claims description 8
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 8
- 201000005202 lung cancer Diseases 0.000 claims description 8
- 208000020816 lung neoplasm Diseases 0.000 claims description 8
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 8
- 239000000047 product Substances 0.000 claims description 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 8
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 8
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 7
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 7
- 239000006228 supernatant Substances 0.000 claims description 7
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims description 6
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 6
- 229940011051 isopropyl acetate Drugs 0.000 claims description 6
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 6
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 5
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 5
- TVMXDCGIABBOFY-UHFFFAOYSA-N n-Octanol Natural products CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 claims description 5
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 5
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 4
- 125000004966 cyanoalkyl group Chemical group 0.000 claims description 4
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- 125000003566 oxetanyl group Chemical group 0.000 claims description 4
- 238000001228 spectrum Methods 0.000 claims description 4
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 4
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 3
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims description 3
- MTZPUHWJHCRYCK-UHFFFAOYSA-N CC(C(N(CC1)CCC1N1CC(COC)C1)=C1)=CC(NC(N=C2NC(C=CC3=C4OCCO3)=C4P(C)C)=NC=C2Br)=C1OC Chemical compound CC(C(N(CC1)CCC1N1CC(COC)C1)=C1)=CC(NC(N=C2NC(C=CC3=C4OCCO3)=C4P(C)C)=NC=C2Br)=C1OC MTZPUHWJHCRYCK-UHFFFAOYSA-N 0.000 claims description 3
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 125000004455 (C1-C3) alkylthio group Chemical group 0.000 claims description 2
- 125000006642 (C1-C6) cyanoalkyl group Chemical group 0.000 claims description 2
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- PBSKPWJFBLTCSD-UHFFFAOYSA-N CCC1=CC(=C(C=C1N2CCC(CC2)N3CC(C3)N(C)C)OC)NC4=NC=C(C(=N4)NC5=C(C6=C(C=C5)OCCO6)P(C)C)Cl Chemical compound CCC1=CC(=C(C=C1N2CCC(CC2)N3CC(C3)N(C)C)OC)NC4=NC=C(C(=N4)NC5=C(C6=C(C=C5)OCCO6)P(C)C)Cl PBSKPWJFBLTCSD-UHFFFAOYSA-N 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 102000001301 EGF receptor Human genes 0.000 description 67
- 108060006698 EGF receptor Proteins 0.000 description 67
- 239000000243 solution Substances 0.000 description 47
- 238000005481 NMR spectroscopy Methods 0.000 description 45
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 39
- 238000006243 chemical reaction Methods 0.000 description 33
- 238000012360 testing method Methods 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 30
- 238000002474 experimental method Methods 0.000 description 27
- 102200048955 rs121434569 Human genes 0.000 description 26
- 230000002401 inhibitory effect Effects 0.000 description 24
- 230000005764 inhibitory process Effects 0.000 description 23
- 230000035772 mutation Effects 0.000 description 22
- 108091000080 Phosphotransferase Proteins 0.000 description 21
- 102000020233 phosphotransferase Human genes 0.000 description 21
- 238000004440 column chromatography Methods 0.000 description 19
- 230000000694 effects Effects 0.000 description 19
- 239000003960 organic solvent Substances 0.000 description 19
- 238000003756 stirring Methods 0.000 description 18
- 125000003342 alkenyl group Chemical group 0.000 description 17
- 239000013642 negative control Substances 0.000 description 17
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 16
- 239000012074 organic phase Substances 0.000 description 16
- 125000005605 benzo group Chemical group 0.000 description 14
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 13
- 238000001514 detection method Methods 0.000 description 13
- 235000019439 ethyl acetate Nutrition 0.000 description 13
- 102200048928 rs121434568 Human genes 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 239000013641 positive control Substances 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 10
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 10
- 125000004414 alkyl thio group Chemical group 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 125000001424 substituent group Chemical group 0.000 description 10
- 239000002585 base Substances 0.000 description 9
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 8
- 125000003282 alkyl amino group Chemical group 0.000 description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 8
- 125000005366 cycloalkylthio group Chemical group 0.000 description 8
- 238000010586 diagram Methods 0.000 description 8
- 239000013024 dilution buffer Substances 0.000 description 8
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- 150000007942 carboxylates Chemical group 0.000 description 7
- 125000000000 cycloalkoxy group Chemical group 0.000 description 7
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 125000001188 haloalkyl group Chemical group 0.000 description 7
- 125000006413 ring segment Chemical group 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 239000002274 desiccant Substances 0.000 description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000026731 phosphorylation Effects 0.000 description 6
- 238000006366 phosphorylation reaction Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- 125000003944 tolyl group Chemical group 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 206010059866 Drug resistance Diseases 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 238000005469 granulation Methods 0.000 description 5
- 230000003179 granulation Effects 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- SAWKFRBJGLMMES-UHFFFAOYSA-N methylphosphine Chemical compound PC SAWKFRBJGLMMES-UHFFFAOYSA-N 0.000 description 5
- 229960003278 osimertinib Drugs 0.000 description 5
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- 208000012124 AIDS-related disease Diseases 0.000 description 4
- LOPXXGJHIWBECT-UHFFFAOYSA-N COC1=C(N)C=C(C(=C1)N1CCC2(OCCO2)CC1)C Chemical compound COC1=C(N)C=C(C(=C1)N1CCC2(OCCO2)CC1)C LOPXXGJHIWBECT-UHFFFAOYSA-N 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 102400001368 Epidermal growth factor Human genes 0.000 description 4
- 101800003838 Epidermal growth factor Proteins 0.000 description 4
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 238000010009 beating Methods 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 238000012054 celltiter-glo Methods 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 229940116977 epidermal growth factor Drugs 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 208000019423 liver disease Diseases 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 4
- 125000004043 oxo group Chemical group O=* 0.000 description 4
- 125000003367 polycyclic group Chemical group 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000003672 processing method Methods 0.000 description 4
- 238000010298 pulverizing process Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 4
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
- BAADLJBNKVHGKS-UHFFFAOYSA-N 2-bromo-6-methoxy-3-nitrophenol Chemical compound COC1=CC=C([N+]([O-])=O)C(Br)=C1O BAADLJBNKVHGKS-UHFFFAOYSA-N 0.000 description 3
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 description 3
- HNLRHOMTOLFPBZ-UHFFFAOYSA-N 4-bromo-5-methyl-2,3-dihydro-1-benzofuran-7-amine Chemical compound CC1=CC(N)=C2OCCC2=C1Br HNLRHOMTOLFPBZ-UHFFFAOYSA-N 0.000 description 3
- VRJHQPZVIGNGMX-UHFFFAOYSA-N 4-piperidinone Chemical compound O=C1CCNCC1 VRJHQPZVIGNGMX-UHFFFAOYSA-N 0.000 description 3
- FHNWBXOWINFMEC-UHFFFAOYSA-N 5-bromo-2,3-dihydro-1,4-benzodioxin-6-amine Chemical compound Nc1ccc2OCCOc2c1Br FHNWBXOWINFMEC-UHFFFAOYSA-N 0.000 description 3
- OLHBKXYPKCHVNW-UHFFFAOYSA-N 5-methyl-2,3-dihydro-1-benzofuran Chemical compound CC1=CC=C2OCCC2=C1 OLHBKXYPKCHVNW-UHFFFAOYSA-N 0.000 description 3
- WALQPXMNTGSWDW-UHFFFAOYSA-N 5-methyl-2,3-dihydro-1-benzofuran-7-amine Chemical compound NC1=CC(C)=CC2=C1OCC2 WALQPXMNTGSWDW-UHFFFAOYSA-N 0.000 description 3
- OZDILRBMIPFPPF-UHFFFAOYSA-N 5-methyl-7-nitro-2,3-dihydro-1-benzofuran Chemical compound [O-][N+](=O)C1=CC(C)=CC2=C1OCC2 OZDILRBMIPFPPF-UHFFFAOYSA-N 0.000 description 3
- MCUBZISJGSUZSQ-UHFFFAOYSA-N 8-(5-methoxy-2-methyl-4-nitrophenyl)-1,4-dioxa-8-azaspiro[4.5]decane Chemical compound C1=C([N+]([O-])=O)C(OC)=CC(N2CCC3(CC2)OCCO3)=C1C MCUBZISJGSUZSQ-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- RKCOYYPYDQVBGB-UHFFFAOYSA-N C(C)(=O)NC1=CC(=C(C=2CCOC21)Br)C Chemical compound C(C)(=O)NC1=CC(=C(C=2CCOC21)Br)C RKCOYYPYDQVBGB-UHFFFAOYSA-N 0.000 description 3
- ONQXHLPURDWDNB-UHFFFAOYSA-N C1COC2=C(O1)C=CC(=C2Br)[N+](=O)[O-] Chemical compound C1COC2=C(O1)C=CC(=C2Br)[N+](=O)[O-] ONQXHLPURDWDNB-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Substances IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 3
- KYTLGODHXYXRLI-UHFFFAOYSA-N NC1=CC(=C(C=C1OC)N1CCC(CC1)N1CC(C1)N(C)C)CC Chemical compound NC1=CC(=C(C=C1OC)N1CCC(CC1)N1CC(C1)N(C)C)CC KYTLGODHXYXRLI-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 150000001335 aliphatic alkanes Chemical group 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 229940043355 kinase inhibitor Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 3
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 3
- 125000003226 pyrazolyl group Chemical group 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 125000003003 spiro group Chemical group 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 238000005550 wet granulation Methods 0.000 description 3
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 2
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 2
- SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 description 2
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 2
- 125000005916 2-methylpentyl group Chemical group 0.000 description 2
- CUYKNJBYIJFRCU-UHFFFAOYSA-N 3-aminopyridine Chemical compound NC1=CC=CN=C1 CUYKNJBYIJFRCU-UHFFFAOYSA-N 0.000 description 2
- KMJLMIUUHPKLMN-UHFFFAOYSA-N 3-bromo-4-nitrobenzene-1,2-diol Chemical compound Oc1ccc(c(Br)c1O)[N+]([O-])=O KMJLMIUUHPKLMN-UHFFFAOYSA-N 0.000 description 2
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000005917 3-methylpentyl group Chemical group 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- JKXUEQDIAAEAHR-UHFFFAOYSA-N BrC1=C(C=C(C(=C1)[N+](=O)[O-])OC)N1CCC(CC1)N1CC(C1)N(C)C Chemical compound BrC1=C(C=C(C(=C1)[N+](=O)[O-])OC)N1CCC(CC1)N1CC(C1)N(C)C JKXUEQDIAAEAHR-UHFFFAOYSA-N 0.000 description 2
- NYKZECIMGIKRQB-UHFFFAOYSA-N C(C)(=O)NC1=CC(=C(C=2CCOC21)N2CCC(CC2)N2CCN(CC2)C)C Chemical compound C(C)(=O)NC1=CC(=C(C=2CCOC21)N2CCC(CC2)N2CCN(CC2)C)C NYKZECIMGIKRQB-UHFFFAOYSA-N 0.000 description 2
- ROSMMFTXEXJWJK-SZPZYZBQSA-N CC(C(N(CC1)CCC1N1C[C@H](CN(C)C2)[C@H]2C1)=C1)=CC(NC(N=C2NC(C=C3)=CC4=C3OCCO4)=NC=C2Cl)=C1OC Chemical compound CC(C(N(CC1)CCC1N1C[C@H](CN(C)C2)[C@H]2C1)=C1)=CC(NC(N=C2NC(C=C3)=CC4=C3OCCO4)=NC=C2Cl)=C1OC ROSMMFTXEXJWJK-SZPZYZBQSA-N 0.000 description 2
- MRPHDDQEUVCGPI-UHFFFAOYSA-N CC(C=CCC1)=C1N(CC1)CCC1N1CCN(C)CC1 Chemical compound CC(C=CCC1)=C1N(CC1)CCC1N1CCN(C)CC1 MRPHDDQEUVCGPI-UHFFFAOYSA-N 0.000 description 2
- IHVBSHXOCUKHET-UHFFFAOYSA-N CC1=CC(=C(C=C1N2CCC(CC2)N3CC(C3)(CCF)O)OC)NC4=NC=C(C(=N4)NC5=C(C6=C(C=C5)OCCO6)P(C)C)Br Chemical compound CC1=CC(=C(C=C1N2CCC(CC2)N3CC(C3)(CCF)O)OC)NC4=NC=C(C(=N4)NC5=C(C6=C(C=C5)OCCO6)P(C)C)Br IHVBSHXOCUKHET-UHFFFAOYSA-N 0.000 description 2
- DBYYXPVBNRSGPD-UHFFFAOYSA-N CC1=CC(=C(C=C1N2CCC(CC2)N3CC(C3)CC#N)OC)NC4=NC=C(C(=N4)NC5=C(C6=C(C=C5)OCCO6)P(=O)(C)C)SC Chemical compound CC1=CC(=C(C=C1N2CCC(CC2)N3CC(C3)CC#N)OC)NC4=NC=C(C(=N4)NC5=C(C6=C(C=C5)OCCO6)P(=O)(C)C)SC DBYYXPVBNRSGPD-UHFFFAOYSA-N 0.000 description 2
- VXLRGBGXGWYMBC-SZPZYZBQSA-N CC1=CC(=C(C=C1N2CCC(CC2)N3C[C@H]4CN(C[C@H]4C3)C)OC)NC5=NC=C(C(=N5)NC6=CC7=C(C=C6)OCCO7)Br Chemical compound CC1=CC(=C(C=C1N2CCC(CC2)N3C[C@H]4CN(C[C@H]4C3)C)OC)NC5=NC=C(C(=N5)NC6=CC7=C(C=C6)OCCO7)Br VXLRGBGXGWYMBC-SZPZYZBQSA-N 0.000 description 2
- AXMDBWVRYZCXAE-UHFFFAOYSA-N CC=1C=C(C2=C(CCO2)C1N1CCC(CC1)N1CCN(CC1)C)N Chemical compound CC=1C=C(C2=C(CCO2)C1N1CCC(CC1)N1CCN(CC1)C)N AXMDBWVRYZCXAE-UHFFFAOYSA-N 0.000 description 2
- OXAFWIUIMJCCII-UHFFFAOYSA-N CCC(C(N(CC1)CCC1N(C1)CC1N(C)C)=C1)=CC(NC2=NC=C(C(F)(F)F)C(NC(C=CC3=C4OCCO3)=C4P(C)C)=N2)=C1OC Chemical compound CCC(C(N(CC1)CCC1N(C1)CC1N(C)C)=C1)=CC(NC2=NC=C(C(F)(F)F)C(NC(C=CC3=C4OCCO3)=C4P(C)C)=N2)=C1OC OXAFWIUIMJCCII-UHFFFAOYSA-N 0.000 description 2
- DVASJIGKXKQPQA-UHFFFAOYSA-N CCOC(C1)CN1C(CC1)CCN1C(C(C)=C1)=CC(OC)=C1NC1=NC=C(C(F)(F)F)C(NC(C=CC2=C3OCCO2)=C3P(C)C)=N1 Chemical compound CCOC(C1)CN1C(CC1)CCN1C(C(C)=C1)=CC(OC)=C1NC1=NC=C(C(F)(F)F)C(NC(C=CC2=C3OCCO2)=C3P(C)C)=N1 DVASJIGKXKQPQA-UHFFFAOYSA-N 0.000 description 2
- SPKUGDIWMVLDRB-UHFFFAOYSA-N COC=1C(=CC(=C(C1)N1CCC(CC1)N1CC(C1)N(C)C)C=C)[N+](=O)[O-] Chemical compound COC=1C(=CC(=C(C1)N1CCC(CC1)N1CC(C1)N(C)C)C=C)[N+](=O)[O-] SPKUGDIWMVLDRB-UHFFFAOYSA-N 0.000 description 2
- BRQURNNJFABNNS-UHFFFAOYSA-N CP(C)C(C1=C(C=C2)OCCO1)=C2N Chemical compound CP(C)C(C1=C(C=C2)OCCO1)=C2N BRQURNNJFABNNS-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 description 2
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 229960005395 cetuximab Drugs 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 125000005047 dihydroimidazolyl group Chemical group N1(CNC=C1)* 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000004404 heteroalkyl group Chemical group 0.000 description 2
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 238000000021 kinase assay Methods 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- KWOHPNYWDDHIFQ-UHFFFAOYSA-N n,n-dimethyl-1-piperidin-4-ylazetidin-3-amine Chemical compound C1C(N(C)C)CN1C1CCNCC1 KWOHPNYWDDHIFQ-UHFFFAOYSA-N 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- VMXUWOKSQNHOCA-UKTHLTGXSA-N ranitidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-UKTHLTGXSA-N 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- HQQVXVKQOPZRBJ-OLQVQODUSA-N (3as,6ar)-3,3a,4,5,6,6a-hexahydro-1h-furo[3,4-c]pyrrole Chemical compound C1OC[C@@H]2CNC[C@@H]21 HQQVXVKQOPZRBJ-OLQVQODUSA-N 0.000 description 1
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 description 1
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 description 1
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 description 1
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 1
- KPKNTUUIEVXMOH-UHFFFAOYSA-N 1,4-dioxa-8-azaspiro[4.5]decane Chemical compound O1CCOC11CCNCC1 KPKNTUUIEVXMOH-UHFFFAOYSA-N 0.000 description 1
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 1
- DHSGXAGGBXJPEL-UHFFFAOYSA-N 1-bromo-2-fluoro-4-methoxy-5-nitrobenzene Chemical compound COC1=CC(F)=C(Br)C=C1[N+]([O-])=O DHSGXAGGBXJPEL-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- JQNHPTUQNTUAJC-UHFFFAOYSA-N 1-fluoro-5-methoxy-2-methyl-4-nitrobenzene Chemical compound COC1=CC(F)=C(C)C=C1[N+]([O-])=O JQNHPTUQNTUAJC-UHFFFAOYSA-N 0.000 description 1
- MRYYJGQKVGZGSB-UHFFFAOYSA-N 1-methyl-4-piperidin-4-ylpiperazine Chemical compound C1CN(C)CCN1C1CCNCC1 MRYYJGQKVGZGSB-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000003562 2,2-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003660 2,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003764 2,4-dimethylpentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- KXKCTSZYNCDFFG-UHFFFAOYSA-N 2-Methoxy-5-nitrophenol Chemical compound COC1=CC=C([N+]([O-])=O)C=C1O KXKCTSZYNCDFFG-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000004336 3,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- NBZVHTDOPPPKBG-UHFFFAOYSA-N 3-(methoxymethyl)azetidine;2,2,2-trifluoroacetic acid Chemical compound COCC1CNC1.OC(=O)C(F)(F)F NBZVHTDOPPPKBG-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000004337 3-ethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- SIKXIUWKPGWBBF-UHFFFAOYSA-N 5-bromo-2,4-dichloropyrimidine Chemical compound ClC1=NC=C(Br)C(Cl)=N1 SIKXIUWKPGWBBF-UHFFFAOYSA-N 0.000 description 1
- AILRADAXUVEEIR-UHFFFAOYSA-N 5-chloro-4-n-(2-dimethylphosphorylphenyl)-2-n-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]pyrimidine-2,4-diamine Chemical compound COC1=CC(N2CCC(CC2)N2CCN(C)CC2)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1P(C)(C)=O AILRADAXUVEEIR-UHFFFAOYSA-N 0.000 description 1
- KCZQNAOFWQGLCN-UHFFFAOYSA-N 5-methyl-1-benzofuran Chemical compound CC1=CC=C2OC=CC2=C1 KCZQNAOFWQGLCN-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 241000349731 Afzelia bipindensis Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000008720 Bone Marrow Neoplasms Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- FUJHZCCDPGDLRH-SZPZYZBQSA-N CC(C(N(CC1)CCC1N(C1)C[C@@H]2[C@H]1COC2)=C1)=CC(NC(N=C2NC(C=CC3=C4OCCO3)=C4P(C)C)=NC=C2Br)=C1OC Chemical compound CC(C(N(CC1)CCC1N(C1)C[C@@H]2[C@H]1COC2)=C1)=CC(NC(N=C2NC(C=CC3=C4OCCO3)=C4P(C)C)=NC=C2Br)=C1OC FUJHZCCDPGDLRH-SZPZYZBQSA-N 0.000 description 1
- HTXLFGCZPALLGP-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCC(CC1)N2CC(C2)N(C)C Chemical compound CC(C)(C)OC(=O)N1CCC(CC1)N2CC(C2)N(C)C HTXLFGCZPALLGP-UHFFFAOYSA-N 0.000 description 1
- SYYCCQIGFBZZBQ-UHFFFAOYSA-N CC1=CC(=C(C=C1N2CCC(=O)CC2)OC)NC3=NC=C(C(=N3)NC4=C(C5=C(C=C4)OCCO5)P(=O)(C)C)Br Chemical compound CC1=CC(=C(C=C1N2CCC(=O)CC2)OC)NC3=NC=C(C(=N3)NC4=C(C5=C(C=C4)OCCO5)P(=O)(C)C)Br SYYCCQIGFBZZBQ-UHFFFAOYSA-N 0.000 description 1
- JCTOOLCDQZMUSD-UHFFFAOYSA-N CC1=CC(=C(C=C1N2CCC3(CC2)OCCO3)OC)NC4=NC=C(C(=N4)NC5=C(C6=C(C=C5)OCCO6)P(=O)(C)C)Br Chemical compound CC1=CC(=C(C=C1N2CCC3(CC2)OCCO3)OC)NC4=NC=C(C(=N4)NC5=C(C6=C(C=C5)OCCO6)P(=O)(C)C)Br JCTOOLCDQZMUSD-UHFFFAOYSA-N 0.000 description 1
- HNHHAEYCILVQSI-UHFFFAOYSA-N CCC(C(N(CC1)CCC1N(C1)CC1N(C)C)=C1)=CC(NC(N=C2NC(C=CC3=C4OCCO3)=C4P(C)C)=NC=C2Br)=C1OC Chemical compound CCC(C(N(CC1)CCC1N(C1)CC1N(C)C)=C1)=CC(NC(N=C2NC(C=CC3=C4OCCO3)=C4P(C)C)=NC=C2Br)=C1OC HNHHAEYCILVQSI-UHFFFAOYSA-N 0.000 description 1
- GGPRCZILAIXPEL-UHFFFAOYSA-N CN(C)C(C1)CN1C(CC1)CCN1C(C(Br)=C1)=CC(OC)=C1NC(N=C1NC(C=CC2=C3OCCO2)=C3P(C)C)=NC=C1Cl Chemical compound CN(C)C(C1)CN1C(CC1)CCN1C(C(Br)=C1)=CC(OC)=C1NC(N=C1NC(C=CC2=C3OCCO2)=C3P(C)C)=NC=C1Cl GGPRCZILAIXPEL-UHFFFAOYSA-N 0.000 description 1
- VZMSTKAHTGRVIF-UHFFFAOYSA-N CN(CC1)CCN1C(CC1)CCN1C(C(C#C)=C1)=CC(OC)=C1NC(N=C1NC(C=CC2=C3OCCO2)=C3P(C)C)=NC=C1Br Chemical compound CN(CC1)CCN1C(CC1)CCN1C(C(C#C)=C1)=CC(OC)=C1NC(N=C1NC(C=CC2=C3OCCO2)=C3P(C)C)=NC=C1Br VZMSTKAHTGRVIF-UHFFFAOYSA-N 0.000 description 1
- CHZAZLLVPIKTPL-UHFFFAOYSA-N CP(=O)(C)C1=C(C=CC2=C1OCCO2)NC3=NC(=NC=C3Br)Cl Chemical compound CP(=O)(C)C1=C(C=CC2=C1OCCO2)NC3=NC(=NC=C3Br)Cl CHZAZLLVPIKTPL-UHFFFAOYSA-N 0.000 description 1
- INZDVRYOLZSWFK-UHFFFAOYSA-N CP(C)C(C1=C(C=C2)OCCO1)=C2NC1=NC(Cl)=NC=C1Br Chemical compound CP(C)C(C1=C(C=C2)OCCO1)=C2NC1=NC(Cl)=NC=C1Br INZDVRYOLZSWFK-UHFFFAOYSA-N 0.000 description 1
- MSACNODAXJVUDF-UHFFFAOYSA-N CP(C)[O] Chemical compound CP(C)[O] MSACNODAXJVUDF-UHFFFAOYSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 229910005429 FeSSIF Inorganic materials 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 229940125497 HER2 kinase inhibitor Drugs 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229940124647 MEK inhibitor Drugs 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical class [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 229940125528 allosteric inhibitor Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000006909 anti-apoptosis Effects 0.000 description 1
- OVDSPTSBIQCAIN-UHFFFAOYSA-N ap26113 Chemical compound COC1=CC(N2CCC(CC2)N(C)C)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1P(C)(C)=O OVDSPTSBIQCAIN-UHFFFAOYSA-N 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000006491 bone marrow cancer Diseases 0.000 description 1
- 229950004272 brigatinib Drugs 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000013098 chemical test method Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 150000001975 deuterium Chemical group 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 125000005052 dihydropyrazolyl group Chemical group N1(NCC=C1)* 0.000 description 1
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- IHLVCKWPAMTVTG-UHFFFAOYSA-N lithium;carbanide Chemical compound [Li+].[CH3-] IHLVCKWPAMTVTG-UHFFFAOYSA-N 0.000 description 1
- 238000002796 luminescence method Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229940050176 methyl chloride Drugs 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 1
- UIUXUFNYAYAMOE-UHFFFAOYSA-N methylsilane Chemical compound [SiH3]C UIUXUFNYAYAMOE-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 229940125645 monoclonal antibody drug Drugs 0.000 description 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
- IRQWCOFOSMREBQ-UHFFFAOYSA-N n,n-dimethylazetidin-3-amine Chemical compound CN(C)C1CNC1 IRQWCOFOSMREBQ-UHFFFAOYSA-N 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 235000020925 non fasting Nutrition 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 238000013031 physical testing Methods 0.000 description 1
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 102220014441 rs397517109 Human genes 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000009475 tablet pressing Methods 0.000 description 1
- UCTKRHACHNKUPB-UHFFFAOYSA-N tert-butyl 4-(oxomethylidene)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=C=O)CC1 UCTKRHACHNKUPB-UHFFFAOYSA-N 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 229940121646 third-generation egfr tyrosine kinase inhibitor Drugs 0.000 description 1
- 238000002877 time resolved fluorescence resonance energy transfer Methods 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- PBIMIGNDTBRRPI-UHFFFAOYSA-N trifluoro borate Chemical compound FOB(OF)OF PBIMIGNDTBRRPI-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the invention belongs to the field of biomedicine, and in particular relates to a crystal form of an aryl phosphorus oxide derivative free base and a preparation method and application thereof.
- EGFR Extracellular Growth Factor Receptor
- EGF epidermal growth factor
- TGF ⁇ transforming growth factor alpha
- Activated EGFR forms homodimers on the cell membrane or heterodimers with other receptors in the family (eg, ErbB-2, ErbB-3, or ErbB-4), resulting in the critical intracellular tyrosine of EGFR Phosphorylation of acid residues, thereby activating downstream signaling pathways in cells, plays an important role in cell proliferation, survival and anti-apoptosis.
- Activating mutation, overexpression or gene amplification of EGFR can lead to overactivation of EGFR, promote the transformation of cells to tumor cells, and play an important role in the proliferation, invasion, metastasis and angiogenesis of tumor cells. Important targets for drug development in lung cancer therapy.
- the first-generation EGFR small-molecule inhibitors including gefitinib (Iressa) and erlotinib (Tarceva), have shown good efficacy in the treatment of lung cancer, and have been used as first-line drugs for the treatment of patients with EGFR activating mutations ( Non-small cell lung cancer (NSCLC) including L858R and delE746_A750).
- NSCLC Non-small cell lung cancer
- L858R Long-small cell lung cancer
- delE746_A750 Non-small cell lung cancer
- a secondary mutation of residue T790M results.
- Osimertinib (Osimertinib or AZD9291) is a third-generation EGFR TKI inhibitor, which has a high response rate and good therapeutic effect against drug resistance caused by EGFR T790M mutation. Clinically, it can effectively treat patients with advanced non-small cell lung cancer with EGFR T790M resistance mutation. Although osimertinib has achieved great success in the clinical treatment of EGFR T790M-mutated non-small cell lung cancer, patients still inevitably develop drug resistance after 9 to 14 months of treatment. Studies have shown that up to 20 to 40% of drug-resistant patients are drug-resistant due to the EGFR C797S mutation.
- the EGFR C797S mutation changes the cysteine at position 797 to serine, which prevents osimertinib from forming a covalent bond with the EGFR protein, resulting in drug resistance.
- EGFR C797S resistance mutation there is no effective inhibitor against EGFR C797S resistance mutation in clinical practice. Therefore, there is an urgent need to develop novel and highly active EGFR inhibitors to address the drug resistance problem caused by the EGFR C797S mutation.
- Lung cancer is a major disease that threatens human health, and the mortality rate of lung cancer ranks first among all malignant tumors.
- the incidence of lung cancer is increasing year by year, with about 700,000 new cases each year.
- my country's lung cancer cases with EGFR activating mutations account for about 35% of all NSCLC.
- the use of first- or third-generation EGFR inhibitors can have a good therapeutic effect, but new drug resistance mutations will occur in the later stage, so the development of new The first generation of anti-resistance EGFR inhibitors has great clinical and market value.
- the object of the present invention is to provide a crystal form of the compound represented by the general formula (I),
- R 1 is selected from hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, alkyl, deuterated alkyl, haloalkyl, alkoxy, alkylthio, haloalkoxy, cycloalkyl, heterocyclyl , aryl or heteroaryl;
- R is selected from hydrogen , deuterium, halogen, amino, nitro, hydroxy, cyano, alkyl, deuterated alkyl, haloalkyl, alkoxy, alkylthio, haloalkoxy, alkenyl, alkynyl, ring alkyl, heterocyclyl, aryl or heteroaryl;
- any two R 2 are linked to the carbon atom to which they are attached to form a cycloalkyl or heterocyclyl;
- Ring A is selected from cycloalkyl, heterocyclyl, aryl or heteroaryl;
- Ra is selected from hydrogen, deuterium, halogen, amino, nitro, hydroxy, cyano, alkyl, deuterated alkyl, haloalkyl, hydroxyalkyl, cyanoalkyl, alkoxy, haloalkoxy, cycloalkane radical, heterocyclyl, aryl, heteroaryl, -(CH 2 ) n OR aa , -(CH 2 ) n NR aa R bb , -(CH 2 ) n C(O)R aa or -(CH 2 ) n S(O) m R aa ;
- R aa and R bb are each independently selected from hydrogen, deuterium, halogen, amino, nitro, hydroxy, cyano, alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl , cycloalkyl, heterocyclyl, aryl or heteroaryl;
- x is an integer from 0 to 4.
- y is an integer from 0 to 4.
- t is an integer from 0 to 1;
- n is an integer from 0 to 2;
- n is an integer of 0-2.
- R aa and R bb are each independently selected from hydrogen, deuterium, halogen, amino, nitro, hydroxy, cyano, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl;
- x is an integer from 0-2.
- fluorine chlorine, bromine, methyl, ethyl, isopropyl, trifluoromethyl or methylthio
- any two R 2 are linked to the carbon atoms to which they are attached to form a 3-8 membered heterocyclic group; preferably a 5-6 membered heterocyclic group containing 1-2 N or O atoms; more preferably a tetrahydrofuranyl group;
- y is an integer from 0-3.
- the compound (6-((5-bromo-2-((2-methoxy-5-methyl-4-(4-((3aR,6aS)-tetrahydro-1H) is provided. - Furo[3,4-c]pyrrol-5(3H)-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)-2,3-dihydrobenzo[b ][1,4]dioxin-5-yl)dimethylphosphine oxidation; (6-((5-chloro-2-((4-(4-(3-(dimethylamino)azetidine- 1-yl)piperidin-1-yl)-5-ethyl-2-methoxyphenyl)amino)pyrimidin-4-yl)amino)-2,3-dihydrobenzo[b][1,4 ] dioxin-5-yl) dimethylphosphin
- the X-ray powder diffraction pattern of Form H has a diffraction peak at 2 ⁇ of 4.8 ⁇ 0.2°; or has a diffraction peak at 21.7 ⁇ 0.2°; or has a diffraction peak at 24.2 ⁇ 0.2°; or has a diffraction peak at 11.4 ⁇ 0.2° or a diffraction peak at 22.9 ⁇ 0.2°; or a diffraction peak at 23.8 ⁇ 0.2°; or a diffraction peak at 14.7 ⁇ 0.2°; or a diffraction peak at 12.9 ⁇ 0.2°; or Diffraction peak at 26.4 ⁇ 0.2°; or diffraction peak at 8.0 ⁇ 0.2°; or diffraction peak at 10.8 ⁇ 0.2°; or diffraction peak at 24.9 ⁇ 0.2°; or diffraction peak at 12.0 ⁇ 0.2°
- Has a diffraction peak; preferably contains any 2-5, or 3-5, or 3-6, or 3-8, or 5-8, or 6-8 of the above-mentioned diffraction peaks;
- the X-ray powder diffraction pattern of crystal form H at least comprises one or more diffraction peaks at 2 ⁇ of 21.7 ⁇ 0.2°, 24.2 ⁇ 0.2°, 11.4 ⁇ 0.2°, preferably two of them, more preferably three of them; Optionally, it may further comprise at least one of 2 ⁇ of 22.9 ⁇ 0.2°, 23.8 ⁇ 0.2°, 14.7 ⁇ 0.2°, 12.9 ⁇ 0.2°, 26.4 ⁇ 0.2°, preferably 2, 3, 4 Article or 5; for example,
- the X-ray powder diffraction pattern of Form H optionally further comprises positions at 2 ⁇ of 21.7 ⁇ 0.2°, 24.2 ⁇ 0.2°, 11.4 ⁇ 0.2°, 22.9 ⁇ 0.2°, 23.8 ⁇ 0.2°, 14.7 ⁇ 0.2°, 12.9 ⁇ 0.2 °, 26.4 ⁇ 0.2°, 8.0 ⁇ 0.2°, 10.8 ⁇ 0.2° have one or more diffraction peaks; preferably at least any 2-3, or 4-5, or 6-7 place; further preferably, including any 2 places, 3 places, 4 places, 5 places, 6 places, 7 places; for example,
- the X-ray powder diffraction pattern of Form H contains 2 ⁇ at 21.7 ⁇ 0.2°, 24.2 ⁇ 0.2°, 11.4 ⁇ 0.2°, 22.9 ⁇ 0.2°, 23.8 ⁇ 0.2°, 14.7 ⁇ 0.2°, 12.9 ⁇ 0.2°, 26.4°
- Diffraction peaks preferably, include diffraction peaks at optional 4, 5, 6, 8 or 10 locations; for example,
- the X-ray powder diffraction pattern of crystal form N has a diffraction peak at 2 ⁇ of 6.7 ⁇ 0.2°; or has a diffraction peak at 8.5 ⁇ 0.2°; or has a diffraction peak at 9.0 ⁇ 0.2°; or has a diffraction peak at 18.7 ⁇ 0.2° or a diffraction peak at 21.8 ⁇ 0.2°; or a diffraction peak at 12.3 ⁇ 0.2°; or a diffraction peak at 12.7 ⁇ 0.2°; or a diffraction peak at 14.5 ⁇ 0.2°; or It has a diffraction peak at 15.0 ⁇ 0.2°; or a diffraction peak at 22.3 ⁇ 0.2°; or a diffraction peak at 18.5 ⁇ 0.2°; or a diffraction peak at 24.6 ⁇ 0.2°; preferably included in the above-mentioned diffraction peaks Any 2-5 places, or 3-5 places, or 3-6 places, or 3-8 places, or 5-8 places, or 6-8 places; more preferably including any
- the X-ray powder diffraction pattern of crystal form N at least comprises one or more diffraction peaks located at 2 ⁇ of 6.7 ⁇ 0.2°, 8.5 ⁇ 0.2°, 9.0 ⁇ 0.2°, preferably two of them, more preferably three of them; Optionally, it may further comprise at least one of 2 ⁇ of 18.7 ⁇ 0.2°, 21.8 ⁇ 0.2°, 12.3 ⁇ 0.2°, 12.7 ⁇ 0.2°, 14.5 ⁇ 0.2°, preferably 2, 3, 4 Article or 5; for example,
- the X-ray powder diffraction pattern of Form N optionally further comprises positions at 2 ⁇ of 6.7 ⁇ 0.2°, 8.5 ⁇ 0.2°, 9.0 ⁇ 0.2°, 18.7 ⁇ 0.2°, 21.8 ⁇ 0.2°, 12.3 ⁇ 0.2°, 12.7 ⁇ 0.2 °, 14.5 ⁇ 0.2°, 15.0 ⁇ 0.2°, 22.3 ⁇ 0.2° have one or more diffraction peaks; preferably at least any of 2-3, or 4-5, or 6-7 place; further preferably, including any 2 places, 3 places, 4 places, 5 places, 6 places, 7 places; for example,
- the X-ray powder diffraction pattern of Form N contains 2 ⁇ at 6.7 ⁇ 0.2°, 8.5 ⁇ 0.2°, 9.0 ⁇ 0.2°, 18.7 ⁇ 0.2°, 21.8 ⁇ 0.2°, 12.3 ⁇ 0.2°, 12.7 ⁇ 0.2°, 14.5
- One or more diffraction peaks in ⁇ 0.2°, 15.0 ⁇ 0.2°, 22.3 ⁇ 0.2°, 18.5 ⁇ 0.2°, 24.6 ⁇ 0.2°, 18.0 ⁇ 0.2°, 23.7 ⁇ 0.2°, 17.8 ⁇ 0.2°, preferred including optional 4, 5, 6, 8 or 10 diffraction peaks; for example,
- the X-ray powder diffraction pattern of the crystal form N contains 2 ⁇ at 6.7 ⁇ 0.2°, 8.5 ⁇ 0.2°, 10.8 ⁇ 0.2°, 9.0 ⁇ 0.2°, 18.7 ⁇ 0.2°, 21.8 ⁇ 0.2°, 12.3 ⁇ 0.2°, 12.7 ⁇ 0.2°, 13.7 ⁇ 0.2°, 14.5 ⁇ 0.2°, 15.0 ⁇ 0.2°, 20.1 ⁇ 0.2°, 21.4 ⁇ 0.2°, 21.9 ⁇ 0.2°, 22.3 ⁇ 0.2°, 18.5 ⁇ 0.2°, 24.6 ⁇ 0.2°, 18.0
- the X-ray powder diffraction pattern is basically shown in FIG. 4 ; the DSC pattern is basically shown in FIG. 5 , and the TGA pattern is basically shown in FIG. 6 .
- the X-ray powder diffraction pattern of crystal form O has a diffraction peak at 2 ⁇ of 5.0 ⁇ 0.2°; or has a diffraction peak at 6.2 ⁇ 0.2°; or has a diffraction peak at 7.2 ⁇ 0.2°; or has a diffraction peak at 8.7 ⁇ 0.2° or a diffraction peak at 12.9 ⁇ 0.2°; or a diffraction peak at 17.3 ⁇ 0.2°; or a diffraction peak at 17.9 ⁇ 0.2°; or a diffraction peak at 20.4 ⁇ 0.2°; or It has a diffraction peak at 14.4 ⁇ 0.2°; or a diffraction peak at 12.4 ⁇ 0.2°; or a diffraction peak at 19.7 ⁇ 0.2°; or a diffraction peak at 18.7 ⁇ 0.2°; preferably included in the above-mentioned diffraction peaks Any 2-5 places, or 3-5 places, or 3-6 places, or 3-8 places, or 5-8 places, or 6-8 places; more preferably including any
- the X-ray powder diffraction pattern of crystal form O contains at least one or more diffraction peaks located at 2 ⁇ of 5.0 ⁇ 0.2°, 6.2 ⁇ 0.2°, 7.2 ⁇ 0.2°, preferably two of them, more preferably three of them; Optionally, it can further comprise at least one of 2 ⁇ of 8.7 ⁇ 0.2°, 12.9 ⁇ 0.2°, 17.3 ⁇ 0.2°, 17.9 ⁇ 0.2°, 20.4 ⁇ 0.2°, preferably 2, 3, 4 Article or 5; for example,
- the X-ray powder diffraction pattern of Form O optionally further comprises positions at 2 ⁇ of 5.0 ⁇ 0.2°, 6.1 ⁇ 0.2°, 7.2 ⁇ 0.2°, 8.7 ⁇ 0.2°, 12.9 ⁇ 0.2°, 17.3 ⁇ 0.2°, 17.9 ⁇ 0.2 °, 20.4 ⁇ 0.2°, 14.4 ⁇ 0.2°, 12.4 ⁇ 0.2° have one or more diffraction peaks; preferably at least any of 2-3, or 4-5, or 6-7 place; further preferably, including any 2 places, 3 places, 4 places, 5 places, 6 places, 7 places; for example,
- the X-ray powder diffraction pattern of crystal form O contains 2 ⁇ at 5.0 ⁇ 0.2°, 6.1 ⁇ 0.2°, 7.2 ⁇ 0.2°, 8.7 ⁇ 0.2°, 12.9 ⁇ 0.2°, 17.3 ⁇ 0.2°, 17.9 ⁇ 0.2°, 20.4
- the X-ray powder diffraction pattern of Form I has a diffraction peak at 20.8 ⁇ 0.2°; or a diffraction peak at 13.7 ⁇ 0.2°; or a diffraction peak at 12.7 ⁇ 0.2°; or a diffraction peak at 14.4 ⁇ 0.2° or a diffraction peak at 17.2 ⁇ 0.2°; or a diffraction peak at 11.3 ⁇ 0.2°; or a diffraction peak at 20.2 ⁇ 0.2°; or a diffraction peak at 25.1 ⁇ 0.2°; or It has a diffraction peak at 22.5 ⁇ 0.2°; or a diffraction peak at 14.6 ⁇ 0.2°; or a diffraction peak at 22.2 ⁇ 0.2°; or a diffraction peak at 26.0 ⁇ 0.2°; preferably included in the above-mentioned diffraction peaks Any 2-5 places, or 3-5 places, or 3-6 places, or 3-8 places, or 5-8 places, or 6-8 places; more preferably including any 6 places, 7 places or 8
- the X-ray powder diffraction pattern of crystal form I at least comprises one or more diffraction peaks at 20.8 ⁇ 0.2°, 13.7 ⁇ 0.2°, 12.7 ⁇ 0.2°, preferably two of them, more preferably three of them; Optionally, it can further comprise at least one of 2 ⁇ of 14.4 ⁇ 0.2°, 17.2 ⁇ 0.2°, 11.3 ⁇ 0.2°, 20.2 ⁇ 0.2°, 25.1 ⁇ 0.2°, preferably 2, 3, 4 Article or 5; for example,
- the X-ray powder diffraction pattern of Form I optionally further comprises positions at 2 ⁇ of 20.8 ⁇ 0.2°, 13.7 ⁇ 0.2°, 12.7 ⁇ 0.2°, 14.4 ⁇ 0.2°, 17.2 ⁇ 0.2°, 11.3 ⁇ 0.2°, 20.2 ⁇ 0.2 °, 25.1 ⁇ 0.2°, 22.5 ⁇ 0.2° have one or more diffraction peaks; preferably at least any 2-3, or 4-5, or 6-7 of them are included; further preferably, Including any 2, 3, 4, 5, 6, 7 of them; for example,
- the X-ray powder diffraction pattern of Form I comprises positions at 2 ⁇ of 20.8 ⁇ 0.2°, 13.7 ⁇ 0.2°, 12.7 ⁇ 0.2°, 14.4 ⁇ 0.2°, 17.2 ⁇ 0.2°, 11.3 ⁇ 0.2°, 20.2 ⁇ 0.2°, 25.1
- the crystal form is anhydrous or hydrate; when the crystal form is a hydrate, the number of water is 0.2-3, preferably 0.2, 0.5, 1, 1.5, 2, 2.5 or 3, more preferably 0.5, 1, 2 or 3; preferably, the crystal form is anhydrous.
- the positions of the top ten diffraction peaks with relative peak intensities in the X-ray powder diffraction patterns of crystal form H, crystal form N, crystal form O and crystal form I are respectively shown in Figure 1, Figure 4,
- the 2 ⁇ errors of the diffraction peaks at the corresponding positions in FIGS. 7 and 9 are ⁇ 0.2° to ⁇ 0.5°, preferably ⁇ 0.2° to ⁇ 0.3°, and most preferably ⁇ 0.2°.
- the preparation method of the compound crystal form represented by the general formula (I) comprises the following steps:
- the benign solvent is selected from methanol, ethanol, acetone, sec-amyl alcohol, n-butanol, n-octanol, n-hexanol, ethyl acetate, acetonitrile, ethanol, 88% acetone, tetrahydrofuran, dichloromethane, 1,4- Dioxane, benzene, toluene, isopropanol, n-butanol, isobutanol, N,N-dimethylformamide, N,N-dimethylacetamide, n-propanol, tert-butanol, 2 -butanone or 3-pentanone; preferably methanol, ethanol, acetone, sec-amyl alcohol, n-butanol, n-octanol or n-hexanol.
- the poor solvent is selected from heptane, water, methyl tert-butyl ether, toluene and isopropyl ether.
- the preparation method of the compound crystal form represented by the general formula (I) comprises the following steps:
- the poor solvent is selected from acetone, ethyl acetate, isopropyl acetate, acetonitrile, ethanol, 88% acetone, tetrahydrofuran, 2-methyltetrahydrofuran, dichloromethane, 1,4-dioxane, benzene, Toluene, isopropanol, n-butanol, isobutanol, N,N-dimethylformamide, N,N-dimethylacetamide, n-propanol, tert-butanol, 2-butanone or 3-pentane ketone, methyl tert-butyl ether, water; preferably acetone, ethyl acetate, isopropyl acetate, acetonitrile, ethanol, 88% acetone, tetrahydrofuran, 2-methyltetrahydrofuran, dichloromethane, 1,4-dioxane Cyclo
- the preparation method of the compound crystal form represented by the general formula (I) comprises the following steps:
- the suspension density is preferably 50-200 mg/mL
- the poor solvent is selected from acetone, ethyl acetate, isopropyl acetate, acetonitrile, ethanol, 88% acetone, tetrahydrofuran, 2-methyltetrahydrofuran, dichloromethane, 1,4-dioxane, benzene, Toluene, isopropanol, n-butanol, isobutanol, N,N-dimethylformamide, N,N-dimethylacetamide, n-propanol, tert-butanol, 2-butanone or 3-pentane ketone, methyl tert-butyl ether, water; preferably acetone, ethyl acetate, isopropyl acetate, acetonitrile, ethanol, 88% acetone, tetrahydrofuran, 2-methyltetrahydrofuran, dichloromethane, 1,4-dioxane Cyclo
- Another object of the present invention is to provide the compound represented by the general formula (I) (6-((5-bromo-2-((2-methoxy-4-(4-(3-(methoxy) Methyl)azetidin-1-yl)piperidin-1-yl)-5-methylphenyl)amino)pyrimidin-4-yl)amino)-2,3-dihydrobenzo[B][1 , 4]
- the kinase inhibitor is a MEK inhibitor
- the kinase inhibitor is a receptor tyrosine kinase inhibitor, preferably a HER2 inhibitor, an EGFR inhibitor and an EGFR monoclonal antibody and their combination related drugs, more preferably a HER2 exon 20 mutant inhibitor, EGFR exon 20 Mutant inhibitors and EGFR exon mutant monoclonal antibodies and their combination related drugs.
- the purpose of the present invention is to provide the crystalline form of the compound represented by the general formula (I) and the application of the pharmaceutical composition in the treatment of cancer, inflammation, chronic liver disease, diabetes, cardiovascular disease and AIDS-related diseases.
- the cancer, inflammation, chronic liver disease, diabetes, cardiovascular disease and AIDS-related diseases are diseases mediated by HER2 exon 20 mutation and/or EGFR20 exon mutation.
- Another object of the present invention is to provide the compound represented by the general formula (I) (6-((5-bromo-2-((2-methoxy-4-(4-(3-(methoxy) Methyl)azetidin-1-yl)piperidin-1-yl)-5-methylphenyl)amino)pyrimidin-4-yl)amino)-2,3-dihydrobenzo[B][1 , 4]
- the oxidized crystal form of dioxin-5-yl) dimethyl phosphine and the application of the pharmaceutical composition in the medicine for the treatment of cancer, inflammation, chronic liver disease, diabetes, cardiovascular disease and AIDS-related diseases preferably Typically, the cancer, inflammation, chronic liver disease, diabetes, cardiovascular disease and AIDS-related diseases are diseases mediated by HER2 exon 20 mutations and/or EGFR20 exon mutations.
- the cancer is selected from breast cancer, cervical cancer, colon cancer, lung cancer, gastric cancer, rectal cancer, pancreatic cancer, brain cancer, liver cancer, solid tumor, glioma, glioblastoma, leukemia, lymphoma, bone marrow tumor and non-small cell lung cancer.
- the third-generation EGFR inhibitors are mainly directed against EGFR activating mutants and T790M drug-resistant mutants with high inhibition.
- the compounds of the present invention are more effective than third-generation EGFR inhibitors in terms of EGFR and/or HER2 exon 20 insertion mutation targets. Demonstrates the following significant advantages:
- the compound has an activity that is more than 10 times higher, or even 20 times higher;
- the compound is more than 3 times higher, or even 10 times higher;
- alkyl refers to a saturated aliphatic hydrocarbon group, which is a straight or branched chain group containing 1 to 20 carbon atoms, preferably an alkyl group containing 1 to 8 carbon atoms, more preferably 1 to 6 carbon atoms , most preferably an alkyl group of 1 to 3 carbon atoms.
- Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1 ,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2- Methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3 -Dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2 -Methylhexyl, 3-methylhexyl, 4-methylhe
- lower alkyl groups containing 1 to 6 carbon atoms include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl base, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-Methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylpropyl butyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl base, 2,3-dimethylbutyl, etc.
- Alkyl groups may be substituted or unsubstituted, and when substituted, substituents may be substituted at any available point of attachment, preferably one or more of the following groups, independently selected from alkanes group, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkane Oxy group, heterocycloalkoxy group, cycloalkylthio group, heterocycloalkylthio group, oxo group, carboxyl group or carboxylate group, the present invention is preferably methyl, ethyl, isopropyl, tert-butyl, haloalkyl , deuterated alkyl, alkoxy substituted alkyl and hydroxy substituted alkyl.
- alkylene means that one hydrogen atom of the alkyl group is further substituted, for example: "methylene” means -CH2- , “ethylene” means -( CH2 ) 2- , "propylene” Refers to -(CH 2 ) 3 -, “butylene” refers to -(CH 2 ) 4 - and the like.
- alkenyl refers to an alkyl group as defined above consisting of at least two carbon atoms and at least one carbon-carbon double bond, such as vinyl, 1-propenyl, 2-propenyl, 1-, 2- or 3 -Butenyl, etc.
- Alkenyl groups may be substituted or unsubstituted, and when substituted, the substituents are preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, Alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycle Alkylthio.
- cycloalkyl refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent, the cycloalkyl ring containing 3 to 20 carbon atoms, preferably 3 to 12 carbon atoms, more preferably 3 to 8 carbon atoms carbon atoms, most preferably 3 to 6 carbon atoms.
- Non-limiting examples of monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatriene
- Polycyclic cycloalkyl groups include spiro, fused and bridged cycloalkyl groups, preferably cyclopropyl, cyclobutyl, cyclohexyl, cyclopentyl and cycloheptyl.
- heterocyclyl refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent containing from 3 to 20 ring atoms, one or more of which is selected from nitrogen, oxygen or S(O) m (where m is an integer from 0 to 2) heteroatoms, excluding ring moieties of -OO-, -OS- or -SS-, the remaining ring atoms being carbon.
- ring atoms excluding ring moieties of -OO-, -OS- or -SS-, the remaining ring atoms being carbon.
- it contains 3 to 12 ring atoms, of which 1 to 4 are heteroatoms; more preferably 3 to 8 ring atoms; most preferably 3 to 6 ring atoms.
- Non-limiting examples of monocyclic heterocyclyl groups include oxetanyl, thietanyl, pyrrolidinyl, pyrrolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothienyl, dihydroimidazolyl, dihydroimidazolyl Hydrofuranyl, dihydropyrazolyl, dihydropyrrolyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, pyranyl, etc., preferably oxetanyl , pyrrolidone, tetrahydrofuranyl, pyrazolidine, morpholinyl, piperazinyl and pyranyl.
- Polycyclic heterocyclic groups include spiro, condensed and bridged heterocyclic groups; the spiro, condensed and bridged heterocyclic groups are optionally connected with other groups through a single bond, or through a ring Any two or more atoms above are further cyclo-linked to other cycloalkyl, heterocyclyl, aryl and heteroaryl groups.
- fused heterocyclyl refers to a 5- to 20-membered polycyclic heterocyclic group in which each ring in the system shares an adjacent pair of atoms with other rings in the system, and one or more of the rings may contain one or more Double bonds, but none of the rings have a fully conjugated pi-electron system, where one or more ring atoms are heteroatoms selected from nitrogen, oxygen, or S(O) m (where m is an integer from 0 to 2), the remaining rings Atom is carbon.
- it is 6 to 14 yuan, more preferably 7 to 10 yuan.
- fused heterocyclyl groups include:
- Heterocyclyl may be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkane Thio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio , heterocycloalkylthio, oxo, carboxyl or carboxylate.
- the substituents are preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkane Thio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl,
- aryl refers to a 6- to 14-membered all-carbon monocyclic or fused polycyclic (ie, rings that share adjacent pairs of carbon atoms) groups having a conjugated pi-electron system, preferably 6 to 10 membered, such as benzene base and naphthyl. More preferred is phenyl.
- the aryl ring can be fused to a heteroaryl, heterocyclyl or cycloalkyl ring, including benzo 3-8 membered cycloalkyl, benzo 3-8 membered heteroalkyl, preferably benzo 3-6 Membered cycloalkyl, benzo 3-6 membered heteroalkyl, wherein the heterocyclic group is a heterocyclic group containing 1-3 nitrogen atoms, oxygen atoms, sulfur atoms; or also includes a three-membered nitrogen-containing fused ring containing a benzene ring , where the ring connected to the parent structure is an aryl ring.
- Non-limiting examples thereof include:
- Aryl may be substituted or unsubstituted, and when substituted, the substituents are preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, Alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycle Alkylthio, carboxyl or carboxylate.
- heteroaryl refers to a heteroaromatic system comprising 1 to 4 heteroatoms, 5 to 14 ring atoms, wherein the heteroatoms are selected from oxygen, sulfur and nitrogen.
- Heteroaryl is preferably 5 to 10-membered, more preferably 5- or 6-membered, such as imidazolyl, furyl, thienyl, thiazolyl, pyrazolyl, oxazolyl, pyrrolyl, triazolyl, tetrazolyl , pyridyl, pyrimidinyl, thiadiazole, pyrazinyl, etc., preferably triazolyl, thienyl, imidazolyl, pyrazolyl, oxazolyl, pyrimidinyl or thiazolyl; more preferably pyrazolyl and oxa azolyl.
- the heteroaryl ring can be fused to an aryl, heterocyclyl or cycloalkyl ring
- Non-limiting examples thereof include:
- alkoxy refers to -O-(alkyl) and -O-(unsubstituted cycloalkyl), wherein alkyl is as defined above.
- alkoxy groups include: methoxy, ethoxy, propoxy, butoxy, cyclopropoxy, cyclobutoxy, cyclopentyloxy, cyclohexyloxy.
- Alkoxy can be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkoxy Thio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio , heterocycloalkylthio, carboxyl or carboxylate.
- alkylthio refers to -S-(alkyl) and -S-(unsubstituted cycloalkyl), wherein alkyl is as defined above.
- alkyl groups containing 1 to 8 carbon atoms, more preferably 1 to 6 carbon atoms, and most preferably 1 to 3 carbon atoms.
- alkoxy groups include: methylthio, ethylthio, propylthio, butylthio.
- Alkylthio can be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkane Thio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio , heterocycloalkylthio, carboxyl or carboxylate.
- Haloalkyl refers to an alkyl group substituted with one or more halogens, wherein alkyl is as defined above.
- Hydroalkyl refers to an alkyl group substituted with one or more hydroxy groups, wherein alkyl is as defined above.
- Cyanoalkyl refers to an alkyl group substituted with one or more cyano groups, wherein alkyl is as defined above.
- Haloalkoxy refers to an alkoxy group substituted with one or more halogens, wherein alkoxy is as defined above.
- Alkenyl refers to an alkenyl group, also known as an alkenyl group, preferably an alkyl group containing 2 to 8 carbon atoms, more preferably an alkyl group of 2 to 6 carbon atoms, most preferably an alkyl group of 2 to 3 carbon atoms .
- the alkenyl group may be further substituted by other related groups, such as: alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, Cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, carboxyl or carboxylate.
- other related groups such as: alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, Cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, carboxyl or carboxylate.
- Alkynyl refers to (CH ⁇ C-), preferably an alkyl group containing 2 to 8 carbon atoms, more preferably an alkyl group of 2 to 6 carbon atoms, and most preferably an alkyl group of 2 to 3 carbon atoms.
- the alkynyl group may be further substituted by other related groups, such as: alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, Cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, carboxyl or carboxylate.
- other related groups such as: alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, Cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, carboxyl or carboxylate.
- Halogen refers to fluorine, chlorine, bromine or iodine.
- Amino refers to -NH2 .
- Cyano refers to -CN.
- Niro refers to -NO2 .
- Carboxyl refers to -C(O)OH.
- THF tetrahydrofuran
- EtOAc refers to ethyl acetate
- MeOH refers to methanol
- DMF N,N-dimethylformamide
- DIPEA diisopropylethylamine
- TFA trifluoroacetic acid
- MeCN means acetonitrile
- DMA refers to N,N-dimethylacetamide.
- Et2O refers to diethyl ether.
- DCE 1,2 dichloroethane
- DIPEA N,N-diisopropylethylamine
- NBS N-bromosuccinimide
- NIS N-iodosuccinimide
- Cbz-Cl refers to benzyl chloroformate
- Pd2(dba )3 refers to tris(dibenzylideneacetone)dipalladium.
- Dppf refers to 1,1'-bisdiphenylphosphinoferrocene.
- HATU refers to 2-(7-benzotriazole oxide)-N,N,N',N'-tetramethylurea hexafluorophosphate.
- KHMDS refers to potassium hexamethyldisilazide
- LiHMDS refers to lithium bistrimethylsilylamide.
- MeLi refers to methyl lithium
- n-BuLi refers to n-butyllithium
- NaBH(OAc) 3 refers to sodium triacetoxyborohydride.
- DMAP refers to 4-dimethylaminopyridine.
- SEM-Cl refers to chloromethyltrimethylsilyl ethyl ether.
- Xantphos refers to 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene.
- DCM dichloromethane
- X is selected from A, B, or C
- X is selected from A, B and C
- X is A, B or C
- X is A, B and C
- X is A, B and C
- the hydrogen atom in the present invention can be replaced by its isotope deuterium, and any hydrogen atom in the example compounds involved in the present invention can also be replaced by deuterium atom.
- Optional or “optionally” means that the subsequently described event or circumstance can, but need not, occur, and that the description includes instances where the event or circumstance occurs or instances where it does not.
- a heterocyclic group optionally substituted with an alkyl group means that an alkyl group may, but need not, be present, and the description includes the case where the heterocyclic group is substituted with an alkyl group and the case where the heterocyclic group is not substituted with an alkyl group .
- Substituted means that one or more hydrogen atoms in a group, preferably up to 5, more preferably 1 to 3 hydrogen atoms, independently of one another, are substituted by the corresponding number of substituents. It goes without saying that the substituents are only in their possible chemical positions, and the person skilled in the art can determine (either experimentally or theoretically) possible or impossible substitutions without undue effort. For example, amino or hydroxyl groups with free hydrogens may be unstable when combined with carbon atoms with unsaturated (eg, olefinic) bonds.
- Optional substituents include deuterium, halo, amino, hydroxy, cyano, oxo, thio, alkyl, alkenyl, alkynyl, deuterated alkyl, haloalkyl, hydroxyalkyl, alkoxy , alkylthio, haloalkoxy, cycloalkyl, heterocyclyl, aryl and heteroaryl are substituted with one or more substituents, preferably deuterium, halogen, amino, hydroxyl, cyano, oxo, Thio, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 alkylthio, C 1-6 haloalkoxy, C 3-12 cycloalkyl, 3-12 membered heterocyclyl, C 6-14 aryl and 5-14 membered
- “Pharmaceutical composition” means a mixture containing one or more of the compounds described herein, or a physiologically/pharmaceutically acceptable salt or prodrug thereof, with other chemical components, and other components such as a physiological/pharmaceutically acceptable carrier and excipients.
- the purpose of the pharmaceutical composition is to facilitate the administration to the organism, facilitate the absorption of the active ingredient and then exert the biological activity.
- “Pharmaceutically acceptable salts” refer to salts of the compounds of the present invention, which are safe and effective when used in mammals, and possess the desired biological activity.
- Figure 1 is an XRPD representation of the free base Form H.
- FIG. 2 is a DSC graph of the free base Form H.
- FIG. 3 is a TGA diagram of the free base Form H.
- Figure 4 is an XRPD representation of the free base Form N.
- FIG. 5 is a DSC graph of the free base form N.
- FIG. 6 is a TGA diagram of the free base form N.
- Figure 7 is an XRPD representation of the free base Form O.
- Figure 8 is a DSC graph of the free base Form O.
- Figure 9 is an XRPD representation of the free base Form I.
- Figure 10 is a DSC graph of the free base Form I.
- the structures of the compounds of the present invention are determined by nuclear magnetic resonance (NMR) or/and liquid chromatography-mass spectrometry (LC-MS). NMR chemical shifts ([delta]) are given in parts per million (ppm). NMR was measured by Bruker AVANCE-400 nuclear magnetic instrument, and the solvent was deuterated dimethyl sulfoxide (DMSO-d 6 ), deuterated methanol (CD 3 OD) and deuterated chloroform (CDCl 3 ), and the internal standard was four Methylsilane (TMS).
- DMSO-d 6 dimethyl sulfoxide
- CD 3 OD deuterated methanol
- CDCl 3 deuterated chloroform
- TMS Methylsilane
- the thin layer chromatography silica gel plate uses Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plate, the specifications used for TLC are 0.15mm ⁇ 0.20mm, and the specifications used for TLC separation and purification products are 0.4mm ⁇ 0.5mm.
- Column chromatography generally uses 200-300 mesh Yantai Huanghai silica gel as the carrier.
- the starting materials in the examples of the present invention are known and commercially available, or can be synthesized using methods known in the art.
- the first step the preparation of 2-bromo-6-methoxy-3-nitrophenol
- the second step the preparation of 3-bromo-4-nitrobenzene-1,2-diphenol
- the third step preparation of 5-bromo-6-nitro-2,3-dihydrobenzo[b][1,4]dioxin
- the fourth step the preparation of 5-bromo-2,3-dihydrobenzo[b][1,4]dioxin-6-amine
- the fifth step preparation of (6-amino-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)dimethylphosphine oxidation
- the first step the preparation of 8-(5-methoxy-2-methyl-4-nitrophenyl)-1,4-dioxa-8-azaspiro[4.5]decane
- the second step preparation of 2-methoxy-5-methyl-4-(1,4-dioxa-8-azaspiro[4.5]decane-8-yl)aniline
- the second step (6-((5-bromo-2-((2-methoxy-5-methyl-4-(1,4-dioxa-8-azaspiro[4.5]decane- Preparation of 8-yl)phenyl)amino)pyrimidin-4-yl)amino)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)dimethylphosphine oxidation
- the reaction was cooled to room temperature, saturated aqueous sodium bicarbonate solution was added, extracted with ethyl acetate, the organic phase was separated and washed with saturated brine, the organic phase was dried over anhydrous sodium sulfate, the desiccant was filtered, and the organic solvent was concentrated under reduced pressure, and separated by column chromatography.
- the fourth step (6-((5-bromo-2-((2-methoxy-4-(4-(3-(methoxymethyl)azetidin-1-yl)piperidine-1) -yl)-5-methylphenyl)amino)pyrimidin-4-yl)amino)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)dimethylphosphine
- oxidation of oxidation (6-((5-bromo-2-((2-methoxy-4-(4-(3-(methoxymethyl)azetidin-1-yl)piperidine-1) -yl)-5-methylphenyl)amino)pyrimidin-4-yl)amino)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)dimethylphosphine
- the first step the preparation of tert-butyl 4-(3-(dimethylamino) azetidine-1-yl) piperidine-1-carboxylate
- tert-butyl 4-carbonylpiperidine-1-carboxylate 500 mg, 2.51 mmol
- N,N-dimethylazetidin-3-amine 302 mg, 3.01 mmol
- acetic acid 2 drops
- sodium triacetoxyborohydride 1.06g, 5.02mmol
- the second step the preparation of N,N-dimethyl-1-(piperidin-4-yl)azetidine-3-amine
- the third step 1-(1-(2-bromo-5-methoxy-4-nitrophenyl)piperidin-4-yl)-N,N-dimethylazetidine-3-amine preparation
- Step 4 1-(1-(5-methoxy-4-nitro-2-vinylphenyl)piperidin-4-yl)-N,N-dimethylazetidine-3-amine preparation
- the fifth step the preparation of 1-(1-(4-amino-2-ethyl-5-methoxyphenyl) piperidin-4-yl)-N,N-dimethylazetidine-3-amine
- Example 1 the prepared 1-(1-(4-amino-2-ethyl-5-methoxyphenyl)piperidin-4-yl)-N,N-dimethyl Azetidine-3-amine and (6-((5-bromo-2-chloropyrimidin-4-yl)amino)-2,3-dihydrobenzo[b][1,4]dioxin-5 -yl) dimethylphosphine oxidation reaction to prepare the target product (6-((5-bromo-2-((4-(4-(3-(dimethylamino)azetidine-1-yl)piperidine-1 -yl)-5-ethyl-2-methoxyphenyl)amino)pyrimidin-4-yl)amino)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl ) dimethylphosphine oxidation.
- Example 1 (6-((5-Bromo-2-((2-methoxy-5-methyl-4-(4-(3-(methyl(oxetan-3-yl)amino)azetidine- 1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)di
- Example 1 for the preparation method of methylphosphine oxidation.
- the first step (6-((5-bromo-2-((2-methoxy-5-methyl-4-(4-((3aR,6aS)-tetrahydro-1H-furo[3, 4-c]pyrrol-5(3H)-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)-2,3-dihydrobenzo[b][1,4] Preparation of Dioxin-5-yl)Dimethylphosphine Oxidation
- the first step the preparation of 5-methyl-2,3-dihydrobenzofuran
- the second step the preparation of 5-methyl-7-nitro-2,3-dihydrobenzofuran
- the third step the preparation of 5-methyl-2,3-dihydrobenzofuran-7-amine
- the fourth step the preparation of 4-bromo-5-methyl-2,3-dihydrobenzofuran-7-amine
- NBS 4-bromo-5-methyl-2,3-di Hydrobenzofuran-7-amine (600 mg, yield: 60%).
- the fifth step the preparation of N-(4-bromo-5-methyl-2,3-dihydrobenzofuran-7-yl)acetamide
- the seventh step the preparation of 5-methyl-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)-2,3-dihydrobenzofuran-7-amine
- Test Example 1 Determination of Inhibitory Activity of Compounds of the Invention on EGFR Wild-type, EGFR del746-750/T790M/C797S and EGFR L858R/T790M/C797S Mutated Kinases
- the purpose of this test case is to test the inhibitory activity of compounds against EGFR wild-type, EGFR del746-750/T790M/C797S and EGFR L858R/T790M/C797S mutant kinases.
- centrifuge (5810R) was purchased from Eppendorf company, pipette was purchased from Eppendorf or Rainin company, microplate reader was purchased from BioTek company of the United States, the model is SynergyH1 full-function microplate reader.
- Cisbio's HTRF kinase assay method (Cisbio #62TK0PEB) was used in this experiment, and the substrate polypeptides TK and ATP were detected in tyrosine kinase EGFR wild-type, EGFR del746-750/T790M/C797S or EGFR L858R/T790M/C797S mutant A catalytic reaction occurs in the presence of the substrate, and the substrate is phosphorylated.
- the activity of the kinase is characterized by measuring the content of the phosphorylated substrate generated in the reaction, and it is concluded that the compound has no effect on EGFR wild-type, EGFR del746-750/T790M/C797S or The half inhibitory concentration IC50 of EGFR L858R/T790M/C797S mutant kinase activity inhibition.
- the kinase reaction was performed in a white 384-well plate (Perkin Elmer #6008280), 1-5 ⁇ L of different concentrations of compounds diluted with ddH 2 O containing 1% DMSO were added to each well, and 1-5 ⁇ L of 1% DMSO containing 1% DMSO was added to the positive control well.
- ddH 2 O then add 1-5 ⁇ L per well of 0.5-5 nM 4 ⁇ EGFR wild-type, EGFR del746-750 diluted with Dilution buffer (5 ⁇ kinase buffer, MgCl 2 6.65 mM, MnCl 2 1.33 mM, DTT 1.33 mM) /T790M/C797S or EGFR L858R/T790M/C797S mutant kinase solution, add 1-5 ⁇ L of Dilution buffer to negative control wells, add 1-5 ⁇ L of 4 ⁇ M 4 ⁇ substrate TK solution prepared with 10 ⁇ Dilution buffer to all wells, and finally add 1 ⁇ 5 ⁇ L of 24 ⁇ M 4 ⁇ ATP solution diluted with Dilution buffer was used to initiate the reaction.
- Dilution buffer 5 ⁇ kinase buffer, MgCl 2 6.65 mM, MnCl 2 1.33 mM, DTT 1.33 mM
- the example compounds shown in the present invention have a strong inhibitory effect on the kinase activity of EGFR mutants, but have less inhibitory effect on the EGFR wild-type kinase activity.
- the comparison data shows that the series of example compounds of the present invention have a strong inhibitory effect on the kinase activity of EGFR mutation. Inhibition of EGFR mutant/wild-type kinase activity is highly selective.
- Test Example 2 Determination of the kinase inhibitory activity of the compounds of the present invention on EGFR del746-750/C797S and EGFR L858R/C797S mutations
- the purpose of this test case is to test the inhibitory activity of compounds against EGFR del746-750/C797S and EGFR L858R/C797S mutant kinases.
- centrifuge (5810R) was purchased from Eppendorf company, pipette was purchased from Eppendorf or Rainin company, microplate reader was purchased from BioTek company of the United States, the model is SynergyH1 full-function microplate reader.
- HTRF kinase assay method (Cisbio #62TKOPEB) was used in this experiment.
- the substrate polypeptide TK and ATP undergo catalytic reaction in the presence of tyrosine kinase EGFR del746-750/C797S or EGFR L858R/C797S mutation.
- the substrate is phosphorylated, and the activity of the kinase is characterized by measuring the amount of phosphorylated substrate generated in the reaction, and the median inhibitory concentration IC50 of the compound for EGFR del746-750/C797S or EGFR L858R/C797S mutant kinase activity inhibition is obtained. .
- the kinase reaction was carried out in a white 384-well plate (Perkin Elmer #6008280), 1-5 ⁇ L of different concentrations of compounds diluted with ddH 2 O containing 1% DMSO were added to each well, and 1-5 ⁇ L of 1% DMSO containing 1% DMSO was added to the positive control well.
- ddH 2 O then add 1-5 ⁇ L per well of 0.5-5 nM 4 ⁇ EGFR del746-750/C797S or EGFR diluted with Dilution buffer (5 ⁇ Kinase Buffer, MgCl 2 6.65 mM, MnCl 2 1.33 mM, DTT 1.33 mM) L858R/C797S mutant kinase solution, add 1-5 ⁇ L of Dilution buffer to negative control wells, add 1-5 ⁇ L of 4 ⁇ M 4 ⁇ substrate TK solution prepared with 10 ⁇ Dilution buffer to all wells, and finally add 1-5 ⁇ L of Dilution buffer diluted 24 ⁇ M 4 ⁇ ATP solution was used to initiate the reaction.
- Dilution buffer 5 ⁇ Kinase Buffer, MgCl 2 6.65 mM, MnCl 2 1.33 mM, DTT 1.33 mM
- L858R/C797S mutant kinase solution add 1-5 ⁇ L of Dilution buffer to negative
- the example compounds shown in the present invention have a strong inhibitory effect on the kinase activity of EGFR del746-750/C797S or EGFR L858R/C797S mutation
- the purpose of this test example is to test the proliferation inhibitory activity of the compound on cells.
- CTG CELL TITER-GLO
- Ba/F3 EGFR del746-750/T790M/C797S
- A431 cells on the first day, plate 90 ⁇ L of A431 cell suspension in a 96-well assay plate, the number of cells in each well is 3000, in which no cells are added to the negative control, and the plate is placed in a 37°C containing 5% CO2 Incubate overnight in an incubator. The next day, 10 ⁇ L of the compound solution diluted in gradient was added to each well, and only 10 ⁇ L of medium containing DMSO was added to the positive and negative control wells, and the plate was placed in a carbon dioxide incubator for 72 hours.
- the example compounds shown in the present invention have a good inhibitory effect on the proliferation activity of Ba/F3 (EGFR del746-750/T790M/C797S) mutant cells, but have a weaker effect on A431 cells. Inhibitory effect, compared with the data, it can be seen that the compounds of the series of examples of the present invention have high selectivity in inhibiting the proliferation activity of Ba/F3 (EGFR del746-750/T790M/C797S) mutant cells.
- Test Example 4 Determination of the Inhibitory Effect of the Compounds of the Invention on Cellular EGFR Phosphorylation
- the purpose of this test case is to test the inhibitory activity of compounds on cellular EGFR phosphorylation.
- Microplate shaker (88880024) was purchased from Thermo Scientific TM company, centrifuge (5702R) was purchased from Eppendorf company, pipette was purchased from Eppendorf company, microplate reader was purchased from American Biotech company, the model is SynergyH1 full function Microplate reader.
- IC50 values were calculated using GraphPad prism to fit the different concentrations and corresponding percent inhibition data to a 4-parameter nonlinear logistic formula.
- Example 13 1.65 Example 15 5.00 Example 16 0.21 Example 20 1.74 Example 34 0.11 Example 38 1.15 Example 42 6.93 Example 48 2.65 Example 52 5.00 Example 34 0.11 Example 55 0.88 Example 57 0.82 Example 58 0.95 Example 59 2.63
- the example compounds shown in the present invention have a good inhibitory effect on EGFR phosphorylation in Ba/F3 (EGFR del746-750/T790M/C797S) cells.
- Balb/C mice were used as test animals to study the pharmacokinetic behavior of compound examples in the plasma of mice administered orally at a dose of 5 mg/kg.
- Balb/C Mouse (6 animals/example), male, Shanghai Jisijie Laboratory Animal Co., Ltd., animal production license number (SCXK (Shanghai) 2013-0006N0.311620400001794).
- mice (6 mice/example), male; p.o. after overnight fasting, respectively, the dose is 5 mg/kg, and the administration volume is 10 mL/kg.
- mice Before and after administration of mice, at 0, 0.5, 1, 2, 4, 6, 8 and 24 hours, 0.1 mL of blood was collected from the orbit, placed in an EDTA-K 2 test tube, and centrifuged at 6000 rpm at 4°C for 6 min to separate plasma. , and stored at -80°C.
- a solution is 0.1% formic acid aqueous solution
- B solution is acetonitrile
- FA is the formate salt of the corresponding compound.
- Test Example 6 In vivo efficacy test of the compounds of the embodiments of the present invention
- NOD/SCID mice, 6-8 weeks, ⁇ were purchased from Jiangsu Jicui Yaokang Biotechnology Co., Ltd.
- PC9 EGFR Del19/T790M/C797S cells were cultured in RPMI1640 medium containing 10% fetal bovine serum. PC9 (EGFR Del19/T790M/C797S) cells in exponential growth phase were collected.
- mice were inoculated with 1 ⁇ 10 7 PC9 (EGFR Del19/T790M/C797S) cells subcutaneously on the right back of the mouse (the right back of the mouse, near the forelimb), and the cells were resuspended in 1:1 PBS and Matrigel ( 0.1ml/only), the tumor growth was observed regularly, and the day of tumor cell inoculation was defined as day 0.
- PC9 EGFR Del19/T790M/C797S
- a, Day 7 Measure tumor volume data, and select mice with tumor volume in the range of 100-200 mm 3 , according to the average volume of 140 mm 3 , and randomly grouped and administered according to tumor size and mouse body weight.
- Tumors were measured and weighed twice a week after the test drug was started.
- TGI% [1-(T i -T 0 )/(C i -C 0 )] ⁇ 100%; wherein, T i is the tumor volume on day i of the administration group , T 0 is the tumor volume of the administration group on the day of the grouping, C i is the tumor volume of the solvent control group on the i day, and C 0 is the tumor volume of the solvent control group on the day of the grouping.
- test data is as follows:
- Mobile phase A: water (0.05% trifluoroacetic acid); B: acetonitrile (0.05% trifluoroacetic acid)
- organic solvent can be selected from Acetone, ACN and EA
- beating for 12h at room temperature and finally the solid is centrifuged quickly to remove the supernatant, Drying under vacuum at 40°C gave crystal form H.
- organic solvent can be selected from Acetone, ACN and EA
- the physicochemical stability of the free base crystal form H at a high temperature of 60 °C was investigated to provide a basis for crystal form screening and compound storage.
- the hygroscopicity of the free base crystal form H of the compound under different relative humidity conditions was investigated to provide a basis for the screening and storage of the compound crystal form.
- the free base crystal form H of the compound was placed in saturated water vapor with different relative humidity, so that the compound and water vapor reached a dynamic equilibrium, and the percentage of weight gain by moisture absorption of the compound after the equilibrium was calculated.
- the XRPD spectrum of the free alkali crystalline form H was not changed after one cycle of moisture absorption and desorption under the condition of 0-95% relative humidity, that is, the crystal form did not change.
- thermodynamic solubility of the compound at 37°C was determined by HPLC, external standard method.
- SD rats were used as test animals to study the pharmacokinetic behavior of free base crystal form H in rats (plasma) after a single oral administration, and compare the changes of exposure; bioavailability.
- Moisture heat treatment Weigh 0.992 g of the raw material, granulate with 0.515 g of purified water, and dry at 60° C. for 60 min.
- Pulverization When designing the pulverization of raw materials, weigh the raw material crystal form N50g, the screw speed gear is 5, and investigate three rotation speeds/rpm: 3000, 7500, and 12000.
- the bulk drug crystal form N was weighed and made into tablets according to the preparation process, and the stability of the bulk drug and the preparation samples were compared.
- Granulation Set the relevant parameters according to the process requirements, start the equipment, perform granulation at I speed (the rotating speed of the mixing knife is 100 rpm, the rotating speed of the granulating knife is 1000 rpm), and the wetting agent water is pumped into the wet method through the peristaltic pump at a constant speed. In the granulator; after the I-speed granulation is completed, the II-speed granulation is performed (the rotating speed of the mixing knife is 150 rpm, and the rotating speed of the granulating knife is 1500 rpm).
- wet granulation Set relevant parameters according to the process requirements, and wet the material through a 4750 ⁇ m square screen for wet granulation (the speed of the granulating knife is 995.7 rpm).
- V. Drying Start the fan to start drying. After the temperature of the material reaches 40 °C, take a sample to measure the moisture. If it is qualified, the material will be discharged; %the following.
- Total mixing add the dry granulated material, sodium starch glycolate (extra), and magnesium stearate to the hopper mixer. According to the process requirements, set the mixer speed to 10rpm and the mixing time to 10min.
- the coating operation is carried out using the prescribed amount of film coating premix (gastric dissolving type).
- Target weight gain 3.0%
- API Formulation sample (30mg tablet) Form N Form N
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
涉及一种芳基磷氧化物类衍生物自由碱的晶型及其制备方法和应用,具体涉及一种通式(I)所示化合物晶型、制备方法和含有治疗有效量的该化合物或其晶型的药物组合物以及其作为EGFR抑制剂在制备治疗癌症相关疾病的药物中的用途。
Description
本发明属于生物医药领域,具体涉及一种芳基磷氧化物类衍生物自由碱的晶型及其制备方法和应用。
EGFR(Epidermal Growth Factor Receptor)是跨膜受体酪氨酸激酶ErbB家族中的一员,通过与其配体表皮生长因子(EGF)或转化生长因子α(TGFα)结合激活。激活的EGFR在细胞膜上形成同源二聚体,或与家族中其它受体(如ErbB-2,ErbB-3,或ErbB-4)形成异源二聚体,引起EGFR细胞内关键的酪氨酸残基磷酸化,从而激活细胞内下游信号通路,在细胞增殖、生存及抗凋亡中起重要作用。EGFR的激活突变、过表达或基因扩增等可导致EGFR的过度激活,促进细胞向肿瘤细胞转化,并在肿瘤细胞的增殖、侵袭、转移以及血管形成中起重要作用,是抗癌药物特别是肺癌治疗药物开发的重要靶点。
第一代EGFR小分子抑制剂包括吉非替尼(易瑞沙)和厄洛替尼(特罗凯)在肺癌治疗中显示出良好的疗效,己作为一线药物用于治疗伴随EGFR激活突变(包括L858R和delE746_A750)的非小细胞肺癌(NSCLC)。但经第一代小分子EGFR抑制剂治疗10-12月后,几乎所有的NSCLC患者对第一代小分子抑制剂均产生耐药性,其耐药机制中有半数以上是由于EGFR看门基因残基T790M的继发突变导致。
奥希替尼(Osimertinib或AZD9291)是第三代EGFR TKI抑制剂,针对EGFR T790M突变导致的耐药具有高响应率和良好治疗效果,并于2015年11月获得美国FDA加速批准上市,其在临床上能有效治疗EGFR T790M耐药突变的晚期非小细胞肺癌患者。尽管奥希替尼在临床上治疗EGFR T790M突变的非小细胞肺癌取得了巨大的成功,患者在经过9~14个月治疗后仍不可避免出现了耐药的现象。经研究表明,高达20~40%的耐药患者耐药是由于EGFR C797S突变导致。EGFR C797S突变使797位的半肮氨酸转变为丝氨酸,导致奥希替尼无法与EGFR蛋白形成共价结合健,从而引起耐药。目前临床还没有针对EGFR C797S耐药突变的有效抑制剂。因此,迫切需要开发新型高活性的EGFR抑制剂以解决EGFR C797S突变导致的药物耐药性问题。
诺华公司报道了针对EGFR C797S耐药的化合物EAI0450,属于一种EGFR变构抑制剂,在联合EGFR单抗药物如西妥昔单抗后,对L858R/T790M/C797S突变的小鼠体内药效模型中显示了较好的抗肿瘤效果,但该化合物单药无效且不能抑制含deIE746_A750的C797S耐药突变,未能进入临床研究。2017年Ken Uchibori 等报道了Brigatinib(AP26113)和EGFR单抗(如西妥昔单抗)联用,能克服C797S这个突变导致的第三代EGFR抑制剂耐药,在PC9(EGFR-C797S/T790M/de119)小鼠药效模型显示了良好的抗肿瘤药效,但Brigatinib同样面临单药体外活性低和体内无显著抗肿瘤活性,同样未有进一步临床研究。
肺癌是威胁人类健康的重大疾病,肺癌死亡率己占所有恶性肿瘤首位。在我国,肺癌发病率逐年上升,每年新发病例70万左右。我国肺癌伴有EGFR激活性突变的病例占所有NSCLC约35%左右,使用第一代或第三代EGFR抑制剂能起到良好的治疗效果,但后期都会产生新的耐药突变,因此开发新一代抗耐药的EGFR抑制剂具有巨大的临床和市场价值。
发明内容
专利PCT/CN2020/097362和PCT/CN2020/097369中所涉及的所有内容均以引证的方式添加到本发明中。
本发明的目的在于提供一种通式(I)所示化合物的晶型,
其中:
R
1选自氢、氘、卤素、氨基、硝基、羟基、氰基、烷基、氘代烷基、卤代烷基、烷氧基、烷硫基、卤代烷氧基、环烷基、杂环基、芳基或杂芳基;
R
2选自氢、氘、卤素、氨基、硝基、羟基、氰基、烷基、氘代烷基、卤代烷基、烷氧基、烷硫基、卤代烷氧基、烯基、炔基、环烷基、杂环基、芳基或杂芳基;
或者,任意两个R
2与其连接的碳原子链接形成环烷基或杂环基;
环A选自环烷基、杂环基、芳基或杂芳基;
R
a选自氢、氘、卤素、氨基、硝基、羟基、氰基、烷基、氘代烷基、卤代烷基、羟烷基、氰基烷基、烷氧基、卤代烷氧基、环烷基、杂环基、芳基、杂芳基、-(CH
2)
nOR
aa、-(CH
2)
nNR
aaR
bb、-(CH
2)
nC(O)R
aa或-(CH
2)
nS(O)
mR
aa;
R
aa和R
bb各自独立地选自氢、氘、卤素、氨基、硝基、羟基、氰基、烷基、 氘代烷基、卤代烷基、烷氧基、卤代烷氧基、烯基、炔基、环烷基、杂环基、芳基或杂芳基;
x为0-4的整数;
y为0-4的整数;
t为0-1的整数;
m为0-2的整数;且
n为0-2的整数。
在本发明优选方案中,通式(I)所示化合物的晶型,其中环A选自3-12元杂环基;优选3-8元杂环基;更优选含1-2个N或O原子的3-8元单环杂环基或稠杂环基;进一步优选以下基团:
在本发明优选方案中,通式(I)所示化合物的晶型,其中R
a选自氢、氘、卤素、氨基、硝基、羟基、氰基、C
1-6烷基、C
1-6氘代烷基、C
1-6卤代烷基、C
1-6羟烷基、C
1-6氰基烷基、C
1-6烷氧基、C
1-6卤代烷氧基、-(CH
2)
nOR
aa、-(CH
2)
nNR
aaR
bb、-(CH
2)
nC(O)R
aa或-(CH
2)
nS(O)
mR
aa;
优选氢、氘、卤素、羟基、C
1-3烷基、C
1-3卤代烷基、C
1-3羟烷基、C
1-3氰基烷基、C
1-3烷氧基、-(CH
2)
nOR
aa、-(CH
2)
nNR
aaR
bb、-(CH
2)
nC(O)R
aa或-(CH
2)
nS(O)
mR
aa;
更优选氢、氘、氟、氯、溴、羟基、甲基、乙基、异丙基、-(CH
2)
2F、-CH
2OH、-C(CH
3)
2OH、-CH
2CN、-OCH
2CH
3、-CH
2OCH
3、-C(O)CH
3、-S(O)
2CH
3、-N(CH
3)
2、-NCH
3(CH
2CH
3)或
R
aa和R
bb各自独立地选自氢、氘、卤素、氨基、硝基、羟基、氰基、C
1-6烷基、C
1-6氘代烷基、C
1-6卤代烷基、C
1-6烷氧基、卤代烷氧基、C
2-6烯基、C
2-6炔基、环烷基、杂环基、芳基或杂芳基;
优选氢、甲基、乙基或氧杂环丁基;
x为0-2的整数。
在本发明优选方案中,通式(I)所示化合物的晶型,其中R
1选自氢、氘、卤素、氨基、硝基、羟基、氰基、C
1-6烷基、C
1-6氘代烷基、C
1-6卤代烷基、C
1-6烷氧基或C
1-6烷硫基;
优选氢、氘、卤素、C
1-6烷基、C
1-3卤代烷基或C
1-3烷硫基;
更优选氟、氯、溴、甲基、乙基、异丙基、三氟甲基或甲硫基;
最优选氯、溴、三氟甲基或甲硫基。
在本发明优选方案中,通式(I)所示化合物的晶型,其中R
2选自氢、氘、卤素、氨基、硝基、羟基、氰基、C
1-6烷基、C
1-6氘代烷基、C
1-6卤代烷基、C
1-6烷氧基、C
1-6烷硫基、C
2-6烯基或C
2-6炔基;
优选氢、氘、卤素、C
1-6烷基、C
1-3卤代烷基、C
1-3烷氧基或C
2-4炔基;
更优选氢、氘、氟、氯、溴、甲基、乙基、异丙基、三氟甲基、甲氧基或乙炔基;
最优选氢、氟、甲基、乙基、三氟甲基、甲氧基或乙炔基;
或者,任意两个R
2与其连接的碳原子链接形成3-8元杂环基;优选含1-2个N或O原子的5-6元杂环基;更优选四氢呋喃基;
y为0-3的整数。
在本发明进一步优选的实施方式中,通式(I)所示化合物的晶型,其化合物具体结构如下:
在本发明更优选方案中,提供化合物(6-((5-溴-2-((2-甲氧基-5-甲基-4-(4-((3aR,6aS)-四氢-1H-呋喃并[3,4-c]吡咯-5(3H)-基)哌啶-1-基)苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化;(6-((5-氯-2-((4-(4-(3-(二甲氨基)吖丁啶-1-基)哌啶-1-基)-5-乙基-2-甲氧苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化;
2-(1-(1-(4-((5-溴-4-((5-(二甲基磷基)-2,3-二氢苯并[b][1,4]二噁英-6-基)氨基)嘧啶-2-基)氨基)-5-甲氧基-2-甲基苯基)哌啶-4-基)吖丁啶-3-基)乙酰腈;
(6-((5-溴-2-((2-甲氧基-4-(4-(3-(甲氧基甲基)吖丁啶-1-基)哌啶-1-基)-5-甲基苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[B][1,4]二噁英-5-基)二甲基膦氧化的晶型。
最优选的,为(6-((5-溴-2-((2-甲氧基-4-(4-(3-(甲氧基甲基)吖丁啶-1-基)哌啶-1-基)-5-甲基苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[B][1,4]二噁英-5-基)二甲基膦氧化的晶型H、晶型N、晶型O和晶型I,其中:
在本发明进一步优选的实施方式中,(6-((5-溴-2-((2-甲氧基-4-(4-(3-(甲氧基甲基)吖丁啶-1-基)哌啶-1-基)-5-甲基苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[B][1,4]二噁英-5-基)二甲基膦氧化的晶型H。
晶型H的X-射线粉末衍射图谱在2θ为4.8±0.2°处具有衍射峰;或者在21.7±0.2°处具有衍射峰;或者在24.2±0.2°处具有衍射峰;或者在11.4±0.2°处具有衍射峰;或者在22.9±0.2°处具有衍射峰;或者在23.8±0.2°处具有衍射峰;或者在14.7±0.2°处具有衍射峰;或者在12.9±0.2°处具有衍射峰;或者在26.4±0.2°处具有衍射峰;或者在8.0±0.2°处具有衍射峰;或者在10.8±0.2°处具有衍射峰;或者在24.9±0.2°处具有衍射峰;或者在12.0±0.2°处具有衍射峰;优选包含上述衍射衍射峰中的任意2-5处,或者3-5处,或者3-6处,或者3-8处,或者5-8 处,或者6-8处;更优选包含其中任意6处、7处或8处;
晶型H的X-射线粉末衍射图谱至少包含位于2θ为21.7±0.2°、24.2±0.2°、11.4±0.2°中的一处或多处衍射峰,优选包含其中两条,更优选包含三条;任选的,进一步还可以包含位于2θ为22.9±0.2°、23.8±0.2°、14.7±0.2°、12.9±0.2°、26.4±0.2°中的至少一条,优选包含其中2条、3条、4条或5条;例如,
21.7±0.2°、24.2±0.2°;
24.2±0.2°、11.4±0.2°;
21.7±0.2°、24.2±0.2°、11.4±0.2°;
24.2±0.2°、11.4±0.2°、22.9±0.2°;
21.7±0.2°、24.2±0.2°、11.4±0.2°、22.9±0.2°;
24.2±0.2°、11.4±0.2°、22.9±0.2°、23.8±0.2°;
21.7±0.2°、24.2±0.2°、11.4±0.2°、22.9±0.2°、23.8±0.2°;
24.2±0.2°、11.4±0.2°、22.9±0.2°、23.8±0.2°、14.7±0.2°;
晶型H的X-射线粉末衍射图谱任选还包含位于2θ为21.7±0.2°、24.2±0.2°、11.4±0.2°、22.9±0.2°、23.8±0.2°、14.7±0.2°、12.9±0.2°、26.4±0.2°、8.0±0.2°、10.8±0.2°处具有衍射峰中的一处或多处衍射峰;优选至少包含其中任意2-3处,或者4-5处,或者6-7处;进一步优选,包含其中任意2处、3处、4处、5处、6处、7处;例如,
21.7±0.2°、24.2±0.2°、11.4±0.2°、22.9±0.2°、23.8±0.2°、14.7±0.2°;
24.2±0.2°、11.4±0.2°、22.9±0.2°、23.8±0.2°、14.7±0.2°、12.9±0.2°;
21.7±0.2°、24.2±0.2°、11.4±0.2°、22.9±0.2°、23.8±0.2°、14.7±0.2°、12.9±0.2°、26.4±0.2°;
24.2±0.2°、11.4±0.2°、22.9±0.2°、23.8±0.2°、14.7±0.2°、12.9±0.2°、26.4±0.2°、8.0±0.2°;
24.2±0.2°、11.4±0.2°、22.9±0.2°、23.8±0.2°、14.7±0.2°、12.9±0.2°、26.4±0.2°、4.8±0.2°;
晶型H的X-射线粉末衍射图谱包含位于2θ为21.7±0.2°、24.2±0.2°、11.4±0.2°、22.9±0.2°、23.8±0.2°、14.7±0.2°、12.9±0.2°、26.4±0.2°、8.0±0.2°、10.8±0.2°、24.9±0.2°、12.0±0.2°、32.5±0.2°、31.3±0.2°、17.0±0.2°、4.8±0.2°中的一处或多处衍射峰,优选的,包含其中任选的4处、5处、6处、8处或10处有衍射峰;例如,
21.7±0.2°、22.9±0.2°、23.8±0.2°、14.7±0.2°;
24.2±0.2°、23.8±0.2°、14.7±0.2°、12.9±0.2°;
11.4±0.2°、12.9±0.2°、26.4±0.2°、8.0±0.2°、10.8±0.2°;
22.9±0.2°、8.0±0.2°、10.8±0.2°、24.9±0.2°、32.5±0.2°;
11.4±0.2°、22.9±0.2°、23.8±0.2°、14.7±0.2°、12.9±0.2°、26.4±0.2°;
22.9±0.2°、23.8±0.2°、14.7±0.2°、12.9±0.2°、26.4±0.2°、8.0±0.2°;
21.7±0.2°、22.9±0.2°、23.8±0.2°、14.7±0.2°、12.9±0.2°、26.4±0.2°、8.0±0.2°、10.8±0.2°;
24.2±0.2°、23.8±0.2°、14.7±0.2°、12.9±0.2°、26.4±0.2°、8.0±0.2°、10.8±0.2°、24.9±0.2°;
11.4±0.2°、22.9±0.2°、23.8±0.2°、14.7±0.2°、12.9±0.2°、26.4±0.2°、8.0±0.2°、10.8±0.2°、24.9±0.2°、12.0±0.2°;
21.7±0.2°、23.8±0.2°、14.7±0.2°、12.9±0.2°、26.4±0.2°、8.0±0.2°、10.8±0.2°、24.9±0.2°、12.0±0.2°、32.5±0.2°;
使用Cu-Kα辐射,以2θ角和晶面间距d值表示的X-射线特征衍射峰如表1所示。
表1
本发明(6-((5-溴-2-((2-甲氧基-4-(4-(3-(甲氧基甲基)吖丁啶-1-基)哌啶-1-基)-5-甲基苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[B][1,4]二噁英-5-基)二甲基膦氧化的晶型H,其X-射线粉末衍射图谱基本如图1所示;其DSC图谱基本如图2所示;其TGA图谱基本如图3所示。
在本发明进一步优选的实施方式中,(6-((5-溴-2-((2-甲氧基-4-(4-(3-(甲氧基甲基)吖丁啶-1-基)哌啶-1-基)-5-甲基苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[B][1,4]二噁英-5-基)二甲基膦氧化的晶型N。
晶型N的X-射线粉末衍射图谱在2θ为6.7±0.2°处具有衍射峰;或者在8.5±0.2°处具有衍射峰;或者在9.0±0.2°处具有衍射峰;或者在18.7±0.2°处具有衍射峰;或者在21.8±0.2°处具有衍射峰;或者在12.3±0.2°处具有衍射峰;或者在12.7±0.2°处具有衍射峰;或者在14.5±0.2°处具有衍射峰;或者在15.0±0.2°处具有衍射峰;或者在22.3±0.2°处具有衍射峰;或者在18.5±0.2°处具有衍射峰;或者在24.6±0.2°处具有衍射峰;优选包含上述衍射衍射峰中的任意2-5处,或者3-5处,或者3-6处,或者3-8处,或者5-8处,或者6-8处;更优选包含其中任意6处、7处或8处;
晶型N的X-射线粉末衍射图谱至少包含位于2θ为6.7±0.2°、8.5±0.2°、9.0±0.2°中的一处或多处衍射峰,优选包含其中两条,更优选包含三条;任选的,进一步还可以包含位于2θ为18.7±0.2°、21.8±0.2°、12.3±0.2°、12.7±0.2°、14.5±0.2°中的至少一条,优选包含其中2条、3条、4条或5条;例如,
6.7±0.2°、8.5±0.2°;
9.0±0.2°、18.7±0.2°;
6.7±0.2°、8.5±0.2°、9.0±0.2°;
9.0±0.2°、18.7±0.2°、21.8±0.2°;
6.7±0.2°、8.5±0.2°、9.0±0.2°、18.7±0.2°;
9.0±0.2°、18.7±0.2°、21.8±0.2°、12.3±0.2°;
6.7±0.2°、8.5±0.2°、9.0±0.2°、18.7±0.2°、21.8±0.2°;
9.0±0.2°、18.7±0.2°、21.9±0.2°、12.3±0.2°、12.7±0.2°;
晶型N的X-射线粉末衍射图谱任选还包含位于2θ为6.7±0.2°、8.5±0.2°、9.0±0.2°、18.7±0.2°、21.8±0.2°、12.3±0.2°、12.7±0.2°、14.5±0.2°、15.0±0.2°、22.3±0.2°处具有衍射峰中的一处或多处衍射峰;优选至少包含其中任意2-3处,或者4-5处,或者6-7处;进一步优选,包含其中任意2处、3处、4处、5处、6处、7处;例如,
6.7±0.2°、8.5±0.2°、9.0±0.2°、18.7±0.2°、21.8±0.2°、12.3±0.2°;
9.0±0.2°、18.7±0.2°、21.8±0.2°、12.3±0.2°、12.7±0.2°、14.5±0.2°;
9.0±0.2°、18.7±0.2°、21.8±0.2°、12.3±0.2°、12.7±0.2°、14.5±0.2°、15.0±0.2°;
18.7±0.2°、21.8±0.2°、12.3±0.2°、12.7±0.2°、14.5±0.2°、15.0±0.2°、22.3±0.2°;
6.7±0.2°、8.5±0.2°、9.0±0.2°、18.7±0.2°、21.8±0.2°、12.3±0.2°、12.7±0.2°、14.5±0.2°;
8.5±0.2°、9.0±0.2°、18.7±0.2°、21.8±0.2°、12.3±0.2°、12.7±0.2°、14.5±0.2°、15.0±0.2°;
6.7±0.2°、9.0±0.2°、18.7±0.2°、21.8±0.2°、12.3±0.2°、12.7±0.2°、14.5±0.2°、15.0±0.2°;
9.0±0.2°、18.7±0.2°、21.8±0.2°、12.3±0.2°、12.7±0.2°、14.5±0.2°、15.0±0.2°、22.3±0.2°;
6.7±0.2°、8.5±0.2°、9.0±0.2°、21.8±0.2°、12.3±0.2°、12.7±0.2°、14.5±0.2°、15.0±0.2°;
晶型N的X-射线粉末衍射图谱包含位于2θ为6.7±0.2°、8.5±0.2°、9.0±0.2°、18.7±0.2°、21.8±0.2°、12.3±0.2°、12.7±0.2°、14.5±0.2°、15.0±0.2°、22.3±0.2°、18.5±0.2°、24.6±0.2°、18.0±0.2°、23.7±0.2°、17.8±0.2°中的一处或多处衍射峰,优选的,包含其中任选的4处、5处、6处、8处或10处有衍射峰;例如,
6.7±0.2°、18.7±0.2°、21.8±0.2°、12.3±0.2°;
8.5±0.2°、21.8±0.2°、12.3±0.2°、12.7±0.2°;
6.7±0.2°、18.7±0.2°、21.8±0.2°、12.3±0.2°、12.7±0.2°、14.5±0.2°;
8.5±0.2°、21.8±0.2°、12.3±0.2°、12.7±0.2°、14.5±0.2°、15.0±0.2°;
6.7±0.2°、18.7±0.2°、21.8±0.2°、12.3±0.2°、12.7±0.2°、14.5±0.2°、15.0±0.2°、22.3±0.2°;
8.5±0.2°、21.8±0.2°、12.3±0.2°、12.7±0.2°、14.5±0.2°、15.0±0.2°、22.3±0.2°、18.5±0.2°;
18.7±0.2°、12.7±0.2°、14.5±0.2°、15.0±0.2°、22.3±0.2°、18.5±0.2°、24.6±0.2°、18.0±0.2°;
21.8±0.2°、14.5±0.2°、15.0±0.2°、22.3±0.2°、18.5±0.2°、24.6±0.2°、18.0±0.2°、23.7±0.2°;
6.7±0.2°、18.7±0.2°、21.8±0.2°、12.3±0.2°、12.7±0.2°、14.5±0.2°、15.0±0.2°、22.3±0.2°、18.5±0.2°、24.6±0.2°;
8.5±0.2°、21.9±0.2°、12.3±0.2°、12.7±0.2°、14.5±0.2°、15.0±0.2°、22.3±0.2°、18.5±0.2°、24.6±0.2°、18.0±0.2°;
18.7±0.2°、6.7±0.2°、18.7±0.2°、21.8±0.2°、12.3±0.2°、12.7±0.2°、14.5±0.2°、15.0±0.2°、22.3±0.2°、18.5±0.2°;
21.8±0.2°、9.0±0.2°、18.7±0.2°、21.8±0.2°、12.3±0.2°、12.7±0.2°、14.5±0.2°、15.0±0.2°、22.3±0.2°、18.5±0.2°;
晶型N的X-射线粉末衍射图谱包含位于2θ为6.7±0.2°、8.5±0.2°、10.8±0.2°、9.0±0.2°、18.7±0.2°、21.8±0.2°、12.3±0.2°、12.7±0.2°、13.7±0.2°、14.5±0.2°、15.0±0.2°、20.1±0.2°、21.4±0.2°、21.9±0.2°、22.3±0.2°、18.5±0.2°、24.6±0.2°、18.0±0.2°、23.7±0.2°、17.8±0.2°中的一处或多处衍射峰。
本发明(6-((5-溴-2-((2-甲氧基-4-(4-(3-(甲氧基甲基)吖丁啶-1-基)哌啶-1-基)-5-甲基苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[B][1,4]二噁英-5-基)二甲基 膦氧化的晶型N,其X-射线粉末衍射图谱基本如图4所示;其DSC图谱基本如图5所示,其TGA图谱基本如图6所示。
在本发明进一步优选的实施方式中,(6-((5-溴-2-((2-甲氧基-4-(4-(3-(甲氧基甲基)吖丁啶-1-基)哌啶-1-基)-5-甲基苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[B][1,4]二噁英-5-基)二甲基膦氧化的晶型O。
晶型O的X-射线粉末衍射图谱在2θ为5.0±0.2°处具有衍射峰;或者在6.2±0.2°处具有衍射峰;或者在7.2±0.2°处具有衍射峰;或者在8.7±0.2°处具有衍射峰;或者在12.9±0.2°处具有衍射峰;或者在17.3±0.2°处具有衍射峰;或者在17.9±0.2°处具有衍射峰;或者在20.4±0.2°处具有衍射峰;或者在14.4±0.2°处具有衍射峰;或者在12.4±0.2°处具有衍射峰;或者在19.7±0.2°处具有衍射峰;或者在18.7±0.2°处具有衍射峰;优选包含上述衍射衍射峰中的任意2-5处,或者3-5处,或者3-6处,或者3-8处,或者5-8处,或者6-8处;更优选包含其中任意6处、7处或8处;
晶型O的X-射线粉末衍射图谱至少包含位于2θ为5.0±0.2°、6.2±0.2°、7.2±0.2°中的一处或多处衍射峰,优选包含其中两条,更优选包含三条;任选的,进一步还可以包含位于2θ为8.7±0.2°、12.9±0.2°、17.3±0.2°、17.9±0.2°、20.4±0.2°中的至少一条,优选包含其中2条、3条、4条或5条;例如,
5.0±0.2°、6.2±0.2°;
6.2±0.2°、7.2±0.2°;
5.0±0.2°、6.2±0.2°、7.2±0.2°;
6.2±0.2°、7.2±0.2°、8.7±0.2°;
5.0±0.2°、6.2±0.2°、7.2±0.2°、8.7±0.2°;
6.2±0.2°、7.2±0.2°、8.7±0.2°、12.9±0.2°;
5.0±0.2°、6.2±0.2°、7.2±0.2°、8.7±0.2°、12.9±0.2°;
6.2±0.2°、7.2±0.2°、8.7±0.2°、12.9±0.2°、17.3±0.2°;
晶型O的X-射线粉末衍射图谱任选还包含位于2θ为5.0±0.2°、6.1±0.2°、7.2±0.2°、8.7±0.2°、12.9±0.2°、17.3±0.2°、17.9±0.2°、20.4±0.2°、14.4±0.2°、12.4±0.2°处具有衍射峰中的一处或多处衍射峰;优选至少包含其中任意2-3处,或者4-5处,或者6-7处;进一步优选,包含其中任意2处、3处、4处、5处、6处、7处;例如,
5.0±0.2°、7.2±0.2°、8.7±0.2°、12.9±0.2°、17.3±0.2°;
7.2±0.2°、8.7±0.2°、12.9±0.2°、17.3±0.2°、17.9±0.2°;
8.7±0.2°、12.9±0.2°、17.3±0.2°、17.9±0.2°、20.4±0.2°;
5.0±0.2°、6.2±0.2°、7.2±0.2°、8.7±0.2°、12.9±0.2°、17.3±0.2°、17.9±0.2°、20.4±0.2°;
6.2±0.2°、7.2±0.2°、8.7±0.2°、12.9±0.2°、17.3±0.2°、17.9±0.2°、20.4±0.2°、 14.4±0.2°;
晶型O的X-射线粉末衍射图谱包含位于2θ为5.0±0.2°、6.1±0.2°、7.2±0.2°、8.7±0.2°、12.9±0.2°、17.3±0.2°、17.9±0.2°、20.4±0.2°、14.4±0.2°、12.4±0.2°、19.7±0.2°、18.7±0.2°、24.9±0.2°、20.1±0.2°、24.9±0.2°中的一处或多处衍射峰,优选的,包含其中任选的4处、5处、6处、8处或10处有衍射峰;例如,
5.0±0.2°、8.7±0.2°、12.9±0.2°、17.3±0.2°;
6.1±0.2°、12.9±0.2°、17.3±0.2°、17.9±0.2°;
5.0±0.2°、8.7±0.2°、12.9±0.2°、17.3±0.2°、17.9±0.2°、20.4±0.2°;
6.1±0.2°、12.9±0.2°、17.3±0.2°、17.9±0.2°、20.4±0.2°、14.4±0.2°;
5.0±0.2°、8.7±0.2°、12.9±0.2°、17.3±0.2°、17.9±0.2°、20.4±0.2°、14.4±0.2°、12.4±0.2°;
6.1±0.2°、12.9±0.2°、17.3±0.2°、17.9±0.2°、20.4±0.2°、14.4±0.2°、12.4±0.2°、19.7±0.2°;
5.0±0.2°、8.7±0.2°、12.9±0.2°、17.3±0.2°、17.9±0.2°、20.4±0.2°、14.4±0.2°、12.4±0.2°、19.7±0.2°、18.7±0.2°;
6.1±0.2°、12.9±0.2°、17.3±0.2°、17.9±0.2°、20.4±0.2°、14.4±0.2°、12.4±0.2°、19.7±0.2°、18.7±0.2°、24.9±0.2。
本发明(6-((5-溴-2-((2-甲氧基-4-(4-(3-(甲氧基甲基)吖丁啶-1-基)哌啶-1-基)-5-甲基苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[B][1,4]二噁英-5-基)二甲基膦氧化的晶型O,其X-射线粉末衍射图谱基本如图7所示;其DSC图谱基本如图8所示。在本发明进一步优选的实施方式中,(6-((5-溴-2-((2-甲氧基-4-(4-(3-(甲氧基甲基)吖丁啶-1-基)哌啶-1-基)-5-甲基苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[B][1,4]二噁英-5-基)二甲基膦氧化的晶型I。
晶型I的X-射线粉末衍射图谱在2θ为20.8±0.2°处具有衍射峰;或者在13.7±0.2°处具有衍射峰;或者在12.7±0.2°处具有衍射峰;或者在14.4±0.2°处具有衍射峰;或者在17.2±0.2°处具有衍射峰;或者在11.3±0.2°处具有衍射峰;或者在20.2±0.2°处具有衍射峰;或者在25.1±0.2°处具有衍射峰;或者在22.5±0.2°处具有衍射峰;或者在14.6±0.2°处具有衍射峰;或者在22.2±0.2°处具有衍射峰;或者在26.0±0.2°处具有衍射峰;优选包含上述衍射衍射峰中的任意2-5处,或者3-5处,或者3-6处,或者3-8处,或者5-8处,或者6-8处;更优选包含其中任意6处、7处或8处;
晶型I的X-射线粉末衍射图谱至少包含位于2θ为20.8±0.2°、13.7±0.2°、12.7±0.2°中的一处或多处衍射峰,优选包含其中两条,更优选包含三条;任选的,进一步还可以包含位于2θ为14.4±0.2°、17.2±0.2°、11.3±0.2°、20.2±0.2°、25.1±0.2°中的至少一条,优选包含其中2条、3条、4条或5条;例如,
20.8±0.2°、13.7±0.2°;
13.7±0.2°、12.7±0.2°;
20.8±0.2°、13.7±0.2°、12.7±0.2°;
13.7±0.2°、12.7±0.2°、14.4±0.2°;
20.8±0.2°、13.7±0.2°、12.7±0.2°、14.4±0.2°;
13.7±0.2°、12.7±0.2°、14.4±0.2°、17.2±0.2°;
20.8±0.2°、13.7±0.2°、12.7±0.2°、14.4±0.2°、17.2±0.2°;
13.7±0.2°、12.7±0.2°、14.4±0.2°、17.2±0.2°、11.3±0.2°;
晶型I的X-射线粉末衍射图谱任选还包含位于2θ为20.8±0.2°、13.7±0.2°、12.7±0.2°、14.4±0.2°、17.2±0.2°、11.3±0.2°、20.2±0.2°、25.1±0.2°、22.5±0.2°处具有衍射峰中的一处或多处衍射峰;优选至少包含其中任意2-3处,或者4-5处,或者6-7处;进一步优选,包含其中任意2处、3处、4处、5处、6处、7处;例如,
20.8±0.2°、13.7±0.2°、12.7±0.2°、14.4±0.2°、17.2±0.2°、11.3±0.2°;
13.7±0.2°、12.7±0.2°、14.4±0.2°、17.2±0.2°、11.3±0.2°、20.2±0.2°;
20.8±0.2°、13.7±0.2°、12.7±0.2°、14.4±0.2°、17.2±0.2°、11.3±0.2°、20.2±0.2°;
13.7±0.2°、12.7±0.2°、14.4±0.2°、17.2±0.2°、11.3±0.2°、20.2±0.2°、25.1±0.2°;
晶型I的X-射线粉末衍射图谱包含位于2θ为20.8±0.2°、13.7±0.2°、12.7±0.2°、14.4±0.2°、17.2±0.2°、11.3±0.2°、20.2±0.2°、25.1±0.2°、22.5±0.2°、14.6±0.2°、22.2±0.2°、26.0±0.2°、23.4±0.2°、17.6±0.2°、8.5±0.2°中的一处或多处衍射峰,优选的,包含其中任选的4处、5处、6处、8处或10处有衍射峰;例如,
20.8±0.2°、14.4±0.2°、17.2±0.2°、11.3±0.2°;
13.7±0.2°、17.2±0.2°、11.3±0.2°、20.2±0.2°;
12.7±0.2°、11.3±0.2°、20.2±0.2°、25.1±0.2°、22.5±0.2°;
20.8±0.2°、20.2±0.2°、25.1±0.2°、22.5±0.2°、14.6±0.2°;
12.7±0.2°、14.4±0.2°、17.2±0.2°、11.3±0.2°、20.2±0.2°、25.1±0.2°;
20.8±0.2°、17.2±0.2°、11.3±0.2°、20.2±0.2°、25.1±0.2°、22.5±0.2°;
13.7±0.2°、14.4±0.2°、17.2±0.2°、11.3±0.2°、20.2±0.2°、25.1±0.2°、22.5±0.2°、14.6±0.2°;
12.7±0.2°、17.2±0.2°、11.3±0.2°、20.2±0.2°、25.1±0.2°、22.5±0.2°、14.6±0.2°、22.2±0.2°;
14.4±0.2°、17.2±0.2°、11.3±0.2°、20.2±0.2°、25.1±0.2°、22.5±0.2°、14.6±0.2°、22.2±0.2°、26.0±0.2°、8.5±0.2°;
17.2±0.2°、11.3±0.2°、20.2±0.2°、25.1±0.2°、22.5±0.2°、14.6±0.2°、22.2±0.2°、26.0±0.2°、23.4±0.2°、17.6±0.2°;
使用Cu-Kα辐射,以2θ角和晶面间距d值表示的X-射线特征衍射峰如表2所示。
表2
本发明(6-((5-溴-2-((2-甲氧基-4-(4-(3-(甲氧基甲基)吖丁啶-1-基)哌啶-1-基)-5-甲基苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[B][1,4]二噁英-5-基)二甲基膦氧化的晶型I,其X-射线粉末衍射图谱基本如图9所示;其DSC图谱基本如图10所示。
在本发明进一步优选的方案中,所述晶型为无水物或水合物;当晶型为水合物时,水的个数为0.2-3,优选0.2、0.5、1、1.5、2、2.5或3,更优选0.5、1、2或3;优选地,晶型为无水物。
在本发明进一步优选方案中,晶型H、晶型N、晶型O和晶型I的X-射线粉末衍射图谱中相对峰强度为前十强的衍射峰位置分别与图1、图4、图7和图9对应位置衍射峰的2θ误差为±0.2°~±0.5°,优先±0.2°~±0.3°,最优选±0.2°。
在本发明进一步优选方案中,通式(I)所示化合物晶型的制备方法,包括如下步骤:
1)称取适量的自由碱,用良溶剂加热溶解;
2)向以上所得溶液中滴加不良溶剂;
3)将以上混悬液冷却,去除上清液,剩余固体干燥得到目标产物;
其中:
所述的良性溶剂选自甲醇、乙醇、丙酮、仲戊醇、正丁醇、正辛醇、正己醇、乙酸乙酯、乙腈、乙醇、88%丙酮、四氢呋喃、二氯甲烷、1,4-二氧六环、苯、甲苯、异丙醇、正丁醇、异丁醇、N,N-二甲基甲酰胺、N,N-二甲基乙酰胺、正丙醇、叔丁醇、2-丁酮或3-戊酮;优选甲醇、乙醇、丙酮、仲戊醇、正丁醇、正辛醇或正己醇。
所述的不良溶剂选自庚烷、水、甲基叔丁基醚、甲苯、异丙醚。
在本发明进一步优选方案中,通式(I)所示化合物晶型的制备方法,包括如下步骤:
1)称取适量的自由碱,用不良溶剂混悬;
2)将混悬液振摇;
3)将混悬液快速离心,去除上清液,剩余固体干燥得到目标产物;
其中:
所述的不良性溶剂选自丙酮、乙酸乙酯、醋酸异丙酯、乙腈、乙醇、88%丙酮、四氢呋喃、2-甲基四氢呋喃、二氯甲烷、1,4-二氧六环、苯、甲苯、异丙醇、正丁醇、异丁醇、N,N-二甲基甲酰胺、N,N-二甲基乙酰胺、正丙醇、叔丁醇、2-丁酮或3-戊酮、甲基叔丁基醚、水;优选丙酮、乙酸乙酯、醋酸异丙酯、乙腈、乙醇、88%丙酮、四氢呋喃、2-甲基四氢呋喃、二氯甲烷、1,4-二氧六环、甲苯、异丙醇、2-丁酮、3-戊酮、甲基叔丁基醚或水。
在本发明进一步优选方案中,通式(I)所示化合物晶型的制备方法,包括如下步骤:
1)称取适量的自由碱,用不良溶剂混悬,悬浮密度优选为50~200mg/mL;
2)以上所得混悬液振摇,温度优选0~60℃,时间优选0~10天;
3)将以上混悬液快速离心,去除上清液,剩余固体干燥得到目标产物;
其中:
所述的不良性溶剂选自丙酮、乙酸乙酯、醋酸异丙酯、乙腈、乙醇、88%丙酮、四氢呋喃、2-甲基四氢呋喃、二氯甲烷、1,4-二氧六环、苯、甲苯、异丙醇、正丁醇、异丁醇、N,N-二甲基甲酰胺、N,N-二甲基乙酰胺、正丙醇、叔丁醇、2-丁酮或3-戊酮、甲基叔丁基醚、水;优选丙酮、乙酸乙酯、醋酸异丙酯、乙腈、乙醇、88%丙酮、四氢呋喃、2-甲基四氢呋喃、二氯甲烷、1,4-二氧六环、、甲苯、异丙醇、2-丁酮、3-戊酮、甲基叔丁基醚或水。
本发明的目的还在于提供了所述的通式(I)所示化合物(6-((5-溴-2-((2-甲氧基-4-(4-(3-(甲氧基甲基)吖丁啶-1-基)哌啶-1-基)-5-甲基苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[B][1,4]二噁英-5-基)二甲基膦氧化的晶型,以及药物组合物在制备激酶抑制剂药物中的应用。
所述激酶抑制剂为MEK抑制剂;
所述激酶抑制剂为受体酪氨酸激酶抑制剂,优选HER2抑制剂、EGFR抑制剂和EGFR单抗及其联用相关药物,更优选HER2 20外显子突变体抑制剂、EGFR20外显子突变体抑制剂和EGFR20外显子突变体单抗及其联用相关药物。
本发明的目的在于提供了所述的通式(I)所示化合物的晶型以及所述的药物组合物在治疗癌症、炎症、慢性肝病、糖尿病、心血管疾病和AIDS相关疾病药物中的应用,优选地,所述癌症、炎症、慢性肝病、糖尿病、心血管疾病和AIDS相关疾病是由HER2 20外显子突变和/或EGFR20外显子突变介导的疾病。
本发明的目的还在于提供了所述的通式(I)所示化合物(6-((5-溴-2-((2-甲氧基-4-(4-(3-(甲氧基甲基)吖丁啶-1-基)哌啶-1-基)-5-甲基苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[B][1,4]二噁英-5-基)二甲基膦氧化的晶型以及所述的药物组合物在治疗癌症、炎症、慢性肝病、糖尿病、心血管疾病和AIDS相关疾病药物中的应用,优选地,所述癌症、炎症、慢性肝病、糖尿病、心血管疾病和AIDS相关疾病是由HER2 20外显子突变和/或EGFR20外显子突变介导的疾病。
所述的癌症选自乳腺癌、宫颈癌、结肠癌、肺癌、胃癌、直肠癌、胰腺癌、脑癌、肝癌、实体瘤、神经胶质瘤、神经胶母细胞瘤、白血病、淋巴瘤、骨髓瘤和非小细胞肺癌。
第三代EGFR抑制剂主要是针对EGFR激活突变体和T790M耐药性突变体抑制性高,本发明的化合物在EGFR和/或HER2 20外显子插入突变靶点方面较第三代EGFR抑制剂表现出以下显著优势:
1、显著提高Ba/F3 EGFR突变细胞株抑制活性,优选化合物的活性高10倍以上,甚至20倍;
2、提高在Ba/F3 EGFR突变细胞株和A431细胞株增殖抑制活性的选择性,优选化合物高3倍以上,甚至10倍;
3、在小鼠原B细胞Ba/F3 EGFR-D770-N771ins_SVD移植瘤模型上的体内药效肿瘤抑瘤率上也表现出显著性优势。
发明的详细说明
除非有相反陈述,在说明书和权利要求书中使用的术语具有下述含义。
术语“烷基”指饱和脂肪族烃基团,其为包含1至20个碳原子的直链或支链基团,优选含有1至8个碳原子的烷基,更优选1至6个碳原子的烷基,最更优选1至3个碳原子的烷基。非限制性实例包括甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、仲丁基、正戊基、1,1-二甲基丙基、1,2-二甲基丙基、2,2-二甲基丙基、1-乙基丙基、2-甲基丁基、3-甲基丁基、正己基、1-乙基-2-甲基丙基、1,1,2-三甲基丙基、1,1-二甲基丁基、1,2-二甲基丁基、2,2-二甲基丁基、1,3-二甲基丁基、2-乙基丁基、2-甲基戊基、3-甲基戊基、4-甲基戊基、2,3-二甲基丁基、正庚基、2-甲基己基、3-甲基己基、4-甲基己基、5-甲基己基、2,3-二甲基戊基、2,4-二甲基戊基、2,2-二甲基戊基、3,3-二甲基戊基、2-乙基戊基、3-乙基戊 基、正辛基、2,3-二甲基己基、2,4-二甲基己基、2,5-二甲基己基、2,2-二甲基己基、3,3-二甲基己基、4,4-二甲基己基、2-乙基己基、3-乙基己基、4-乙基己基、2-甲基-2-乙基戊基、2-甲基-3-乙基戊基、正壬基、2-甲基-2-乙基己基、2-甲基-3-乙基己基、2,2-二乙基戊基、正癸基、3,3-二乙基己基、2,2-二乙基己基,及其各种支链异构体等。更优选的是含有1至6个碳原子的低级烷基,非限制性实施例包括甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、仲丁基、正戊基、1,1-二甲基丙基、1,2-二甲基丙基、2,2-二甲基丙基、1-乙基丙基、2-甲基丁基、3-甲基丁基、正己基、1-乙基-2-甲基丙基、1,1,2-三甲基丙基、1,1-二甲基丁基、1,2-二甲基丁基、2,2-二甲基丁基、1,3-二甲基丁基、2-乙基丁基、2-甲基戊基、3-甲基戊基、4-甲基戊基、2,3-二甲基丁基等。烷基可以是取代的或非取代的,当被取代时,取代基可以在任何可使用的连接点上被取代,所述取代基优选为一个或多个以下基团,其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、氧代基、羧基或羧酸酯基,本发明优选甲基、乙基、异丙基、叔丁基、卤代烷基、氘代烷基、烷氧基取代的烷基和羟基取代的烷基。
术语“亚烷基”是指烷基的一个氢原子进一步被取代,例如:“亚甲基”指-CH
2-、“亚乙基”指-(CH
2)
2-、“亚丙基”指-(CH
2)
3-、“亚丁基”指-(CH
2)
4-等。术语“烯基”指由至少由两个碳原子和至少一个碳-碳双键组成的如上定义的烷基,例如乙烯基、1-丙烯基、2-丙烯基、1-、2-或3-丁烯基等。烯基可以是取代的或非取代的,当被取代时,取代基优选为一个或多个以下基团,其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基。
术语“环烷基”指饱和或部分不饱和单环或多环环状烃取代基,环烷基环包含3至20个碳原子,优选包含3至12个碳原子,更优选包含3至8个碳原子,最优选包含3至6个碳原子。单环环烷基的非限制性实例包括环丙基、环丁基、环戊基、环戊烯基、环己基、环己烯基、环己二烯基、环庚基、环庚三烯基、环辛基等;多环环烷基包括螺环、稠环和桥环的环烷基,优选环丙基、环丁基、环己基、环戊基和环庚基。
术语“杂环基”指饱和或部分不饱和单环或多环环状烃取代基,其包含3至20个环原子,其中一个或多个环原子为选自氮、氧或S(O)
m(其中m是整数0至2)的杂原子,但不包括-O-O-、-O-S-或-S-S-的环部分,其余环原子为碳。优选包含3至12个环原子,其中1~4个是杂原子;更优选包含3至8个环原子;最优选包含3至6个环原子。
单环杂环基的非限制性实例包括氧杂环丁烷基、硫杂环丁烷基、吡咯烷基、吡咯烷酮基、咪唑烷基、四氢呋喃基、四氢噻吩基、二氢咪唑基、二氢呋喃基、 二氢吡唑基、二氢吡咯基、哌啶基、哌嗪基、吗啉基、硫代吗啉基、高哌嗪基、吡喃基等,优选氧杂环丁烷基、吡咯烷酮基、四氢呋喃基、吡唑烷基、吗啉基、哌嗪基和吡喃基。多环杂环基包括螺环、稠环和桥环的杂环基;其中涉及到的螺环、稠环和桥环的杂环基任选与其他基团通过单键相连接,或者通过环上的任意两个或者两个以上的原子与其他环烷基、杂环基、芳基和杂芳基进一步并环连接。
术语“稠杂环基”指5至20元,系统中的每个环与体系中的其他环共享毗邻的一对原子的多环杂环基团,一个或多个环可以含有一个或多个双键,但没有一个环具有完全共轭的π电子系统,其中一个或多个环原子为选自氮、氧或S(O)
m(其中m是整数0至2)的杂原子,其余环原子为碳。优选为6至14元,更优选为7至10元。根据组成环的数目可以分为双环、三环、四环或多环稠杂环基,优选为双环或三环,更优选为5元/5元或5元/6元双环稠杂环基。稠杂环基的非限制性实例包括:
杂环基可以是任选取代的或非取代的,当被取代时,取代基优选为一个或多个以下基团,其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、氧代基、羧基或羧酸酯基。
术语“芳基”指具有共轭的π电子体系的6至14元全碳单环或稠合多环(也就是共享毗邻碳原子对的环)基团,优选为6至10元,例如苯基和萘基。更优选苯基。所述芳基环可以稠合于杂芳基、杂环基或环烷基环上,包括苯并3-8元环烷基、苯并3-8元杂烷基,优选苯并3-6元环烷基、苯并3-6元杂烷基,其中杂环基为含1-3氮原子、氧原子、硫原子的杂环基;或者还包含含苯环的三元含氮稠环,其中与母体结构连接在一起的环为芳基环。
其非限制性实例包括:
芳基可以是取代的或非取代的,当被取代时,取代基优选为一个或多个以下基团,其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、羧基或羧酸酯基。
术语“杂芳基”指包含1至4个杂原子、5至14个环原子的杂芳族体系,其中杂原子选自氧、硫和氮。杂芳基优选为5至10元,更优选为5元或6元,例如咪唑基、呋喃基、噻吩基、噻唑基、吡唑基、噁唑基、吡咯基、三唑基、四唑基、吡啶基、嘧啶基、噻二唑、吡嗪基等,优选为三唑基、噻吩基、咪唑基、吡唑基、噁唑基、嘧啶基或噻唑基;更有选吡唑基和噁唑基。所述杂芳基环可以稠合于芳基、杂环基或环烷基环上,其中与母体结构连接在一起的环为杂芳基环。
其非限制性实例包括:
术语“烷氧基”指-O-(烷基)和-O-(非取代的环烷基),其中烷基的定义如上所述。烷氧基的非限制性实例包括:甲氧基、乙氧基、丙氧基、丁氧基、环丙氧基、环丁氧基、环戊氧基、环己氧基。烷氧基可以是任选取代的或非取代的,当被取代时,取代基优选为一个或多个以下基团,其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、羧基或羧酸酯基。
术语“烷硫基”指-S-(烷基)和-S-(非取代的环烷基),其中烷基的定义如上所述。 优选含有1至8个碳原子的烷基,更优选1至6个碳原子的烷基,最更优选1至3个碳原子的烷基。烷氧基的非限制性实例包括:甲硫基、乙硫基、丙硫基、丁硫基。烷硫基可以是任选取代的或非取代的,当被取代时,取代基优选为一个或多个以下基团,其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、羧基或羧酸酯基。
“卤代烷基”指被一个或多个卤素取代的烷基,其中烷基如上所定义。
“羟烷基”指被一个或多个羟基取代的烷基,其中烷基如上所定义。
“氰基烷基”指被一个或多个氰基取代的烷基,其中烷基如上所定义。
“卤代烷氧基”指被一个或多个卤素取代的烷氧基,其中烷氧基如上所定义。
“烯基”指链烯基,又称烯烃基,优选含有2至8个碳原子的烷基,更优选2至6个碳原子的烷基,最更优选2至3个碳原子的烷基。其中所述的烯基可以进一步被其他相关基团取代,例如:烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、羧基或羧酸酯基。
“炔基”指(CH≡C-),优选含有2至8个碳原子的烷基,更优选2至6个碳原子的烷基,最更优选2至3个碳原子的烷基。其中所述的炔基可以进一步被其他相关基团取代,例如:烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、羧基或羧酸酯基。
“羟基”指-OH基团。
“卤素”指氟、氯、溴或碘。
“氨基”指-NH
2。
“氰基”指-CN。
“硝基”指-NO
2。
“羧基”指-C(O)OH。
“THF”指四氢呋喃。
“EtOAc”指乙酸乙酯。
“MeOH”指甲醇。
“DMF”指N、N-二甲基甲酰胺。
“DIPEA”指二异丙基乙胺。
“TFA”指三氟乙酸。
“MeCN”指乙晴。
“DMA”指N,N-二甲基乙酰胺。
“Et
2O”指乙醚。
“DCE”指1,2二氯乙烷。
“DIPEA”指N,N-二异丙基乙胺。
“NBS”指N-溴代琥珀酰亚胺。
“NIS”指N-碘代丁二酰亚胺。
“Cbz-Cl”指氯甲酸苄酯。
“Pd
2(dba)
3”指三(二亚苄基丙酮)二钯。
“Dppf”指1,1’-双二苯基膦二茂铁。
“HATU”指2-(7-氧化苯并三氮唑)-N,N,N’,N’-四甲基脲六氟磷酸酯。
“KHMDS”指六甲基二硅基胺基钾。
“LiHMDS”指双三甲基硅基胺基锂。
“MeLi”指甲基锂。
“n-BuLi”指正丁基锂。
“NaBH(OAc)
3”指三乙酰氧基硼氢化钠。
“DMAP”指4-二甲氨基吡啶。
“SEM-Cl”指氯甲基三甲基硅乙基醚。
“Xantphos”指4,5-双(二苯基膦)-9,9-二甲基氧杂蒽。
“DCM”指二氯甲烷。
“X选自A、B、或C”、“X选自A、B和C”、“X为A、B或C”、“X为A、B和C”等不同用语均表达了相同的意义,即表示X可以是A、B、C中的任意一种或几种。
本发明所述的氢原子均可被其同位素氘所取代,本发明涉及的实施例化合物中的任一氢原子也均可被氘原子取代。
“任选”或“任选地”意味着随后所描述的事件或环境可以但不必发生,该说明包括该事件或环境发生或不发生的场合。例如,“任选被烷基取代的杂环基团”意味着烷基可以但不必须存在,该说明包括杂环基团被烷基取代的情形和杂环基团不被烷基取代的情形。
“取代的”指基团中的一个或多个氢原子,优选为最多5个,更优选为1~3个氢原子彼此独立地被相应数目的取代基取代。不言而喻,取代基仅处在它们的可能的化学位置,本领域技术人员能够在不付出过多努力的情况下确定(通过实验或理论)可能或不可能的取代。例如,具有游离氢的氨基或羟基与具有不饱和(如烯属)键的碳原子结合时可能是不稳定的。可选的取代基包括包括氘、卤素、氨基、羟基、氰基、氧代基、硫代基、烷基、烯基、炔基、氘代烷基、卤代烷基、羟烷基、烷氧基、烷硫基、卤代烷氧基、环烷基、杂环基、芳基和杂芳基中的一个或多个取代基所取代,优选氘、卤素、氨基、羟基、氰基、氧代基、硫代基、C
1-6烷基、C
2-6烯基、C
2-6炔基、C
1-6氘代烷基、C
1-6卤代烷基、C
1-6羟烷基、C
1-6烷氧基、C
1-6烷硫基、C
1-6卤代烷氧基、C
3-12环烷基、3-12元杂环基、C
6-14芳基和5-14元杂芳基。
“药物组合物”表示含有一种或多种本文所述化合物或其生理学上/可药用的盐或前体药物与其他化学组分的混合物,以及其他组分例如生理学/可药用的载体和赋形剂。药物组合物的目的是促进对生物体的给药,利于活性成分的吸收进而发挥生物活性。
“可药用盐”是指本发明化合物的盐,这类盐用于哺乳动物体内时具有安全性和有效性,且具有应有的生物活性。
图1为自由碱晶型H的XRPD图示。
图2为自由碱晶型H的DSC图示。
图3为自由碱晶型H的TGA图示。
图4为自由碱晶型N的XRPD图示。
图5为自由碱晶型N的DSC图示。
图6为自由碱晶型N的TGA图示。
图7为自由碱晶型O的XRPD图示。
图8为自由碱晶型O的DSC图示。
图9为自由碱晶型I的XRPD图示。
图10为自由碱晶型I的DSC图示。
以下结合实施例进一步描述本发明,但这些实施例并非限制着本发明的范围。
一、化合物的制备
实施例
本发明的化合物结构是通过核磁共振(NMR)或/和液质联用色谱(LC-MS)来确定的。NMR化学位移(δ)以百万分之一(ppm)的单位给出。NMR的测定是用Bruker AVANCE-400核磁仪,测定溶剂为氘代二甲基亚砜(DMSO-d
6),氘代甲醇(CD
3OD)和氘代氯仿(CDCl
3),内标为四甲基硅烷(TMS)。
液质联用色谱LC-MS的测定用Agilent 1200 Infinity Series质谱仪。HPLC的测定使用安捷伦1200DAD高压液相色谱仪(Sunfire C18 150×4.6mm色谱柱)和Waters 2695-2996高压液相色谱仪(Gimini C18 150×4.6mm色谱柱)。
薄层层析硅胶板使用烟台黄海HSGF254或青岛GF254硅胶板,TLC采用的规格是0.15mm~0.20mm,薄层层析分离纯化产品采用的规格是0.4mm~0.5mm。柱层析一般使用200~300目烟台黄海硅胶为载体。
本发明实施例中的起始原料是已知的并且可以在市场上买到,或者可以采用按照本领域已知的方法来合成。
在无特殊说明的情况下,本发明的所有反应均在连续的磁力搅拌下,在干燥 氮气或氩气氛下进行,溶剂为干燥溶剂,反应温度单位为摄氏度。
中间体的制备1
(6-氨基-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备
第一步:2-溴-6-甲氧基-3-硝基苯酚的制备
往2-甲氧基-5-硝基苯酚(2g,11.8mmol)的DCM(20mL)溶液中加入NBS(2.1g,11.8mmol),室温搅拌一小时后,向反应中加入CH
2Cl
2与水分液,有机相减压浓缩后柱层析分离得到标题化合物2-溴-6-甲氧基-3-硝基苯酚(1.5g,收率:51%)。
MS m/z(ESI):245.9[M-H]
-.
第二步:3-溴-4-硝基苯-1,2-二酚的制备
-78℃下往2-溴-6-甲氧基-3-硝基苯酚(500mg,2.0mmol)的二氯甲烷溶液(5mL)中,加入BBr
3(1M,2.6mL,2.6mmol)的二氯甲烷溶液,搅拌2小时后,缓慢升至室温,搅拌过夜。冷却至0℃,向反应中缓慢滴加MeOH(5ml),有机相减压浓缩后柱层析分离得到标题化合物3-溴-4-硝基苯-1,2-二酚(410mg,收率:87%)。
MS m/z(ESI):231.9[M-H]
-.
第三步:5-溴-6-硝基-2,3-二氢苯并[b][1,4]二噁英的制备
3-溴-4-硝基苯-1,2-二酚(410mg,1.75mmol),碳酸钾(0.73g,5.26mmol),1,2-二溴乙烷(1.32g,7.0mmol)混合于DMF(5mL)中,在90℃下搅拌过夜,冷却,加入大量乙酸乙酯稀释。有机相用饱和食盐水洗涤多次,然后无水硫酸钠干燥,减压浓缩有机溶剂后柱层析得到标题化合物5-溴-6-硝基-2,3-二氢苯并[b][1,4]二噁英(200mg,收率:44%)。
MS m/z(ESI):257.9[M-H]
-.
第四步:5-溴-2,3-二氢苯并[b][1,4]二噁英-6-胺的制备
5-溴-6-硝基-2,3-二氢苯并[b][1,4]二噁英(200mg,0.77mmol)溶于乙醇(9mL)和水(3mL),加入还原铁粉(343mg,6.1mmol)和氯化铵(82mg,1.5mmol),回流反应3h。反应液过滤,滤液减压浓缩后得到标题化合物5-溴-2,3-二氢苯并[b][1,4]二噁英-6-胺(170mg,收率:96%)。
MS m/z(ESI):230.2[M+H]
+.
第五步:(6-氨基-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备
5-溴-2,3-二氢苯并[b][1,4]二噁英-6-胺(0.16g,0.7mmol),二甲基氧化磷(108mg,1.39mmol),磷酸钾(295mg,1.39mmol)混合于N,N-二甲基甲酰胺(5mL)中,加入醋酸钯(31mg,0.14mmol)和Xantphos(161mg,0.28mmol),N2除氧5分钟,然后微波加热至145℃反应3小时。反应冷却至室温,减压浓缩有机溶剂后柱层析分离得到标题化合物(6-氨基-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化(83mg,收率:52%)。
1H NMR(400MHz,CDCl
3)δ1.72(s,3H),1.75(s,3H),4.09-4.13(m,2H),4.15-4.23(m,2H),5.41-5.85(m,2H),6.07-6.15(m,1H),6.72(d,J=6.8,1H);
MS m/z(ESI):228.2[M+H]
+.
中间体的制备2
2-甲氧基-5-甲基-4-(1,4-二氧杂-8-氮杂螺[4.5]癸烷-8-基)苯胺
第一步:8-(5-甲氧基-2-甲基-4-硝基苯基)-1,4-二氧杂-8-氮杂螺[4.5]癸烷的制备
往1-氟-5-甲氧基-2-甲基-4-硝基苯(1.1g,5.9mmol)和4-哌啶酮缩乙二醇(3.4g,23.9mmol)的DMSO(15mL)溶液中加入K
2CO
3(1.6g,11.9mmol),120℃搅拌过夜。反应液冷却至室温,减压浓缩有机溶剂后柱层析分离得到标题化合物8-(5-甲氧基-2-甲基-4-硝基苯基)-1,4-二氧杂-8-氮杂螺[4.5]癸烷(1.3g,收率:71%)。
MS m/z(ESI):309.2[M+H]
+.
第二步:2-甲氧基-5-甲基-4-(1,4-二氧杂-8-氮杂螺[4.5]癸烷-8-基)苯胺的制备
8-(5-甲氧基-2-甲基-4-硝基苯基)-1,4-二氧杂-8-氮杂螺[4.5]癸烷(500mg,1.62mmol)溶于甲醇(10mL),四氢呋喃(3mL)中,加入Pd/C(100mg),氢气氛围下室温搅拌5h。反应液过滤,滤液减压浓缩后得到标题化合物2-甲氧基-5-甲基-4-(1,4-二氧杂-8-氮杂螺[4.5]癸烷-8-基)苯胺(433mg,收率:96%)。
MS m/z(ESI):279.2[M+H]
+.
实施例1
(6-((5-溴-2-((2-甲氧基-4-(4-(3-(甲氧基甲基)吖丁啶-1-基)哌啶-1-基)-5-甲基苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备
第一步:(6-((5-溴-2-氯嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备
室温条件下,5-溴-2,4-二氯嘧啶(2.27g,10mmol),(6-氨基-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化(2.27g,10mmol),磷酸钾(2.76g,20mmol)混合于叔戊醇(20mL)中,微波90℃反应1h。反应冷却至室温,减压浓缩有机溶剂后柱层析分离得到标题化合物(6-((5-溴-2-氯嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化(3.25g,收率:78%)。
1H NMR(400MHz,DMSO-d
6)δ1.81(s,3H),1.85(s,3H),4.24-4.39(m,4H),7.13(d,J=9.2Hz,1H),7.89-7.98(m,1H),8.44(d,J=1.8Hz,1H),12.26(s,1H);
MS m/z(ESI):417.9[M+H]
+.
第二步:(6-((5-溴-2-((2-甲氧基-5-甲基-4-(1,4-二氧杂-8-氮杂螺[4.5]癸烷-8-基)苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备
室温条件下,(6-((5-溴-2-氯嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化(1.0g,2.4mmol),2-甲氧基-5-甲基-4-(1,4-二氧杂-8-氮杂螺[4.5]癸烷-8-基)苯胺(1.0g,3.6mmol),对甲苯磺酸(0.62g,3.6mmol)混合于乙二醇 (40mL)中,升温至90℃反应2h。反应冷却至室温,加入饱和碳酸氢钠水溶液,用乙酸乙酯萃取,分离有机相并用饱和食盐水洗涤,有机相用无水硫酸钠干燥,过滤干燥剂后减压浓缩有机溶剂,柱层析分离得到标题化合物(6-((5-溴-2-((2-甲氧基-5-甲基-4-(1,4-二氧杂-8-氮杂螺[4.5]癸烷-8-基)苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化(1.34g,收率:85%)。
1H NMR(400MHz,DMSO-d
6)δ1.74-1.85(m,10H),2.14(s,3H),2.91(t,J=5.4Hz,4H),3.77(s,3H),3.93(s,4H),4.24(s,2H),4.32(s,2H),6.73(s,1H),6.81(d,J=9.2Hz,1H),7.46(s,1H),7.94(d,J=15.0Hz,2H),8.10(s,1H),11.62(s,1H);
MS m/z(ESI):660.2[M+H]
+.
第三步:1-(4-((5-溴-4-((5-(二甲基磷基)-2,3-二氢苯并[b][1,4]二噁英-6-基)氨基)嘧啶-2-基)氨基)-5-甲氧基-2-甲基苯基)哌啶-4-酮的制备
室温条件下,(6-((5-溴-2-((2-甲氧基-5-甲基-4-(1,4-二氧杂-8-氮杂螺[4.5]癸烷-8-基)苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化(1.34g,2.03mmol)混合于醋酸/水(12mL/12mL)中,升温至90℃反应2h。反应冷却至室温,减压浓缩反应液,加入饱和碳酸氢钠水溶液,用乙酸乙酯萃取,合并有机相并用无水硫酸钠干燥,过滤干燥剂后减压浓缩有机溶剂,柱层析分离得到标题化合物1-(4-((5-溴-4-((5-(二甲基磷基)-2,3-二氢苯并[b][1,4]二噁英-6-基)氨基)嘧啶-2-基)氨基)-5-甲氧基-2-甲基苯基)哌啶-4-酮(1.2g,收率:96%)。
MS m/z(ESI):616.2[M+H]
+.
第四步:(6-((5-溴-2-((2-甲氧基-4-(4-(3-(甲氧基甲基)吖丁啶-1-基)哌啶-1-基)-5-甲基苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备
室温条件下,1-(4-((5-溴-4-((5-(二甲基磷基)-2,3-二氢苯并[b][1,4]二噁英-6-基)氨基)嘧啶-2-基)氨基)-5-甲氧基-2-甲基苯基)哌啶-4-酮(0.8g,1.3mmol),3-(甲氧基甲基)吖丁啶三氟醋酸盐(0.42g,1.95mmol)和醋酸(0.1mL)混溶于二氯乙烷(20mL)中,搅拌30分钟,加入三乙酰氧基硼氢化钠(0.55g,2.6mmol)室温搅拌过夜。加入饱和碳酸氢钠水溶液,用二氯甲烷萃取,有机相用无水硫酸钠干燥,过滤干燥剂后减压浓缩有机溶剂,柱层析分离得到标题化合物(6-((5-溴-2-((2-甲氧基-4-(4-(3-(甲氧基甲基)吖丁啶-1-基)哌啶-1-基)-5-甲基苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化(0.56g,收率:62%)。
1H NMR(400MHz,DMSO-d
6)δ1.26-1.38(m,2H),1.69-1.77(m,2H),1.78(s,3H),1.81(s,3H),2.07-2.22(m,4H),2.56-2.66(m,3H),2.83-2.92(m,1H),2.96-3.05(m,2H),3.15-3.19(m,2H),3.23-3.27(m,3H),3.42-3.46(m,2H),3.76(s,3H),4.07-4.13(m,1H),4.24(s,2H),4.32(s,2H),6.69(s,1H),6.80(d,J=9.0Hz,1H),7.43(s,1H),7.91-7.98(m,2H),8.10(s,1H),11.62(s,1H);
MS m/z(ESI):701.2[M+H]
+.
实施例2
(6-((5-溴-2-((4-(4-(3-(二甲氨基)吖丁啶-1-基)哌啶-1-基)-5-乙基-2-甲氧苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备
第一步:叔-丁基4-(3-(二甲氨基)吖丁啶-1-基)哌啶-1-羧酸酯的制备
室温条件下,将叔-丁基4-羰基哌啶-1-羧酸酯(500mg,2.51mmol)和N,N-二甲基吖丁啶-3-胺(302mg,3.01mmol)溶于1,2-二氯乙烷(15mL)中,加入2滴醋酸,搅拌5分钟,加入三乙酰氧基硼氢化钠(1.06g,5.02mmol),室温搅拌过夜,然后加入饱和碳酸氢钠溶液淬灭反应,用二氯甲烷萃取三次。合并有机相,有机相用无水硫酸钠干燥,过滤干燥剂后减压浓缩有机溶剂后柱层析分离得到标题化合物叔-丁基4-(3-(二甲氨基)吖丁啶-1-基)哌啶-1-羧酸酯(610mg,收率:86%)。
1H NMR(400MHz,CDCl
3)δ1.14-1.23(m,2H),1.44(s,9H),1.62-1.70(m,2H),2.12(s,6H),2.81-2.89(m,6H),3.48-3.53(m,2H),4.03-3.87(m,2H);
MS m/z(ESI):284.1[M+H]
+.
第二步:N,N-二甲基-1-(哌啶-4-基)吖丁啶-3-胺的制备
室温条件下,将叔-丁基4-(3-(二甲氨基)吖丁啶-1-基)哌啶-1-羧酸酯(610mg,2.16mmol)溶于盐酸二氧六环(10mL)中,室温搅拌过夜,减压浓缩有机溶剂 后得到标题化合物N,N-二甲基-1-(哌啶-4-基)吖丁啶-3-胺粗品直接用于下一步反应。
MS m/z(ESI):184.1[M+H]
+.
第三步:1-(1-(2-溴-5-甲氧基-4-硝基苯基)哌啶-4-基)-N,N-二甲基吖丁啶-3-胺的制备
室温条件下,将1-溴-2-氟-4-甲氧基-5-硝基苯(300mg,1.2mmol)N,N-二甲基-1-(哌啶-4-基)吖丁啶-3-胺粗品(220mg,1.2mmol)和碳酸钾(497mg,3.6mmol)溶于N,N-二甲基甲酰胺(8mL)中,升温至60℃搅拌过夜,向反应体系中加入水,用乙酸乙酯萃取三次。合并有机相,然后有机相用无水硫酸钠干燥,过滤干燥剂,减压浓缩有机溶剂后柱层析分离得到标题化合物1-(1-(2-溴-5-甲氧基-4-硝基苯基)哌啶-4-基)-N,N-二甲基吖丁啶-3-胺(430mg,收率:87%)。
MS m/z(ESI):413.1[M+H]
+.
第四步:1-(1-(5-甲氧基-4-硝基-2-乙烯基苯基)哌啶-4-基)-N,N-二甲基吖丁啶-3-胺的制备
室温条件下,将1-(1-(2-溴-5-甲氧基-4-硝基苯基)哌啶-4-基)-N,N-二甲基吖丁啶-3-胺(430mg,1.04mmol),乙烯基三氟硼酸钾(279mg,2.08mmol),[1,1'-双(二苯基膦基)二茂铁]二氯化钯(76mg,0.104mmol),碳酸铯(1.01g,3.12mmol)溶于二氧六环/水(10mL/1.5mL)中,氮气置换三次,升温至90℃搅拌过夜,向反应体系中加入水,用乙酸乙酯萃取三次。合并有机相,然后有机相用无水硫酸钠干燥,过滤干燥剂,减压浓缩有机溶剂后柱层析分离得到标题化合物1-(1-(5- 甲氧基-4-硝基-2-乙烯基苯基)哌啶-4-基)-N,N-二甲基吖丁啶-3-胺(230mg,收率:61%)。
MS m/z(ESI):361.1[M+H]
+.
第五步:1-(1-(4-氨基-2-乙基-5-甲氧苯基)哌啶-4-基)-N,N-二甲基吖丁啶-3-胺的制备
室温条件下,将1-(1-(5-甲氧基-4-硝基-2-乙烯基苯基)哌啶-4-基)-N,N-二甲基吖丁啶-3-胺(230mg,0.64mmol)溶于甲醇(10mL)中,氮气置换三次,加入钯/碳(46mg),氢气氛下室温搅拌过夜,过滤除去催化剂,减压浓缩有机溶剂得到标题化合物1-(1-(4-氨基-2-乙基-5-甲氧苯基)哌啶-4-基)-N,N-二甲基吖丁啶-3-胺(210mg,收率:98%)。
MS m/z(ESI):333.1[M+H]
+.
参考实施例1的第二步,将制备得到的1-(1-(4-氨基-2-乙基-5-甲氧苯基)哌啶-4-基)-N,N-二甲基吖丁啶-3-胺与(6-((5-溴-2-氯嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化反应制备目标产物(6-((5-溴-2-((4-(4-(3-(二甲氨基)吖丁啶-1-基)哌啶-1-基)-5-乙基-2-甲氧苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化。
1H NMR(400MHz,CD
3OD)δ0.98-1.07(m,3H),1.47-1.60(m,2H),1.87(s,3H),1.91(s,3H),1.96-2.05(m,2H),2.24(s,6H),2.50-2.59(m,2H),2.71-2.83(m,4H),3.03-3.10(m,2H),3.12-3.19(m,1H),3.47-3.58(m,2H),3.84(d,J=1.7Hz,2H),3.90-3.97(m,2H),4.26-4.32(m,2H),4.33-4.39(m,2H),6.77(s,1H),6.88-6.94(m,1H),7.75(d,J=1.6Hz,1H),7.79-7.84(m,1H),8.07(s,1H);
MS m/z(ESI):714.2[M+H]
+.
实施例3
(6-((5-溴-2-((4-(4-(3-(2-氟乙基)-3-羟基吖丁啶-1-基)哌啶-1-基)-2-甲氧基-5-甲基苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备
(6-((5-溴-2-((4-(4-(3-(2-氟乙基)-3-羟基吖丁啶-1-基)哌啶-1-基)-2-甲氧基-5-甲基苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备方法参照实施例1。
1H NMR(400MHz,CD
3OD)δ1.56-1.67(m,2H),1.88(s,3H),1.92(s,3H),2.03-2.11(m,2H),2.12-2.18(m,4H),2.20-2.26(m,1H),2.73(t,J=11.7Hz,3H),3.11-3.20(m,2H),3.81-3.89(m,4H),4.08-4.14(m,2H),4.25-4.31(m,2H),4.33-4.38(m,2H),4.55-4.66(m,3H),4.75(t,J=5.6Hz,1H),6.72(s,1H),6.92(d,J=9.2Hz,1H),7.72(s,1H),7.87-7.93(m,1H),8.07(s,1H);
MS m/z(ESI):719.2[M+H]
+.
实施例4
(6-((5-溴-2-((5-乙基-4-(4-(3-氟-3-(2-羟基丙烷-2-基)吖丁啶-1-基)哌啶-1-基)-2-甲氧苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备
(6-((5-溴-2-((5-乙基-4-(4-(3-氟-3-(2-羟基丙烷-2-基)吖丁啶-1-基)哌啶-1-基)-2-甲氧苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备方法参照实施例2。
1H NMR(400MHz,CD
3OD)δ1.03(t,J=7.6Hz,3H),1.23-1.26(m,6H),1.60-1.65(m,2H),1.91-1.93(m,6H),2.03-2.05(m,2H),2.56-2.58(m,2H),2.75-2.78(m,3H),3.08-3.12(m,2H),3.78-3.96(m,5H),4.12-4.16(m,2H),4.22-4.48(m,4H),6.78(s,1H),6.91-6.93(m,1H),7.63-7.90(m,2H),8.08(s,1H);
MS m/z(ESI):747.2[M+H]
+.
实施例5
(6-((5-溴-2-((5-乙基-3-氟-2-甲氧基-4-(4-(4-甲基哌嗪-1-基)哌啶-1-基)苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备
(6-((5-溴-2-((5-乙基-3-氟-2-甲氧基-4-(4-(4-甲基哌嗪-1-基)哌啶-1-基)苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备方法参照实施例2。
MS m/z(ESI):732.2[M+H]
+.
实施例6
(6-((5-溴-2-((3-乙基-2-氟-6-甲氧基-4-(4-(4-甲基哌嗪-1-基)哌啶-1-基)苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备
(6-((5-溴-2-((3-乙基-2-氟-6-甲氧基-4-(4-(4-甲基哌嗪-1-基)哌啶-1-基)苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备方法参照实施例2。
MS m/z(ESI):732.2[M+H]
+.
实施例7
(5-((5-溴-2-((5-乙炔基-2-甲氧基-4-(4-(4-甲基哌嗪-1-基)哌啶-1-基)苯基)氨基)嘧啶-4-基)氨基)苯并[d][1,3]二噁唑-4-基)二甲基膦氧化的制备
(5-((5-溴-2-((5-乙炔基-2-甲氧基-4-(4-(4-甲基哌嗪-1-基)哌啶-1-基)苯基)氨基)嘧啶-4-基)氨基)苯并[d][1,3]二噁唑-4-基)二甲基膦氧化的制备方法参照实施例1。
MS m/z(ESI):696.2[M+H]
+.
实施例8
(6-((5-溴-2-((4-(4-(3-氟-3-(2-羟基丙烷-2-基)吖丁啶-1-基)哌啶-1-基)-2-甲氧基-5-甲基苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备
(6-((5-溴-2-((4-(4-(3-氟-3-(2-羟基丙烷-2-基)吖丁啶-1-基)哌啶-1-基)-2-甲氧基-5-甲基苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备方法参照实施例1。
1H NMR(400MHz,CD
3OD)δ1.23-1.25(m,6H),1.63-1.65(m,2H),1.89-1.91(m,6H),2.02-2.21(m,5H),2.71-2.73(m,2H),3.12-3.16(m,3H),3.84(s,3H),4.11-4.13(m 2H),4.36-4.39(m,6H),6.72(s,1H),6.91-6.93(m,1H),7.72(s,1H),7.87-7.89(m,1H),8.06(s,1H);
MS m/z(ESI):733.2[M+H]
+.
实施例9
(6-((5-溴-2-((2-甲氧基-5-甲基-4-(4-((3aR,6aS)-5-甲基六氢吡咯并[3,4-c]吡咯-2(1H)-基)哌啶-1-基)苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备
(6-((5-溴-2-((2-甲氧基-5-甲基-4-(4-((3aR,6aS)-5-甲基六氢吡咯并[3,4-c]吡咯-2(1H)-基)哌啶-1-基)苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备方法参照实施例1。
MS m/z(ESI):726.3[M+H]
+.
实施例10
(6-((5-氯-2-((2-甲氧基-5-甲基-4-(4-((3aR,6aS)-5-甲基六氢吡咯并[3,4-c]吡咯-2(1H)-基)哌啶-1-基)苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备
(6-((5-氯-2-((2-甲氧基-5-甲基-4-(4-((3aR,6aS)-5-甲基六氢吡咯并[3,4-c]吡咯-2(1H)-基)哌啶-1-基)苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备方法参照实施例1。
MS m/z(ESI):682.3[M+H]
+.
实施例11
(6-((2-((2-甲氧基-5-甲基-4-(4-((3aR,6aS)-5-甲基六氢吡咯并[3,4-c]吡咯-2(1H)-基)哌啶-1-基)苯基)氨基)-5-(三氟甲基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备
(6-((2-((2-甲氧基-5-甲基-4-(4-((3aR,6aS)-5-甲基六氢吡咯并[3,4-c]吡咯-2(1H)-基)哌啶-1-基)苯基)氨基)-5-(三氟甲基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备方法参照实施例1。
MS m/z(ESI):716.3[M+H]
+.
实施例12
2-(1-(1-(4-((5-溴-4-((5-(二甲基磷基)-2,3-二氢苯并[b][1,4]二噁英-6-基)氨基)嘧啶-2-基)氨基)-5-甲氧基-2-甲基苯基)哌啶-4-基)吖丁啶-3-基)乙酰腈的制备
2-(1-(1-(4-((5-溴-4-((5-(二甲基磷基)-2,3-二氢苯并[b][1,4]二噁英-6-基)氨基)嘧啶-2-基)氨基)-5-甲氧基-2-甲基苯基)哌啶-4-基)吖丁啶-3-基)乙酰腈的制备方法参照实施例1。
1H NMR(400MHz,CD
3OD)δ1.49-1.51(m,3H),1.91-1.93(m,9H),2.12(s,3H),2.57-2.59(m,1H),2.69-2.72(m,2H),2.78-2.80(m,2H),2.89-2.93(m,1H),3.12-3.15(m,2H),3.78-3.81(m,2H),3.84(s,3H),4.33-4.36(m,4H),6.72(s,1H),6.91-6.95(m,1H),7.70-7.76(m,1H),7.88-7.91(m,1H),8.06(s,1H);
MS m/z(ESI):696.2[M+H]
+.
实施例13
2-(1-(1-(4-((5-氯-4-((5-(二甲基磷基)-2,3-二氢苯并[b][1,4]二噁英-6-基)氨基)嘧啶-2-基)氨基)-5-甲氧基-2-甲基苯基)哌啶-4-基)吖丁啶-3-基)乙酰腈的制备
2-(1-(1-(4-((5-氯-4-((5-(二甲基磷基)-2,3-二氢苯并[b][1,4]二噁英-6-基)氨基)嘧啶-2-基)氨基)-5-甲氧基-2-甲基苯基)哌啶-4-基)吖丁啶-3-基)乙酰腈的制备方法参照实施例1。
1H NMR(400MHz,CD
3OD)δ1.46-1.49(m,2H),1.90-1.93(m,8H),2.15-2.19(m,3H),2.37-2.39(m,1H),2.62-2.78(m,4H),2.85-2.89(m,1H),3.06-3.21(m,4H),3.63-3.66(m,2H),3.83(s,3H),4.32-4.38(m,4H),6.72(s,1H),6.89-6.91(m,1H),7.69-7.73(m,1H),7.96-8.10(m,2H);
MS m/z(ESI):652.3[M+H]
+.
实施例14
2-(1-(1-(4-((4-((5-(二甲基磷基)-2,3-二氢苯并[b][1,4]二噁英-6-基)氨基)-5-(三氟甲基)嘧啶-2-基)氨基)-5-甲氧基-2-甲基苯基)哌啶-4-基)吖丁啶-3-基)乙酰腈的制备
2-(1-(1-(4-((4-((5-(二甲基磷基)-2,3-二氢苯并[b][1,4]二噁英-6-基)氨基)-5-(三氟甲基)嘧啶-2-基)氨基)-5-甲氧基-2-甲基苯基)哌啶-4-基)吖丁啶-3-基)乙酰腈的制备方法参照实施例1。
MS m/z(ESI):686.3[M+H]
+.
实施例15
(6-((5-溴-2-((4-(4-(3-(二甲氨基)吖丁啶-1-基)哌啶-1-基)-2-甲氧基-5-甲基苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备
(6-((5-溴-2-((4-(4-(3-(二甲氨基)吖丁啶-1-基)哌啶-1-基)-2-甲氧基-5-甲基苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备方法参照实施例1。
1H NMR(400MHz,CD
3OD)δ1.54-1.61(m,2H),1.89-1.91(m,6H),2.07-2.08(m,2H),2.12(s,3H),2.30(s,6H),2.72-2.79(m,2H),3.04-3.06(m,2H),3.15-3.18(m,2H),3.82-3.88(m,5H),4.05-4.18(m,2H),4.32-4.39(m,4H),6.71(s,1H),6.90-6.93(m,1H),7.71(s,1H),7.88-7.92(m,1H),8.06(s,1H);
MS m/z(ESI):700.2[M+H]
+.
实施例16
(6-((5-溴-2-((4-(4-(3-乙氧基吖丁啶-1-基)哌啶-1-基)-2-甲氧基-5-甲基苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备
(6-((5-溴-2-((4-(4-(3-乙氧基吖丁啶-1-基)哌啶-1-基)-2-甲氧基-5-甲基苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备方法参照实施例1。
1H NMR(400MHz,CD
3OD)δ1.22(t,J=7.0Hz,3H),1.53-1.64(m,2H),1.87(s,3H),1.90(s,3H),2.00-2.08(m,2H),2.11(s,3H),2.64-2.75(m,2H),2.91-3.01(m,1H),3.11-3.18(m,2H),3.48-3.57(m,2H),3.73-3.79(m,2H),3.83(s,3H),4.15-4.23(m,2H),4.25-4.38(m,5H),6.70(s,1H),6.89(d,J=9.1Hz,1H),7.71(s,1H),7.84-7.91(m,1H),8.05(s,1H);
MS m/z(ESI):701.2[M+H]
+.
实施例17
(S)-(6-((5-溴-2-((4-(4-(3-(二甲氨基)吡咯烷-1-基)哌啶-1-基)-2-甲氧基-5-甲基苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备
(S)-(6-((5-溴-2-((4-(4-(3-(二甲氨基)吡咯烷-1-基)哌啶-1-基)-2-甲氧基-5-甲基苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备方法参照实施例1。
1H NMR(400MHz,CD
3OD)δ1.80-1.83(m,2H),1.88-1.90(m,6H),2.09-2.11(m,6H),2.30(s,1H),2.62(s,6H),2.72-2.79(m,3H),3.14-3.18(m,4H),3.25-3.29(m,1H),3.34-3.47(m,2H),3.83(s,3H),4.31-4.33(m,4H),6.69(s,1H),6.88-6.91(m,1H),7.70(s,1H),7.87-7.89(m,1H),8.05(s,1H);
MS m/z(ESI):714.2[M+H]
+.
实施例18
(R)-(6-((5-溴-2-((4-(4-(3-(二甲氨基)吡咯烷-1-基)哌啶-1-基)-2-甲氧基-5-甲基苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备
(R)-(6-((5-溴-2-((4-(4-(3-(二甲氨基)吡咯烷-1-基)哌啶-1-基)-2-甲氧基-5-甲基苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备方法参照实施例1。
1H NMR(400MHz,CD
3OD)δ1.80-1.83(m,2H),1.88-1.90(m,6H),2.09-2.11(m,6H),2.30(s,1H),2.62(s,6H),2.72-2.79(m,3H),3.14-3.18(m,4H),3.25-3.29(m,1H),3.34-3.47(m,2H),3.83(s,3H),4.31-4.33(m,4H),6.69(s,1H),6.88-6.91(m,1H),7.70(s,1H),7.87-7.89(m,1H),8.05(s,1H);
MS m/z(ESI):714.2[M+H]
+.
实施例19
(S)-(6-((5-溴-2-((4-(4-(3-乙氧基吡咯烷-1-基)哌啶-1-基)-2-甲氧基-5-甲基苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备
(S)-(6-((5-溴-2-((4-(4-(3-乙氧基吡咯烷-1-基)哌啶-1-基)-2-甲氧基-5-甲基苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备方法参照实施例1。
1H NMR(400MHz,CD
3OD)δ1.22(t,J=7.0Hz,3H),1.90-1.96(m,8H),2.15(s,3H),2.22-2.28(m,4H),2.75-2.82(m,2H),3.18-3.22(m,3H),3.41-3.46(m,3H),3.50-3.59(m,4H),3.84(s,3H),4.25-4.38(m,5H),6.71(s,1H),6.91-6.96(m,1H),7.73(s,1H),7.90-7.93(m,1H),8.06(s,1H);
MS m/z(ESI):715.2[M+H]
+.
实施例20
(R)-(6-((5-溴-2-((4-(4-(3-乙氧基吡咯烷-1-基)哌啶-1-基)-2-甲氧基-5-甲基苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备
(R)-(6-((5-溴-2-((4-(4-(3-乙氧基吡咯烷-1-基)哌啶-1-基)-2-甲氧基-5-甲基苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备方法参照实施例1。
1H NMR(400MHz,CD
3OD)δ1.22(t,J=7.0Hz,3H),1.90-1.96(m,8H),2.15 (s,3H),2.22-2.28(m,4H),2.75-2.82(m,2H),3.18-3.22(m,3H),3.41-3.46(m,3H),3.50-3.59(m,4H),3.84(s,3H),4.25-4.38(m,5H),6.71(s,1H),6.91-6.96(m,1H),7.73(s,1H),7.90-7.93(m,1H),8.06(s,1H);
MS m/z(ESI):715.2[M+H]
+.
实施例21
(6-((5-氯-2-((4-(4-(3-(二甲氨基)吖丁啶-1-基)哌啶-1-基)-2-甲氧基-5-甲基苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备
(6-((5-氯-2-((4-(4-(3-(二甲氨基)吖丁啶-1-基)哌啶-1-基)-2-甲氧基-5-甲基苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备方法参照实施例1。
1H NMR(400MHz,CD
3OD)δ1.53-1.56(m,2H),1.89-1.91(m,6H),1.98-2.01(m,2H),2.14(s,3H),2.23(s,6H),2.69-2.71(m,3H),3.06-3.22(m,3H),3.40-3.51(m,2H),3.79-3.91(m,5H),4.22-4.38(m,4H),6.72(s,1H),6.89-6.91(m,1H),7.70(s,1H),7.95(s,1H),8.03-8.09(m,1H);
MS m/z(ESI):656.2[M+H]
+.
实施例22
(6-((5-氯-2-((4-(4-(3-乙氧基吖丁啶-1-基)哌啶-1-基)-2-甲氧基-5-甲基苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备
(6-((5-氯-2-((4-(4-(3-乙氧基吖丁啶-1-基)哌啶-1-基)-2-甲氧基-5-甲基苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备方法参照实施例1。
MS m/z(ESI):657.2[M+H]
+.
实施例23
(S)-(6-((5-氯-2-((4-(4-(3-(二甲氨基)吡咯烷-1-基)哌啶-1-基)-2-甲氧基-5-甲基苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备
(S)-(6-((5-氯-2-((4-(4-(3-(二甲氨基)吡咯烷-1-基)哌啶-1-基)-2-甲氧基-5-甲基苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备方法参照实施例1。
MS m/z(ESI):670.2[M+H]
+.
实施例24
(R)-(6-((5-氯-2-((4-(4-(3-(二甲氨基)吡咯烷-1-基)哌啶-1-基)-2-甲氧基-5-甲基苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备
(R)-(6-((5-氯-2-((4-(4-(3-(二甲氨基)吡咯烷-1-基)哌啶-1-基)-2-甲氧基-5-甲基苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备方法参照实施例1。
MS m/z(ESI):670.2[M+H]
+.
实施例25
(S)-(6-((5-氯-2-((4-(4-(3-乙氧基吡咯烷-1-基)哌啶-1-基)-2-甲氧基-5-甲基苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备
(S)-(6-((5-氯-2-((4-(4-(3-乙氧基吡咯烷-1-基)哌啶-1-基)-2-甲氧基-5-甲基苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备方法参照实施例1。
MS m/z(ESI):671.2[M+H]
+.
实施例26
(R)-(6-((5-氯-2-((4-(4-(3-乙氧基吡咯烷-1-基)哌啶-1-基)-2-甲氧基-5-甲基苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备
(R)-(6-((5-氯-2-((4-(4-(3-乙氧基吡咯烷-1-基)哌啶-1-基)-2-甲氧基-5-甲基苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备方法参照实施例1。
MS m/z(ESI):671.2[M+H]
+.
实施例27
(6-((2-((4-(4-(3-(二甲氨基)吖丁啶-1-基)哌啶-1-基)-2-甲氧基-5-甲基苯基)氨基)-5-(三氟甲基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备
(6-((2-((4-(4-(3-(二甲氨基)吖丁啶-1-基)哌啶-1-基)-2-甲氧基-5-甲基苯基)氨基)-5-(三氟甲基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备方法参照实施例1。
MS m/z(ESI):690.2[M+H]
+.
实施例28
(6-((2-((4-(4-(3-乙氧基吖丁啶-1-基)哌啶-1-基)-2-甲氧基-5-甲基苯基)氨基)-5-(三氟甲基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化 的制备
(6-((2-((4-(4-(3-乙氧基吖丁啶-1-基)哌啶-1-基)-2-甲氧基-5-甲基苯基)氨基)-5-(三氟甲基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备方法参照实施例1。
MS m/z(ESI):691.2[M+H]
+.
实施例29
(S)-(6-((2-((4-(4-(3-(二甲氨基)吡咯烷-1-基)哌啶-1-基)-2-甲氧基-5-甲基苯基)氨基)-5-(三氟甲基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备
(S)-(6-((2-((4-(4-(3-(二甲氨基)吡咯烷-1-基)哌啶-1-基)-2-甲氧基-5-甲基苯基)氨基)-5-(三氟甲基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备方法参照实施例1。
MS m/z(ESI):704.2[M+H]
+.
实施例30
(R)-(6-((2-((4-(4-(3-(二甲氨基)吡咯烷-1-基)哌啶-1-基)-2-甲氧基-5-甲基苯基)氨基)-5-(三氟甲基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备
(R)-(6-((2-((4-(4-(3-(二甲氨基)吡咯烷-1-基)哌啶-1-基)-2-甲氧基-5-甲基苯基)氨基)-5-(三氟甲基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备方法参照实施例1。
MS m/z(ESI):704.2[M+H]
+.
实施例31
(S)-(6-((2-((4-(4-(3-乙氧基吡咯烷-1-基)哌啶-1-基)-2-甲氧基-5-甲基苯基)氨基)-5-(三氟甲基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备
(S)-(6-((2-((4-(4-(3-乙氧基吡咯烷-1-基)哌啶-1-基)-2-甲氧基-5-甲基苯基)氨基)-5-(三氟甲基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备方法参照实施例1。
MS m/z(ESI):705.2[M+H]
+.
实施例32
(R)-(6-((2-((4-(4-(3-乙氧基吡咯烷-1-基)哌啶-1-基)-2-甲氧基-5-甲基苯基)氨基)-5-(三氟甲基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化 的制备
(R)-(6-((2-((4-(4-(3-乙氧基吡咯烷-1-基)哌啶-1-基)-2-甲氧基-5-甲基苯基)氨基)-5-(三氟甲基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备方法参照实施例1。
MS m/z(ESI):705.2[M+H]
+.
实施例33
(6-((5-溴-2-((2-甲氧基-5-甲基-4-(4-(3-(甲基(噁丁环-3-基)氨基)吖丁啶-1-基)哌啶-1-基)苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备
(6-((5-溴-2-((2-甲氧基-5-甲基-4-(4-(3-(甲基(噁丁环-3-基)氨基)吖丁啶-1-基)哌啶-1-基)苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备方法参照实施例1。
1H NMR(400MHz,CD
3OD)δ1.50-1.65(m,2H),1.87(s,3H),1.91(s,3H),1.99-2.07(m,2H),2.11(s,3H),2.22(s,3H),2.64-2.74(m,2H),2.90-3.00(m,1H),3.08-3.18(m,2H),3.37-3.46(m,1H),3.73-3.81(m,3H),3.83(s,3H),3.95-4.04(m, 2H),4.24-4.39(m,4H),4.60-4.70(m,4H),6.69(s,1H),6.89(d,J=9.1Hz,1H),7.71(s,1H),7.84-7.91(m,1H),8.05(s,1H);
MS m/z(ESI):742.2[M+H]
+.
实施例34
(5-((5-溴-2-((2-甲氧基-4-(4-(3-(甲氧基甲基)吖丁啶-1-基)哌啶-1-基)-5-甲基苯基)氨基)嘧啶-4-基)氨基)苯并[d][1,3]二噁唑-4-基)二甲基膦氧化的制备
(5-((5-溴-2-((2-甲氧基-4-(4-(3-(甲氧基甲基)吖丁啶-1-基)哌啶-1-基)-5-甲基苯基)氨基)嘧啶-4-基)氨基)苯并[d][1,3]二噁唑-4-基)二甲基膦氧化的制备方法参照实施例1。
1H NMR(400MHz,CD
3OD)δ1.55-1.68(m,2H),1.86-1.89(m,6H),2.09-2.11(m,5H),2.72-2.76(m,2H),3.15-3.18(m,4H),3.45(s,3H),3.52-3.54(m,2H),3.84(s,3H),3.99-4.13(m,2H),4.20-4.31(m,2H),6.07-6.09(m,2H),6.71(s,1H),6.93-6.96(m,1H),7.63-7.88(m,2H),8.07(s,1H);
MS m/z(ESI):687.2[M+H]
+.
实施例35
(5-((5-溴-2-((4-(4-(3-乙氧基吖丁啶-1-基)哌啶-1-基)-2-甲氧基-5-甲基苯基)氨基)嘧啶-4-基)氨基)苯并[d][1,3]二噁唑-4-基)二甲基膦氧化的制备
(5-((5-溴-2-((4-(4-(3-乙氧基吖丁啶-1-基)哌啶-1-基)-2-甲氧基-5-甲基苯基)氨基)嘧啶-4-基)氨基)苯并[d][1,3]二噁唑-4-基)二甲基膦氧化的制备方法参照实施例1。
1H NMR(400MHz,CD
3OD)δ1.23(t,J=7.1Hz,3H),1.53-1.64(m,2H),1.84(s,3H),1.88(s,3H),2.03-2.14(m,5H),2.72(t,J=11.7Hz,2H),3.06-3.19(m,3H),3.49-3.58(m,2H),3.84(s,3H),3.88-3.95(m,2H),4.25-4.38(m,3H),6.07(s,2H),6.71(s,1H),6.93(d,J=8.7Hz,1H),7.71(s,1H),7.74-7.81(m,1H),8.08(s,1H);
MS m/z(ESI):687.2[M+H]
+.
实施例36
(6-((5-溴-2-((5-乙基-2-甲氧基-4-(4-((3aR,6aS)-5-(甲磺酰)六氢吡咯并[3,4-c]吡咯-2(1H)-基)哌啶-1-基)苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备
(6-((5-溴-2-((5-乙基-2-甲氧基-4-(4-((3aR,6aS)-5-(甲磺酰)六氢吡咯并[3,4-c]吡咯-2(1H)-基)哌啶-1-基)苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备方法参照实施例2。
MS m/z(ESI):804.2[M+H]
+.
实施例37
(6-((5-溴-2-((2-甲氧基-5-甲基-4-(4-((3aR,6aS)-5-(甲磺酰)六氢吡咯并[3,4-c]吡咯-2(1H)-基)哌啶-1-基)苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备
(6-((5-溴-2-((2-甲氧基-5-甲基-4-(4-((3aR,6aS)-5-(甲磺酰)六氢吡咯并[3,4-c]吡咯-2(1H)-基)哌啶-1-基)苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备方法参照实施例1。
1H NMR(400MHz,CD
3OD)δ1.85-1.97(m,8H),2.14(s,3H),2.17-2.30(m,2H),2.74(t,J=11.9Hz,2H),2.96(s,3H),3.04-3.26(m,7H),3.34-3.49(m,3H),3.80-3.91(m,5H),4.28(d,J=4.9Hz,2H),4.35(d,J=4.9Hz,2H),6.70(s,1H),6.90(d,J=9.1Hz,1H),7.72(s,1H),7.88(dd,J=9.5,4.4Hz,1H),8.06(s,1H);
MS m/z(ESI):790.2[M+H]
+.
实施例38
(6-((5-溴-2-((4-(4-(3-(乙基(甲基)氨基)吖丁啶-1-基)哌啶-1-基)-2-甲氧基-5-甲基苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备
(6-((5-溴-2-((4-(4-(3-(乙基(甲基)氨基)吖丁啶-1-基)哌啶-1-基)-2-甲氧基-5-甲基苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备方法参照实施例1。
1H NMR(400MHz,CD
3OD)δ1.14(t,J=7.2Hz,3H),1.52-1.63(m,2H),1.87(s,3H),1.91(s,3H),1.99-2.09(m,2H),2.12(s,3H),2.29(s,3H),2.48-2.57(m,2H),2.66-2.77(m,2H),2.83-2.93(m,1H),3.08-3.18(m,2H),3.38-3.45(m,1H),3.63-3.71(m,2H),3.84(s,3H),4.00-4.07(m,2H),4.22-4.40(m,4H),6.71(s,1H),6.88-6.95(m,1H),7.71(s,1H),7.85-7.92(m,1H),8.06(s,1H);
MS m/z(ESI):714.2[M+H]
+.
实施例39
(6-((5-溴-2-((2-甲氧基-5-甲基-4-(4-(4-甲基-1,4-重氮基庚环-1-基)哌啶-1-基)苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备
(6-((5-溴-2-((2-甲氧基-5-甲基-4-(4-(4-甲基-1,4-重氮基庚环-1-基)哌啶-1-基)苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备方法参照实施例1。
1H NMR(400MHz,CD
3OD)δ1.73-1.84(m,2H),1.85-1.97(m,8H),2.00-2.10 (m,2H),2.14(s,3H),2.64-2.74(m,2H),2.78-2.86(m,4H),3.01-3.07(m,2H),3.09-3.18(m,4H),3.19-3.23(m,2H),3.25-3.29(m,2H),3.83(s,3H),4.25-4.39(m,4H),6.70(s,1H),6.90(d,J=9.1Hz,1H),7.68(s,1H),7.86-7.93(m,1H),8.05(s,1H);
MS m/z(ESI):714.2[M+H]
+.
实施例40
(6-((2-((4-(4-(1,4-噁吖庚环-4-基)哌啶-1-基)-2-甲氧基-5-甲基苯基)氨基)-5-溴嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备
(6-((2-((4-(4-(1,4-噁吖庚环-4-基)哌啶-1-基)-2-甲氧基-5-甲基苯基)氨基)-5-溴嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备方法参照
实施例1。
1H NMR(400MHz,CD
3OD)δ1.84-1.94(m,8H),2.02-2.10(m,4H),2.15(s,3H),2.69-2.79(m,2H),3.08-3.26(m,7H),3.80-3.88(m,7H),4.26-4.39(m,4H),6.72(s,1H),6.91(d,J=9.1Hz,1H),7.70(s,1H),7.86-7.92(m,1H),8.06(s,1H);
MS m/z(ESI):701.2[M+H]
+.
实施例41
(6-((2-((4-(4-(3-(二甲氨基)吖丁啶-1-基)哌啶-1-基)-5-乙基-2-甲氧苯基)氨基)-5-(三氟甲基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备
(6-((2-((4-(4-(3-(二甲氨基)吖丁啶-1-基)哌啶-1-基)-5-乙基-2-甲氧苯基)氨基)-5-(三氟甲基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备方法参照实施例2。
1H NMR(400MHz,CD
3OD)δ0.94-1.04(m,3H),1.51-1.60(m,2H),1.84(s,3H),1.88(s,3H),1.98-2.07(m,2H),2.26(s,6H),2.46-2.55(m,2H),2.70-2.81(m,2H),3.04-3.12(m,2H),3.17-3.23(m,2H),3.57-3.65(m,2H),3.84(s,3H),3.99(t,J=8.1Hz,2H),4.26-4.33(m,2H),4.33-4.41(m,2H),6.77(s,1H),6.89(d,J=9.1Hz,1H),7.54-7.64(m,1H),7.72(s,1H),8.25(s,1H);
MS m/z(ESI):704.2[M+H]
+.
实施例42
2-(1-(1-(4-((4-((5-(二甲基磷基)-2,3-二氢苯并[b][1,4]二噁英-6-基)氨基)-5-(甲硫基)嘧啶-2-基)氨基)-5-甲氧基-2-甲基苯基)哌啶-4-基)吖丁啶-3-基)乙酰腈的制备
2-(1-(1-(4-((4-((5-(二甲基磷基)-2,3-二氢苯并[b][1,4]二噁英-6-基)氨基)-5-(甲硫基)嘧啶-2-基)氨基)-5-甲氧基-2-甲基苯基)哌啶-4-基)吖丁啶-3-基)乙酰腈的制备方法参照实施例1。
1H NMR(400MHz,CD
3OD)δ1.51-1.61(m,2H),1.87(s,3H),1.91(s,3H), 1.99-2.07(m,2H),2.13(s,3H),2.29(s,3H),2.67-2.76(m,2H),2.81-2.95(m,3H),3.07-3.19(m,3H),3.65-3.73(m,2H),3.85(s,3H),4.02-4.10(m,2H),4.26-4.31(m,4H),6.72(s,1H),6.91(d,J=9.1Hz,1H),7.75(s,1H),7.89-7.96(m,1H),8.11(s,1H);
MS m/z(ESI):664.2[M+H]
+.
实施例43
(6-((2-((4-(4-(3-(二甲氨基)吖丁啶-1-基)哌啶-1-基)-5-乙基-2-甲氧苯基)氨基)-5-(甲硫基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备
(6-((2-((4-(4-(3-(二甲氨基)吖丁啶-1-基)哌啶-1-基)-5-乙基-2-甲氧苯基)氨基)-5-(甲硫基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备方法参照实施例2。
1H NMR(400MHz,CD
3OD)δ1.01(t,J=7.5Hz,3H),1.51-1.63(m,2H),1.87(s,3H),1.91(s,3H),1.99-2.08(m,2H),2.24-2.32(m,9H),2.50-2.58(m,2H),2.70-2.80(m,2H),2.85-2.96(m,1H),3.03-3.13(m,2H),3.20-3.28(m,1H),3.64-3.71(m,2H),3.85(s,3H),3.98-4.08(m,2H),4.25-4.40(m,4H),6.77(s,1H),6.91(d,J=9.1Hz,1H),7.79-7.88(m,2H),8.12(s,1H);
MS m/z(ESI):682.2[M+H]
+.
实施例44
(6-((5-溴-2-((5-乙炔基-2-甲氧基-4-(4-(4-甲基哌嗪-1-基)哌啶-1-基)苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备
(6-((5-溴-2-((5-乙炔基-2-甲氧基-4-(4-(4-甲基哌嗪-1-基)哌啶-1-基)苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备方法参照
实施例2。
MS m/z(ESI):710.2[M+H]
+.
实施例45
(6-((5-溴-2-((5-乙基-2-甲氧基-4-(4-(3-(甲氧基甲基)吖丁啶-1-基)哌啶-1-基)苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备
(6-((5-溴-2-((5-乙基-2-甲氧基-4-(4-(3-(甲氧基甲基)吖丁啶-1-基)哌啶-1-基)苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备方法参照实施例2。
1H NMR(400MHz,CD
3OD)δ1.02(t,J=7.5Hz,3H),1.53-1.64(m,2H),1.87(s,3H),1.91(s,3H),2.02-2.09(m,2H),2.49-2.60(m,2H),2.71-2.81(m,2H),2.97-3.13(m,4H),3.44(s,3H),3.52(d,J=4.5Hz,2H),3.84(s,3H),3.87-3.91(m,2H),4.08(t,J=9.4Hz,2H),4.26-4.33(m,2H),4.33-4.40(m,2H),6.77(s,1H),6.91(d,J=9.2Hz,1H),7.77(s,1H),7.79-7.84(m,1H),8.07(s,1H);
MS m/z(ESI):715.2[M+H]
+.
实施例46
2-(1-(1-(4-((5-溴-4-((5-(二甲基磷基)-2,3-二氢苯并[b][1,4]二噁英-6-基)氨基)嘧啶-2-基)氨基)-2-乙基-5-甲氧苯基)哌啶-4-基)吖丁啶-3-基)乙酰腈的制备
2-(1-(1-(4-((5-溴-4-((5-(二甲基磷基)-2,3-二氢苯并[b][1,4]二噁英-6-基)氨基)嘧啶-2-基)氨基)-2-乙基-5-甲氧苯基)哌啶-4-基)吖丁啶-3-基)乙酰腈的制备方法参照实施例2。
1H NMR(400MHz,CD
3OD)δ1.01(t,J=7.5Hz,3H),1.50-1.60(m,2H),1.87(s,3H),1.91(s,3H),1.96-2.04(m,2H),2.50-2.58(m,2H),2.71-2.79(m,2H),2.80-2.87(m,3H),3.03-3.12(m,3H),3.58-3.68(m,2H),3.84(s,3H),3.97-4.06(m,2H),4.25-4.31(m,4H),6.76(s,1H),6.90(d,J=9.1Hz,1H),7.74-7.83(m,2H),8.07(s,1H);
MS m/z(ESI):710.2[M+H]
+.
实施例47
(6-((5-溴-2-((4-(4-(3-(二甲氨基)吖丁啶-1-基)哌啶-1-基)-2-甲氧基-5-(三氟甲基)苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备
(6-((5-溴-2-((4-(4-(3-(二甲氨基)吖丁啶-1-基)哌啶-1-基)-2-甲氧基-5-(三氟甲基)苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备方法参照实施例1。
1H NMR(400MHz,CD
3OD)δ1.51-1.62(m,2H),1.88(s,3H),1.91(s,3H),2.00-2.07(m,2H),2.28(s,6H),2.85(t,J=11.3Hz,2H),2.91-3.02(m,1H),3.04-3.12(m,2H),3.21-3.27(m,1H),3.67-3.75(m,2H),3.94(s,3H),4.02-4.08(m,2H),4.26-4.32(m,2H),4.33-4.39(m,2H),6.89(d,J=9.1Hz,1H),7.07(s,1H),7.81-7.86(m,1H),8.13(s,1H),8.21(s,1H);
MS m/z(ESI):754.2[M+H]
+.
实施例48
(5-((5-溴-2-((4-(4-(3-(二甲氨基)吖丁啶-1-基)哌啶-1-基)-2-甲氧基-5-甲基苯基)氨基)嘧啶-4-基)氨基)苯并[d][1,3]二噁唑-4-基)二甲基膦氧化的制备
(5-((5-溴-2-((4-(4-(3-(二甲氨基)吖丁啶-1-基)哌啶-1-基)-2-甲氧基-5-甲基苯基)氨基)嘧啶-4-基)氨基)苯并[d][1,3]二噁唑-4-基)二甲基膦氧化的制备方法参照
实施例1。
1H NMR(400MHz,CD
3OD)δ1.58-1.61(m,2H),1.86-1.88(m,6H),1.90-1.92(m,1H),2.04-2.07(m,2H),2.12-2.15(m,3H),2.20-2.37(m,6H),2.70-2.75(m,2H),2.92-2.95(m,1H),3.13-3.16(m,2H),3.61-3.77(m,2H),3.84(s,3H),3.97-4.14(m,2H),6.07(s,2H),6.71(s,1H),6.92-6.95(m,1H),7.70(s,1H),7.74-7.87(m,1H),8.07(s,1H);
MS m/z(ESI):686.2[M+H]
+.
实施例49
(5-((5-溴-2-((4-(4-(3-(二甲氨基)吖丁啶-1-基)哌啶-1-基)-5-乙基-2-甲氧苯基)氨基)嘧啶-4-基)氨基)苯并[d][1,3]二噁唑-4-基)二甲基膦氧化的制备
(5-((5-溴-2-((4-(4-(3-(二甲氨基)吖丁啶-1-基)哌啶-1-基)-5-乙基-2-甲氧苯基)氨基)嘧啶-4-基)氨基)苯并[d][1,3]二噁唑-4-基)二甲基膦氧化的制备方法参照实施例2。
1H NMR(400MHz,CD
3OD)δ1.01(t,J=7.2Hz,3H),1.41-1.58(m,2H),1.86-1.89(m,6H),2.01-2.03(m,2H),2.25(s,6H),2.52-2.55(m,2H),2.76-2.78(m,3H),3.05-3.08(m,2H),3.12-3.24(m,1H),3.57-3.59(m,2H),3.84(s,3H),3.96-3.99(m,2H),6.07(s,2H),6.76(s,1H),6.91-6.93(m,1H),7.61-7.78(m,2H),8.08(s,1H);
MS m/z(ESI):700.2[M+H]
+.
实施例50
(6-((2-((5-溴-4-(4-(3-(二甲氨基)吖丁啶-1-基)哌啶-1-基)-2-甲氧苯基)氨基)-5-氯嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备
(6-((2-((5-溴-4-(4-(3-(二甲氨基)吖丁啶-1-基)哌啶-1-基)-2-甲氧苯基)氨基)-5-氯嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备方法参照实施例1。
MS m/z(ESI):720.2[M+H]
+.
实施例51
(6-((2-((5-溴-4-(4-(3-乙氧基吖丁啶-1-基)哌啶-1-基)-2-甲氧苯基)氨基)-5-氯嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备
(6-((2-((5-溴-4-(4-(3-乙氧基吖丁啶-1-基)哌啶-1-基)-2-甲氧苯基)氨基)-5-氯嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备方法参照
实施例1。
MS m/z(ESI):721.2[M+H]
+.
实施例52
(6-((5-氯-2-((4-(4-(3-(二甲氨基)吖丁啶-1-基)哌啶-1-基)-5-乙基-2-甲氧苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备
(6-((5-氯-2-((4-(4-(3-(二甲氨基)吖丁啶-1-基)哌啶-1-基)-5-乙基-2-甲氧苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备方法参照实施例2。
1H NMR(400MHz,CD
3OD)δ0.96-1.11(m,3H),1.48-1.63(m,2H),1.88(s,3H),1.91(s,3H),1.99-2.08(m,2H),2.27(s,6H),2.50-2.64(m,2H),2.66-2.96(m,4H),3.04-3.12(m,2H),3.16-3.25(m,2H),3.55-3.66(m,2H),3.85(s,3H),3.94-4.05(m,2H),4.23-4.31(m,2H),4.33-4.40(m,2H),6.78(s,1H),6.86-6.93(m,1H),7.76 (d,J=4.4Hz,1H),7.93-8.01(m,2H);
MS m/z(ESI):670.2[M+H]
+.
实施例53
(6-((5-溴-2-((4-(4-(3-氟-3-(羟甲基)吖丁啶-1-基)哌啶-1-基)-2-甲氧基-5-甲基苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备
(6-((5-溴-2-((4-(4-(3-氟-3-(羟甲基)吖丁啶-1-基)哌啶-1-基)-2-甲氧基-5-甲基苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备方法参照实施例1。
1H NMR(400MHz,DMSO-d
6)δ1.35-1.38(m,2H),1.79-1.81(m,8H),2.11(s,3H),2.22-2.25(m,1H),2.58-2.71(m,3H),2.96-3.01(m,5H),3.68-2.71(m,2H),3.76(s,3H),4.28-4.31(m,4H),6.70(s,1H),6.80-6.83(m,1H),7.43(s,1H),7.93-7.95(m 2H),8.10(s,1H),11.62(s,1H);
MS m/z(ESI):705.2[M+H]
+.
实施例54
(6-((5-溴-2-((5-乙基-4-(4-(3-氟-3-(羟甲基)吖丁啶-1-基)哌啶-1-基)-2-甲氧苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备
(6-((5-溴-2-((5-乙基-4-(4-(3-氟-3-(羟甲基)吖丁啶-1-基)哌啶-1-基)-2-甲氧苯 基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备方法参照实施例2。
1H NMR(400MHz,CD
3OD)δ1.02(t,J=7.6Hz,3H),1.49-1.64(m,2H),1.87(s,3H),1.91(s,3H),2.00(d,J=13.4Hz,2H),2.54(q,J=7.5Hz,2H),2.75(t,J=11.5Hz,3H),3.07(d,J=11.7Hz,2H),3.71-3.85(m,7H),3.97(dd,J=15.7,10.4Hz,2H),4.29(s,2H),4.36(s,2H),6.77(s,1H),6.90(d,J=9.1Hz,1H),7.75(s,1H),7.81(dd,J=9.2,4.5Hz,1H),8.07(s,1H);
MS m/z(ESI):719.2[M+H]
+.
实施例55
1-((3aR,6aS)-5-(1-(4-((5-溴-4-((5-(二甲基磷基)-2,3-二氢苯并[b][1,4]二噁英-6-基)氨基)嘧啶-2-基)氨基)-2-乙基-5-甲氧苯基)哌啶-4-基)六氢吡咯并[3,4-c]吡咯-2(1H)-基)乙烷-1-酮的制备
1-((3aR,6aS)-5-(1-(4-((5-溴-4-((5-(二甲基磷基)-2,3-二氢苯并[b][1,4]二噁英-6-基)氨基)嘧啶-2-基)氨基)-2-乙基-5-甲氧苯基)哌啶-4-基)六氢吡咯并[3,4-c]吡咯-2(1H)-基)乙烷-1-酮的制备方法参照实施例2。
1H NMR(400MHz,CD
3OD)δ1.02(t,J=7.7Hz,3H),1.81-1.93(m,8H),2.09(s,3H),2.18(d,J=10.5Hz,2H),2.56(q,J=7.5Hz,2H),2.78(t,J=11.6Hz,2H),2.95-3.20(m,7H),3.52-3.68(m,5H),3.77(d,J=9.6Hz,1H),3.84(s,3H),4.29(s,2H),4.36(s,2H),6.76(s,1H),6.90(d,J=9.2Hz,1H),7.79-7.83(m,2H),8.07(s,1H);
MS m/z(ESI):768.2[M+H]
+.
实施例56
1-((3aR,6aS)-5-(1-(4-((5-溴-4-((5-(二甲基磷基)-2,3-二氢苯并[b][1,4]二噁英-6-基)氨基)嘧啶-2-基)氨基)-5-甲氧基-2-甲基苯基)哌啶-4-基)六氢吡咯并[3,4-c]吡咯-2(1H)-基)乙烷-1-酮的制备
1-((3aR,6aS)-5-(1-(4-((5-溴-4-((5-(二甲基磷基)-2,3-二氢苯并[b][1,4]二噁英-6-基)氨基)嘧啶-2-基)氨基)-5-甲氧基-2-甲基苯基)哌啶-4-基)六氢吡咯并[3,4-c]吡咯-2(1H)-基)乙烷-1-酮的制备方法参照实施例1。
1H NMR(400MHz,CD
3OD)δ1.78-1.90(m,5H),1.91(s,3H),2.09(s,3H),2.12-2.22(m,5H),2.73(t,J=11.8Hz,2H),2.97-3.23(m,7H),3.54-3.67(m,5H),3.75-3.82(m,1H),3.84(s,3H),4.25-4.32(m,2H),4.33-4.39(m,2H),6.71(s,1H),6.91(d,J=9.1Hz,1H),7.72(s,1H),7.87-7.92(m,1H),8.06(s,1H);
MS m/z(ESI):754.2[M+H]
+.
实施例57
(6-((5-溴-2-((2-甲氧基-5-甲基-4-(4-((3aR,6aS)-四氢-1H-呋喃并[3,4-c]吡咯-5(3H)-基)哌啶-1-基)苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备
第一步:(6-((5-溴-2-((2-甲氧基-5-甲基-4-(4-((3aR,6aS)-四氢-1H-呋喃并[3,4-c]吡咯-5(3H)-基)哌啶-1-基)苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备
室温条件下,1-(4-((5-溴-4-((5-(二甲基磷基)-2,3-二氢苯并[b][1,4]二噁英-6-基)氨基)嘧啶-2-基)氨基)-5-甲氧基-2-甲基苯基)哌啶-4-酮(0.25g,0.41mmol),(3aR,6aS)-六氢-1H-呋喃并[3,4-c]吡咯(0.07g,0.61mmol)和醋酸(3滴)混溶于二氯乙烷(10mL)中,搅拌30分钟,加入三乙酰氧基硼氢化钠(0.17g,0.81mmol),室温搅拌过夜,向反应液中加入饱和碳酸氢钠水溶液,用二氯甲烷萃取,分离有机相,用无水硫酸钠干燥,过滤后减压浓缩有机溶剂,柱层析分离得到标题化合物(6-((5-溴-2-((2-甲氧基-5-甲基-4-(4-((3aR,6aS)-四氢-1H-呋喃并[3,4-c]吡咯-5(3H)-基)哌啶-1-基)苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化(0.17g,收率:58%)。
1H NMR(400MHz,DMSO-d
6)δ1.49-1.62(m,2H),1.78(s,3H),1.81(s,3H),1.89-1.95(m,2H),2.04-2.15(m,4H),2.38-2.43(m,2H),2.58-2.72(m,6H),3.02-3.07(m,2H),3.35-3.43(m,2H),3.72-3.80(m,5H),4.24(s,2H),4.32(s,2H),6.70(s,1H),6.80(d,J=8.8Hz,1H),7.43(s,1H),7.91-7.97(m,2H),8.10(s,1H),11.62(s,1H);
MS m/z(ESI):713.2[M+H]
+.
实施例58
(6-((5-溴-2-((5-乙基-2-甲氧基-4-(4-((3aR,6aS)-四氢-1H-呋喃并[3,4-c]吡咯-5(3H)-基)哌啶-1-基)苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备
(6-((5-溴-2-((5-乙基-2-甲氧基-4-(4-((3aR,6aS)-四氢-1H-呋喃并[3,4-c]吡咯-5(3H)-基)哌啶-1-基)苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备方法参照实施例2。
1H NMR(400MHz,CD
3OD)δ1.03(t,J=7.6Hz,3H),1.87-1.91(m,8H),2.17-2.19(m,2H),2.56-2.58(m,2H),2.77-2.79(m,2H),2.90(s,3H),3.08-3.11(m4H),3.65-3.68(m,4H),3.83-3.86(m,5H),4.32-4.35(m,4H),6.76(s,1H),6.91-6.93(m,1H),7.80-7.83(m,2H),8.07(s,1H);
MS m/z(ESI):727.2[M+H]
+.
实施例59
(6-((5-溴-2-((5-甲基-4-(4-(4-甲基哌嗪-1-基)哌啶-1-基)-2,3-二氢苯并呋喃-7-基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备
第一步:5-甲基-2,3-二氢苯并呋喃的制备
往5-甲基苯并呋喃(3.0g,22.7mmol)的甲醇溶液(30mL)中加入Pd/C(300mg,10wt%),在氢气氛下,常温常压,搅拌过夜。用硅藻土滤除不溶物,滤液减压浓缩有机溶剂,柱层析分离得到标题化合物5-甲基-2,3-二氢苯并呋喃(2.70g,收率:89%)。
第二步:5-甲基-7-硝基-2,3-二氢苯并呋喃的制备
冰水浴下,往5-甲基-2,3-二氢苯并呋喃(2.70g,20.1mmol)的TFA溶液(40mL)里分批加入NaNO
2(1.36g,19.7mmol),然后继续在冰水浴下搅拌两小时。向反应中加入冰水,然后用DCM萃取多次,合并有机相,依次用饱和碳酸氢钠水溶液和饱和食盐水洗涤,分离有机相用无水硫酸钠干燥,过滤后减压浓缩有机 溶剂,柱层析分离得到标题化合物5-甲基-7-硝基-2,3-二氢苯并呋喃(900mg,收率:25%)。
第三步:5-甲基-2,3-二氢苯并呋喃-7-胺的制备
往5-甲基-7-硝基-2,3-二氢苯并呋喃(900mg,5.03mmol)的甲醇溶液(30mL)中加入Pd/C(100mg,10wt%),在氢气氛下,常温常压,搅拌过夜。用硅藻土滤除不溶物,滤液浓缩,柱层析分离得到标题化合物5-甲基-2,3-二氢苯并呋喃-7-胺(670mg,收率:89%)。
MS m/z(ESI):150.1[M+H]
+.
第四步:4-溴-5-甲基-2,3-二氢苯并呋喃-7-胺的制备
-30℃下,往5-甲基-2,3-二氢苯并呋喃-7-胺(650mg,4.36mmol)的DMF溶液(20mL)里分批加入NBS(466mg,2.62mmol),反应缓慢升至室温,并在室温下继续搅拌两小时。用EtOAc稀释反应液后,用饱和食盐水洗涤多次,滤液用无水硫酸钠干燥,减压浓缩有机溶剂,柱层析分离得到标题化合物4-溴-5-甲基-2,3-二氢苯并呋喃-7-胺(600mg,收率:60%)。
MS m/z(ESI):228.0[M+H]
+.
第五步:N-(4-溴-5-甲基-2,3-二氢苯并呋喃-7-基)乙酰胺的制备
冰水浴下,往4-溴-5-甲基-2,3-二氢苯并呋喃-7-胺(400mg,1.75mmol)的二氯甲烷溶液(10mL)里依次滴加入乙酸酐(0.233mL,2.46mmol)和DIPEA(0.864mL,5.25mmol),反应然后缓慢升至室温,并在室温下继续搅拌两小时。减压浓缩反应液,柱层析分离纯化得到标题化合物N-(4-溴-5-甲基-2,3-二氢苯并呋喃-7-基)乙酰胺(385mg,收率:81%)。
MS m/z(ESI):270.0[M+H]
+.
第六步:N-(5-甲基-4-(4-(4-甲基哌嗪-1-基)哌啶-1-基)-2,3-二氢苯并呋喃-7-基)乙酰胺的制备
往N-(4-溴-5-甲基-2,3-二氢苯并呋喃-7-基)乙酰胺(385mg,1.43mmol)和1-甲基-4-(哌啶-4-基)哌嗪(783mg,4.28mmol)的THF溶液(10mL)里,依次加入醋酸钯(48mg,0.215mmol)、Johnphos(128mg,0.430mmol)和LiHMDS(1M in THF,4.3mL),氮气保护下,微波115℃下反应2小时。反应冷却至室温,浓缩反应液,柱层析分离得到标题化合物N-(5-甲基-4-(4-(4-甲基哌嗪-1-基)哌啶-1-基)-2,3-二氢苯并呋喃-7-基)乙酰胺(225mg,收率:42%)。
MS m/z(ESI):373.3[M+H]
+.
第七步:5-甲基-4-(4-(4-甲基哌嗪-1-基)哌啶-1-基)-2,3-二氢苯并呋喃-7-胺的制备
往N-(5-甲基-4-(4-(4-甲基哌嗪-1-基)哌啶-1-基)-2,3-二氢苯并呋喃-7-基)乙酰胺(125mg,0.336mmol)的乙醇溶液(10mL)里小心加入浓硫酸(1mL),加热回流下搅拌一小时,冷却,浓缩,用DCM溶解,再依次用饱和碳酸氢钠水溶液、饱和食盐水洗涤,干燥,柱层析,得标题化合物5-甲基-4-(4-(4-甲基哌嗪-1-基)哌啶-1-基)-2,3-二氢苯并呋喃-7-胺(80mg,收率:72%)。
MS m/z(ESI):331.2[M+H]
+.
(6-((5-溴-2-((5-甲基-4-(4-(4-甲基哌嗪-1-基)哌啶-1-基)-2,3-二氢苯并呋喃-7-基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化的制备方法参照实施例1。
1H NMR(400MHz,CD
3OD)δ1.70(d,J=12.0Hz,2H),1.87(s,3H),1.91(s,3H),2.00(d,J=13.2Hz,3H),2.16(s,3H),2.53(s,3H),2.60-2.65(m,1H),2.73-3.17(m,13H),4.27(s,2H),4.34(d,J=4.3Hz,2H),4.48(t,J=8.6Hz,2H),6.84(d,J=9.3Hz,1H),7.30(s,1H),7.97(d,J=9.3Hz,1H),8.03(s,1H);
MS m/z(ESI):712.2[M+H]
+.
二、
生物学测试评价
以下结合测试例进一步描述解释本发明,但这些实施例并非意味着限制本发明的范围。
测试例1、本发明化合物对EGFR野生型、EGFR del746-750/T790M/C797S和EGFR L858R/T790M/C797S突变激酶抑制活性的测定
实验目的:该测试例的目的是测试化合物对EGFR野生型、EGFR del746-750/T790M/C797S和EGFR L858R/T790M/C797S突变激酶的抑制活性。
实验仪器:离心机(5810R)购自Eppendorf公司,移液器购自Eppendorf或Rainin公司,酶标仪购自美国BioTek公司,型号为SynergyH1全功能酶标仪。
实验方法:本实验采用Cisbio公司的HTRF激酶测定方法(Cisbio#62TK0PEB),底物多肽TK和ATP在酪氨酸激酶EGFR野生型、EGFR del746-750/T790M/C797S或EGFR L858R/T790M/C797S突变存在的条件下发生催化反应,底物被磷酸化,通过测定反应中生成的磷酸化底物的含量来表征激酶的活性,并得出化合物对EGFR野生型、EGFR del746-750/T790M/C797S或EGFR L858R/T790M/C797S突变激酶活性抑制的半数抑制浓度IC
50。
具体实验操作如下:
激酶反应在白色384孔板(Perkin Elmer#6008280)中进行,每孔加入1~5μL 用含1%DMSO的ddH
2O稀释的不同浓度的化合物,阳性对照孔加入1~5μL含1%DMSO的ddH
2O,然后每孔加入1~5μL用Dilution buffer(5×激酶缓冲液,MgCl
2 6.65mM,MnCl
2 1.33mM,DTT 1.33mM)稀释的0.5~5nM 4×EGFR野生型、EGFR del746-750/T790M/C797S或EGFR L858R/T790M/C797S突变的激酶溶液,阴性对照孔加入1~5μL的Dilution buffer,所有孔加入1~5μL用10×Dilution buffer配制的4μM 4×底物TK溶液,最后加入1~5μL用Dilution buffer稀释的24μM 4×ATP溶液启动反应,室温反应120分钟后,每孔加入10μL检测液(TK抗体16nM,XL665 0.5μM)室温避光反应20分钟后用BioTek Synergy H1酶标仪检测化学发光值。
实验数据处理方法:
通过于板上阳性对照孔(DMSO对照孔)和阴性对照孔(不添加激酶)计算使用化合物处理的孔的百分比抑制数据{%抑制率=100-[(测试化合物值-阴性对照值)]/(阳性对照值-阴性对照值)×100}。使用GraphPad prism拟合不同浓度和相应百分比抑制率数据至4参数非线性逻辑公式计算出IC
50值,具体数据如下表所示:
实验结论:
通过以上方案得出,本发明所示的实施例化合物对EGFR突变的激酶活性具有较强的抑制作用,而对EGFR野生型激酶活性抑制作用较小,对比数据可知,本发明系列实施例化合物对EGFR突变的/野生型激酶活性的抑制具有高选择性。
测试例2、本发明化合物对EGFR del746-750/C797S和EGFR L858R/C797S突变的激酶抑制活性的测定
实验目的:该测试例的目的是测试化合物对EGFR del746-750/C797S和EGFR L858R/C797S突变激酶的抑制活性。
实验仪器:离心机(5810R)购自Eppendorf公司,移液器购自Eppendorf或Rainin公司,酶标仪购自美国BioTek公司,型号为SynergyH1全功能酶标仪。
实验方法:本实验采用Cisbio公司的HTRF激酶测定方法(Cisbio#62TK0PEB),底物多肽TK和ATP在酪氨酸激酶EGFR del746-750/C797S或EGFR L858R/C797S突变存在的条件下发生催化反应,底物 被磷酸化,通过测定反应中生成的磷酸化底物的含量来表征激酶的活性,并得出化合物对EGFR del746-750/C797S或EGFR L858R/C797S突变激酶活性抑制的半数抑制浓度IC
50。
具体实验操作如下:
激酶反应在白色384孔板(Perkin Elmer#6008280)中进行,每孔加入1~5μL用含1%DMSO的ddH
2O稀释的不同浓度的化合物,阳性对照孔加入1~5μL含1%DMSO的ddH
2O,然后每孔加入1~5μL用Dilution buffer(5×激酶缓冲液,MgCl
2 6.65mM,MnCl
2 1.33mM,DTT 1.33mM)稀释的0.5~5nM 4×EGFR del746-750/C797S或EGFR L858R/C797S突变的激酶溶液,阴性对照孔加入1~5μL的Dilution buffer,所有孔加入1~5μL用10×Dilution buffer配制的4μM 4×底物TK溶液,最后加入1~5μL用Dilution buffer稀释的24μM 4×ATP溶液启动反应,室温反应120分钟后,每孔加入10μL检测液(TK抗体16nM,XL665 0.5μM)室温避光反应20分钟后用BioTek Synergy H1酶标仪检测化学发光值。
实验数据处理方法:
通过于板上阳性对照孔(DMSO对照孔)和阴性对照孔(不添加激酶)计算使用化合物处理的孔的百分比抑制数据{%抑制率=100-[(测试化合物值-阴性对照值)]/(阳性对照值-阴性对照值)×100}。使用GraphPad prism拟合不同浓度和相应百分比抑制率数据至4参数非线性逻辑公式计算出IC
50值,具体数据如下表所示:
实验结论:
通过以上方案得出,本发明所示的实施例化合物对EGFR del746-750/C797S或EGFR L858R/C797S突变的激酶活性具有较强的抑制作用
测试例3:细胞增殖抑制实验
实验目的:该测试例的目的是测试化合物对细胞的增殖抑制活性。
实验仪器:移液器购自Eppendorf公司,CO
2培养箱购自美国Thermo公司,酶标仪购自美国BioTek公司,型号为SynergyH1全功能酶标仪。
实验方法:本实验采用CTG(CELL TITER-GLO)发光法检测化合物对A431细胞和Ba/F3(EGFR del746-750/T790M/C797S)细胞的增殖抑制活性,并得出化合物对细胞增殖活性的半数抑制浓度IC
50。
具体实验操作如下:
对于A431细胞:第一天,在96孔检测板中铺入90μL A431细胞悬液,每孔细胞个数为3000个,其中阴性对照不加细胞,将板放入含5%CO
2的37℃培养箱中培养过夜。第二天,每孔加入10μL梯度稀释好的化合物溶液,阳性和阴性对照孔只加入含DMSO的10μL培养基,将板放入二氧化碳培养箱孵育72小时。培养72h后,向细胞板的每个孔中加入50μL Cell Titer Glo,避光震荡2min后静置10min;之后在BioTek Synergy H1酶标仪检测发光值,通过化学发光信号值计算抑制率,根据不同浓度的抑制率通过曲线拟合得出化合物的IC
50。
对于Ba/F3(EGFR del746-750/T790M/C797S)悬浮细胞:
在96孔检测板中铺入90μL Ba/F3细胞悬液,每孔细胞个数为3000个,其中阴性对照不加细胞;静置2h后每孔加入10μL梯度稀释好的化合物溶液,阳性和阴性对照孔只加入含DMSO的10μL培养基,放入二氧化碳培养箱培养72小时后同前述A431细胞的方法进行CTG检测。
实验数据处理方法:
通过板上阳性对照孔(DMSO对照孔)和阴性对照孔(不加细胞)计算使用化合物处理的孔的百分比抑制数据{%抑制率=100-[(测试化合物值-阴性对照值)]/(阳性对照值-阴性对照值)×100}。使用GraphPad prism拟合不同浓度和相应百分比抑制率数据至4参数非线性逻辑公式计算出IC
50值,具体数据如下表所示:
实验结论:
通过以上方案得出,本发明所示的实施例化合物在Ba/F3(EGFR del746-750/T790M/C797S)突变细胞增殖活性的抑制试验中具有良好的抑制作用,而对A431细胞具有较弱的抑制作用,对比数据可知,本发明系列实施例化合物对Ba/F3(EGFR del746-750/T790M/C797S)突变细胞增殖活性的抑制具有高选择性。
测试例4、本发明化合物对细胞EGFR磷酸化抑制作用的测定
实验目的:该测试例的目的是测试化合物对细胞EGFR磷酸化的抑制活性。
实验仪器:微孔板振荡器(88880024)购自Thermo Scientific
TM公司,离心机(5702R)购自Eppendorf公司,移液器购自Eppendorf公司,酶标仪购自美国Biotech公司,型号为SynergyH1全功能酶标仪。
实验试剂:Phospho-EGFR(Tyr1068)LANCE Ultra TR-FRET Cellular Detection Kit(Perkin Elmer TRF4016C)内含(5X)LANCE Ultra Lysis Buffer 1,LANCE Ultra Eu-labeled Anti-EGFR(Y1068)Antibody,LANCE Ultra ULight-labeled Anti-EGFR Antibody,EGF(Thermo fisher PHG0311);
实验方法:本实验采用Ba/F3(EGFR del746-750/T790M/C797S)细胞系,通过EGF刺激激活EGFR信号通路,检测化合物对其下游EGFR(Y1068)磷酸化的抑制活性,并得出化合物对EGFR信号通路活性的半数抑制浓度IC
50。
具体实验操作如下:
384孔检测板中铺入Ba/F3(EGFR del746-750/T790M/C797S)细胞3-12μL,每孔细胞个数为100-300K,加入2μL梯度稀释好的化合物溶液,室温,350rpm,孵育2小时。2小时后加入2μL EGF,EGF终浓度50nM,室温震荡15min。加入2-5μL(5X)LANCE Ultra Lysis Buffer 1溶液,室温震荡2h。2h后加入5μL终浓度为0.5nM的LANCE Ultra Eu-labeled Anti-EGFR(Y1068)Antibody(PerkinElmer)和终浓度为5nM的LANCE Ultra ULight-labeled Anti-EGFR Antibody(PerkinElmer)溶液,室温孵育过夜。酶标仪测定各板孔的665nm荧光信号值,通过荧光信号值计算抑制率,根据不同浓度的抑制率通过曲线拟合得出化合物的IC
50。
实验数据处理方法:
通过于板上阳性对照孔(DMSO对照孔)和阴性对照孔(不加细胞)计算使用化合物处理的孔的百分比抑制数据{%抑制率=100-[(测试化合物值-阴性对照值)]/(阳性对照值-阴性对照值)×100}。使用GraphPad prism拟合不同浓度和相应百分比抑制率数据至4参数非线性逻辑公式计算出IC
50值。
实施例编号 | Ba/F3(EGFR del746-750/T790M/C797S)pEGFR IC 50(nM) |
实施例1 | 0.06 |
实施例2 | 0.39 |
实施例12 | 2.57 |
实施例13 | 1.65 |
实施例15 | 5.00 |
实施例16 | 0.21 |
实施例20 | 1.74 |
实施例34 | 0.11 |
实施例38 | 1.15 |
实施例42 | 6.93 |
实施例48 | 2.65 |
实施例52 | 5.00 |
实施例34 | 0.11 |
实施例55 | 0.88 |
实施例57 | 0.82 |
实施例58 | 0.95 |
实施例59 | 2.63 |
实验结论:
通过以上方案得出,本发明所示的实施例化合物对Ba/F3(EGFR del746-750/T790M/C797S)细胞的EGFR磷酸化具有良好的抑制作用。
测试例5:Balb/C小鼠药代动力学测定
5.1研究目的:
以Balb/C小鼠为受试动物,研究化合物实施例,在5mg/kg剂量下口服给药在小鼠体内血浆的药代动力学行为。
5.2试验方案
5.2.1试验药品:
本发明实施例化合物,自制。
5.2.2试验动物:
Balb/C Mouse(6只/实施例),雄性,上海杰思捷实验动物有限公司,动物生产许可证号(SCXK(沪)2013-0006N0.311620400001794)。
5.2.3制剂处方:
0.5%CMC-Na(1%Tween80),超声溶解,配制为澄清溶液或均一混悬液。
5.2.4给药:
Balb/C小鼠(6只/实施例),雄性;禁食一夜后分别p.o.,剂量为5mg/kg,给药体积10mL/kg。
5.2.5样品采集:
小鼠给药前和给药后,在0、0.5、1、2、4、6、8和24小时,采用眼眶采 血0.1mL,置于EDTA-K
2试管中,4℃6000rpm离心6min分离血浆,于-80℃保存。
5.2.6样品处理:
1)血浆样品40μL加入160μL乙腈沉淀,混合后3500×g离心5~20分钟。
2)取处理后上清溶液100μL进行LC/MS/MS分析待测化合物的浓度。
5.2.7液相分析
●液相条件:Shimadzu LC-20AD泵
●质谱条件:AB Sciex API 4000质谱仪
●色谱柱:phenomenex Gemiu 5um C18 50×4.6mm
●移动相:A液为0.1%甲酸水溶液,B液为乙腈
●流速:0.8mL/min
●洗脱时间:0-4.0分钟,洗脱液如下:
5.3试验结果与分析
药代动力学主要参数用WinNonlin 6.1计算得到,小鼠药代实验结果见下表:
化合物 | t max(h) | C max(ng/mL) | AUC 0-t(ng/mL*h) | AUC 0-∞(ng/mL*h) | t 1/2(h) | MRT 0-∞(h) |
实施例1-FA | 2.0 | 1933 | 11593 | 11631 | 2.9 | 4.7 |
实施例2-FA | 2.0 | 2113 | 21017 | 21383 | 4.0 | 6.3 |
实施例12-FA | 4.0 | 3233 | 38816 | 38967 | 2.8 | 6.1 |
实施例13-FA | 2.0 | 2707 | 25304 | 25344 | 2.5 | 5.3 |
实施例15-FA | 2.0 | 1680 | 16368 | 16511 | 5.6 | 6.0 |
实施例16-FA | 2.0 | 2027 | 25171 | 25328 | 3.2 | 6.1 |
实施例20-FA | 1.0 | 1257 | 11104 | 11200 | 3.5 | 5.5 |
实施例21-FA | 2.0 | 1340 | 11759 | 11844 | 4.2 | 5.6 |
实施例33-FA | 2.0 | 2280 | 8168 | 8178 | 1.1 | 3.0 |
实施例49-FA | 2.0 | 1470 | 12341 | 12535 | 4.2 | 6.0 |
实施例52-FA | 2.0 | 2323 | 18009 | 18175 | 3.5 | 5.5 |
实施例53-FA | 2.0 | 3327 | 20587 | 20594 | 1.8 | 3.8 |
实施例57-FA | 2.0 | 1793 | 16737 | 16880 | 3.4 | 5.8 |
实施例59-FA | 2.0 | 1143 | 9007 | 9044 | 3.2 | 5.2 |
注:FA为相应化合物的甲酸盐。
实验结论:
从表中小鼠药代实验结果可以看出,本发明实施例化合物表现出良好的代谢性质,暴露量AUC和最大血药浓度C
max都表现良好。
测试例6:本发明实施例化合物的体内药效试验
6.1实验目的
通过体内药效实验筛选出药效较为明显且毒副作用较小的化合物。
6.2实验主要仪器和材料
6.2.1仪器:
仪器 | 供应商 | 型号 |
分析天平 | 梅特勒 | XS 105 |
分析天平 | 梅特勒 | AL204 |
数显卡尺 | Sylvac | 0~150mm |
电子天平 | OHAUS | Scout pro |
移液枪 | RANIN | 100ul-1ml |
移液枪 | RANIN | 20ul-200ul |
电动助吸器 | Pipet-Lite | M20 |
生物安全柜 | 苏净安泰 | BSC-1604IIA2 |
CO 2孵箱 | SANYO | MCO-18AIC |
台式离心机 | Thermo Fisher | ST16R |
生物安全柜 | 苏净安泰 | BHC-1300IIA2 |
6.2.2试剂:
试剂 | 供应商 | 货号 |
Matrigel | Corning | 354234 |
FBS | Gibco | 10099-141C |
Trypsin | Gibco | 25200-072 |
RPMI1640 | Hyclone | SH30809.01 |
Puromycin | Gibco | A11138-03 |
HPMC | Sigma | H3785 |
6.2.3动物:
NOD/SCID小鼠,6-8周,♀,购自江苏集萃药康生物科技有限公司。
6.3实验步骤
6.3.1细胞培养
PC9(EGFR Del19/T790M/C797S)细胞培养在含10%胎牛血清的RPMI1640培养液中。收集指数生长期的PC9(EGFR Del19/T790M/C797S)细胞。
6.3.2细胞接种
实验小鼠于右侧背部皮下(小鼠右侧背部,前肢附近的皮下)接种1×10
7PC9(EGFR Del19/T790M/C797S)细胞,细胞重悬在1:1的PBS与基质胶中(0.1ml/只),定期观察肿瘤生长情况,肿瘤细胞接种当天定义为第0天。
6.3.3荷瘤鼠量瘤、分组、给药
a,day7测量肿瘤体积数据,并选择肿瘤体积在100-200mm
3范围的小鼠,按照平均体积140mm
3,根据肿瘤大小和小鼠体重随机分组给药。
c,根据分组结果,开始给予测试药物(给药方式:口服给药;给药体积:10mL/kg;给药频率:1次/天;给药周期:21天;溶媒:0.5%HPMC)。
d,开始给予测试药物后每周两次量瘤、称重。
e,实验结束后安乐死动物。
f,用Excel等软件处理数据。化合物抑瘤率TGI(%)的计算:TGI%=[1-(T
i-T
0)/(C
i-C
0)]×100%;其中,T
i为给药组第i天瘤体积,T
0为给药组分组当天瘤体积,C
i为溶剂对照组第i天瘤体积,C
0为溶剂对照组分组当天瘤体积。
6.4试验数据如下表:
6.5实验结果
从上述结果中可以看出,本专利的上述化合物有较好的抑瘤率,且安全性较好。
三、晶型研究
1.实验仪器
1.1物理化学检测仪器的一些参数
1.2仪器和液相分析条件
1.2.1仪器与设备
仪器名称 | 型号 |
分析天平 | Sartorius BSA224S-CW |
纯水机 | Milli-Q Plus,Millipore |
高效液相色谱仪 | Agilent1260 |
泵 | Agilent G1311B |
进样器 | G1329B |
柱温箱 | G1316A |
检测器 | G1315D |
1.2.2色谱条件
色谱柱:ZORBAX(SB-C8,3.5μm,4.6*75mm)
流速:1mL/min
柱温:40℃
检测波长:235nm
进样体积:5.0μL
运行时间:15min
稀释剂:ACN-水(v/v,1:1)
流动相:A:水(0.05%三氟乙酸);B:乙腈(0.05%三氟乙酸)
T(min) | A(%) | B(%) |
0.00 | 90 | 10 |
3.00 | 70 | 30 |
10.00 | 50 | 50 |
12.00 | 30 | 70 |
12.01 | 90 | 10 |
15.00 | 90 | 10 |
2.晶型的制备
1.晶型H的制备
称量约20mg的游离碱粗品无定型到2mL的玻璃瓶中,加入100μL有机溶剂(有机溶剂可选Acetone、ACN及EA、),在室温下打浆12h,最后固体快速离心,去除上清液,40℃真空干燥,得到晶型H。经检测分析,其有如下如图1所示的XRPD图、如图2所示的DSC图及如图3所示的TGA图。
2.晶型N的制备
称量约250.0g的游离碱加入2.0L(8.0V)正辛醇,搅拌升温至90℃。控温80-90℃滴加16.0L(64.0V)正庚烷。加毕,油浴中自然冷却到20-30℃,搅拌16h,过滤,60℃真空干燥,得晶型N。
或者称量约1.0g的游离碱加入8.0mL(8.0V)正己醇,搅拌升温至90℃。控温80-90℃滴加60.0mL(64.0V)正庚烷。加毕,油浴中自然冷却到20-30℃,搅拌16h,过滤,60℃真空干燥,得晶型N。经检测分析,其有如下如图4所示的XRPD图、如图5所示的DSC图及如图6所示的TGA图。
3.晶型O的制备
称量约1.0g的游离碱加入14.0mL(14.0V)仲戊醇,搅拌升温至90℃溶清。控温80-90℃滴加84.0mL(84.0V)正庚烷。加毕,油浴中自然冷却到20-30℃,搅拌16h,过滤,60℃真空干燥,得晶型O。经检测分析,其有如下如图7所示的XRPD图、如图8所示的DSC图。
或者称量约1.0g的游离碱加入14.0mL(14.0V)正丁醇,搅拌升温至90℃溶清。控温80-90℃滴加84.0mL(84.0V)正庚烷。加毕,油浴中自然冷却到20-30℃,搅拌16h,过滤,60℃真空干燥,得晶型O。经检测分析,其有如下如图7所示的XRPD图、如图8所示的DSC图。
或者称量约60.0g的游离碱加入180.0mL(3.0V)乙醇,搅拌升温回流。回流状态下滴加1080.0mL(36.0V)甲基叔丁基醚。加毕,油浴中自然冷却到20-30℃,搅拌17h,过滤,60℃真空干燥,得晶型O。经检测分析,其有如下如图7所示的XRPD图、如图8所示的DSC图。
4.晶型I的制备
称量约20mg的游离碱晶型H加入200μL THF50℃下搅拌溶清,转至室温下,加入600μL水仍澄清,继续搅拌一定时间后析出大量白色固体,室温搅拌2h后将固体快速离心,去除上清液,40℃真空干燥,得到晶型I。经检测分析,其有如下如图9所示的XRPD图及如图10所示的DSC图。
3.晶型竞争实验
a、晶型H与晶型O竞争实验
取晶型H样品0.2g,晶型O样品0.2g,加入3.0mL甲基叔丁基醚,20-30℃打浆16h,过滤,60℃真空干燥,得0.35g固体,XRD检测,H晶型转化为O晶型。
b、晶型H与晶型N竞争实验
取晶型H样品0.2g,晶型N样品0.2g,加入3.0mL甲基叔丁基醚,20-30℃打浆16h,过滤,60℃真空干燥,得0.30g固体,XRD检测,H晶型转化为N晶型。
上述实验表明,N晶型及O晶型更稳定,放大后更易制备。
4.固体稳定性实验
4.1实验目的:
考察游离碱晶型H在高温60℃下,化合物的物理化学稳定性,为晶型筛选与化合物贮存提供依据。
4.2实验方案:
取游离碱晶型H约2mg,于烘箱60℃中,考察5天、10天,用HPLC,外标法测定含量,并采用色谱峰面积归一化法计算有关物质的变化。
4.3实验结果:
自由碱晶型H物理化学稳定性结果:
以上实验结果表明,晶型H的物理化学性质比较稳定
5.动态引湿性实验
5.1实验目的
考察化合物自由碱晶型H在不同相对湿度条件下的引湿性,为化合物晶型筛选与贮存提供依据。
5.2实验方案:
将化合物自由碱晶型H置不同相对湿度的饱和水蒸气中,使化合物与水蒸气达到动态平衡,并计算平衡后化合物吸湿增重的百分数。
5.3实验结果:
自由碱晶型H经0-95%相对湿度条件下吸湿与解吸湿循环1次,自由碱晶型H的XRPD谱图并未发生改变,即晶型未转变。
6.不同介质中溶解度实验
6.1实验目的
比较自由碱晶型H在水、人工模拟胃液(SGF)、禁食人工模拟肠液(FaSSIF)及非禁食人工模拟肠液(FeSSIF)等媒介中溶解度大小,为可成药性评估提供依据。
6.2实验方案:
将约2mg自由碱晶型H混悬到不同介质中2小时,用HPLC,外标法测定化合物37℃下的热力学溶解度。
6.3实验结果:
以上实验结果表明,晶型H在不pH值条件下的溶解度较好,适合成药。
7.动物PK研究
7.1实验目的:
以SD大鼠为受试动物,研究游离碱晶型H单次口服给药在大鼠体内(血浆)的药代动力学行为,比较暴露量的变化;计算游离碱晶型H口服给药的生物利用度。
7.2实验方案:
游离碱晶型H用含0.5%的HPMC K
4M的水溶液混悬均匀后,灌胃,大鼠给 药,平行三只大鼠,给药剂量为游离碱晶型H(30mg/kg、100mg/kg为混悬液)。
7.3实验结果:
8.稳定晶型确认实验
8.1实验目的:
通过晶型打浆实验及稳定性考察实验找到比较稳定的化合物晶型。
8.2实验方案:
选择有一定溶解度的有机溶剂、水,将晶型H悬浮于溶剂体系中,一定温度下搅拌打浆;将晶型H分别至于不同条件下考察晶型变化。最后将固体处理,测定固体的XRPD并进行比较。
8.3实验结果:
晶型H在不同溶剂中打浆晶型转变情况:
溶剂 | 晶型H打浆情况 |
MeOH | 50℃1天仍为晶型H |
EtOH | 50℃1天仍为晶型H |
Acetone | 50℃1天仍为晶型H |
ACN | 50℃1天仍为晶型H |
THF | 溶解 |
EA | 50℃1天仍为晶型H |
H 2O | 50℃1天仍为晶型H |
8.4不同晶型在不同影响因素条件下的转变关系:
将晶型H和N放置在不同条件下考察晶型转变的情况:
晶型H的稳定性考察:
高温60℃ | 室温高湿RH=92.5% | 高温50℃高湿RH=75% | |
晶型H | 30天未转晶 | 30天未转晶 | 30天未转晶 |
晶型N的稳定性考察:
(1)影响因素试验
(2)湿热、压片、粉碎后晶型N的稳定性
I.湿热处理:称取原料0.992g,经0.515g纯化水制粒后,60℃下干燥60min。
II.压力处理:片重/g:0.150,硬度/kgf:3.10、1.48、3.41。
III.粉碎:设计原料粉碎时,称取原料晶型N50g,螺杆转速档为5,考察三个转速/rpm:3000、7500、12000。
结果如下:
条件 | 晶型 |
未处理 | 晶型N |
湿热 | 晶型N |
压力 | 晶型N |
粉碎 | 晶型N |
(3)原料和制剂的晶型对比研究
称取原料药晶型N,按照制剂工艺制成片剂,比较原料药和制剂样品的稳定性。
I.粉碎:晶型N原料药采用锤式粉碎机在3000~5000rpm条件下粉碎处理。
II.混合:根据工艺要求设定混合刀转速100rpm,制粒刀转速600rpm。将处方量微晶纤维素、晶型N原料加至湿法制粒锅中,进行预混I,混合时间5min;再将处方量乳糖、羧甲淀粉钠(内加)、预胶化淀粉按顺序加入,进行预混II,混合时间10min。
III.制粒:根据工艺要求设定相关参数,启动设备,进行I速制粒(混合刀转速 100rpm,制粒刀转速1000rpm),将润湿剂水通过蠕动泵匀速的泵入湿法混合制粒机中;I速制粒结束后进行II速制粒(混合刀转速150rpm,制粒刀转速1500rpm)。
IV.湿整粒:根据工艺要求设定相关参数,将湿物料经4750μm方形筛网进行湿整粒处理(整粒刀转速995.7rpm)。
V.干燥:启动风机开始干燥,待物料温度达到40℃后,取样测定水分,若合格,则出料;若不合格,继续干燥,每隔5min取样检测并记录各参数,颗粒水分控制在3.0%以下。
VI.干整粒:将干燥后的物料经991μm平口筛网进行整粒处理。
VII.总混:将干整粒后物料、羧甲淀粉钠(外加)、硬脂酸镁加至料斗混合机中,根据工艺要求,设定混合机转速10rpm,混合时间10min。
VIII.压片:
30mg规格:硬度控制为9.00kgf。
IX.包衣
使用处方量薄膜包衣预混剂(胃溶型),进行包衣操作。目标增重为3.0%
结果如下:
原料药 | 制剂样品(30mg片剂) |
晶型N | 晶型N |
以上结果表明,晶型H和晶型N在光照、高温、高湿、湿热、过筛、压片及制备成制剂产品情况下,未发生转晶,晶型H和N比较稳定。
Claims (16)
- 一种通式(I)所示化合物的晶型,其中,环A选自3-12元杂环基;优选3-8元杂环基;更优选含1-2个N或O原子的3-8元单环杂环基或稠杂环基;进一步优选以下基团:R a选自氢、氘、卤素、氨基、硝基、羟基、氰基、C 1-6烷基、C 1-6氘代烷基、C 1-6卤代烷基、C 1-6羟烷基、C 1-6氰基烷基、C 1-6烷氧基、C 1-6卤代烷氧基、-(CH 2) nOR aa、-(CH 2) nNR aaR bb、-(CH 2) nC(O)R aa或-(CH 2) nS(O) mR aa,优选氢、氘、卤素、羟基、C 1-3烷基、C 1-3卤代烷基、C 1-3羟烷基、C 1-3氰基烷基、C 1-3烷氧基、-(CH 2) nOR aa、-(CH 2) nNR aaR bb、-(CH 2) nC(O)R aa或-(CH 2) nS(O) mR aa,更优选氢、氘、氟、氯、溴、羟基、甲基、乙基、异丙基、-(CH 2) 2F、-CH 2OH、-C(CH 3) 2OH、-CH 2CN、-OCH 2CH 3、-CH 2OCH 3、-C(O)CH 3、-S(O) 2CH 3、-N(CH 3) 2、-NCH 3(CH 2CH 3)或R aa和R bb各自独立地选自氢、氘、卤素、氨基、硝基、羟基、氰基、C 1-6烷基、C 1-6氘代烷基、C 1-6卤代烷基、C 1-6烷氧基、卤代烷氧基、C 2-6烯基、C 2-6炔基、环烷基、杂环基、芳基或杂芳基,优选氢、甲基、乙基或氧杂环丁基;R 1选自氢、氘、卤素、氨基、硝基、羟基、氰基、C 1-6烷基、C 1-6氘代烷基、C 1-6卤代烷基、C 1-6烷氧基或C 1-6烷硫基;优选氢、氘、卤素、C 1-6烷基、C 1-3卤代烷基或C 1-3烷硫基;更优选氟、氯、溴、甲基、乙基、异丙基、三氟甲基或甲硫基;最优选氯、溴、三氟甲基或甲硫基;R 2选自氢、氘、卤素、氨基、硝基、羟基、氰基、C 1-6烷基、C 1-6氘代烷基、C 1-6卤代烷基、C 1-6烷氧基、C 1-6烷硫基、C 2-6烯基或C 2-6炔基;优选氢、氘、卤素、C 1-6烷基、C 1-3卤代烷基、C 1-3烷氧基或C 2-4炔基;更优选氢、氘、氟、氯、溴、甲基、乙基、异丙基、三氟甲基、甲氧基或乙炔基;最优选氢、氟、甲基、乙基、三氟甲基、甲氧基或乙炔基;或者,任意两个R 2与其连接的碳原子链接形成3-8元杂环基;优选含1-2个N或O原子的5-6元杂环基;更优选四氢呋喃基;x为0-2的整数;y为0-3的整数;t为0-1的整数;m为0-2的整数;且n为0-2的整数。
- 根据权利要求1或2所述化合物的晶型,其特征在于,化合物为(6-((5-溴-2-((2-甲氧基-5-甲基-4-(4-((3aR,6aS)-四氢-1H-呋喃并[3,4-c]吡咯-5(3H)-基)哌啶-1-基)苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化;(6-((5-氯-2-((4-(4-(3-(二甲氨基)吖丁啶-1-基)哌啶-1-基)-5-乙基-2-甲氧苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[b][1,4]二噁英-5-基)二甲基膦氧化;2-(1-(1-(4-((5-溴-4-((5-(二甲基磷基)-2,3-二氢苯并[b][1,4]二噁英-6-基)氨基)嘧啶-2-基)氨基)-5-甲氧基-2-甲基苯基)哌啶-4-基)吖丁啶-3-基)乙酰腈;或,(6-((5-溴-2-((2-甲氧基-4-(4-(3-(甲氧基甲基)吖丁啶-1-基)哌啶-1-基)-5-甲基苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[B][1,4]二噁英-5-基)二甲基膦氧化。
- 根据权利要求3所述化合物的晶型,其特征在于,(6-((5-溴-2-((2-甲氧基-4-(4-(3-(甲氧基甲基)吖丁啶-1-基)哌啶-1-基)-5-甲基苯基)氨基)嘧啶-4-基)氨基)-2,3-二氢苯并[B][1,4]二噁英-5-基)二甲基膦氧化的晶型为晶型H、晶型N、晶型O和晶型I,其中:晶型H的X-射线粉末衍射图谱在2θ为21.7±0.2°处具有衍射峰;或者在24.2±0.2°处具有衍射峰;或者在11.4±0.2°处具有衍射峰;或者在22.9±0.2°处具有衍射峰;或者在23.8±0.2°处具有衍射峰;或者在14.7±0.2°处具有衍射峰;或者在12.9±0.2°处具有衍射峰;或者在26.4±0.2°处具有衍射峰;或者在8.0±0.2°处具有衍射峰;或者在10.8±0.2°处具有衍射峰;或者在24.9±0.2°处具有衍射峰;或者在12.0±0.2°处具有衍射峰;优选包含上述衍射衍射峰中的任意2-5处,或者3-5处,或者3-6处,或者3-8处,或者5-8处,或者6-8处;更优选包含其 中任意6处、7处或8处;晶型N的X-射线粉末衍射图谱在2θ为6.7±0.2°处具有衍射峰;或者在8.5±0.2°处具有衍射峰;或者在9.0±0.2°处具有衍射峰;或者在18.7±0.2°处具有衍射峰;或者在21.8±0.2°处具有衍射峰;或者在12.3±0.2°处具有衍射峰;或者在12.7±0.2°处具有衍射峰;或者在14.5±0.2°处具有衍射峰;或者在15.0±0.2°处具有衍射峰;或者在22.3±0.2°处具有衍射峰;或者在18.5±0.2°处具有衍射峰;或者在24.6±0.2°处具有衍射峰;优选包含上述衍射衍射峰中的任意2-5处,或者3-5处,或者3-6处,或者3-8处,或者5-8处,或者6-8处;更优选包含其中任意6处、7处或8处;晶型O的X-射线粉末衍射图谱在2θ为5.0±0.2°处具有衍射峰;或者在6.2±0.2°处具有衍射峰;或者在7.2±0.2°处具有衍射峰;或者在8.7±0.2°处具有衍射峰;或者在12.9±0.2°处具有衍射峰;或者在17.3±0.2°处具有衍射峰;或者在17.9±0.2°处具有衍射峰;或者在20.4±0.2°处具有衍射峰;或者在14.4±0.2°处具有衍射峰;或者在12.4±0.2°处具有衍射峰;或者在19.7±0.2°处具有衍射峰;或者在18.7±0.2°处具有衍射峰;优选包含上述衍射衍射峰中的任意2-5处,或者3-5处,或者3-6处,或者3-8处,或者5-8处,或者6-8处;更优选包含其中任意6处、7处或8处;晶型I的X-射线粉末衍射图谱在2θ为20.8±0.2°处具有衍射峰;或者在13.7±0.2°处具有衍射峰;或者在12.7±0.2°处具有衍射峰;或者在14.4±0.2°处具有衍射峰;或者在17.2±0.2°处具有衍射峰;或者在11.3±0.2°处具有衍射峰;或者在20.2±0.2°处具有衍射峰;或者在25.1±0.2°处具有衍射峰;或者在22.5±0.2°处具有衍射峰;或者在14.6±0.2°处具有衍射峰;或者在22.2±0.2°处具有衍射峰;或者在26.0±0.2°处具有衍射峰;优选包含上述衍射衍射峰中的任意2-5处,或者3-5处,或者3-6处,或者3-8处,或者5-8处,或者6-8处;更优选包含其中任意6处、7处或8处。
- 根据权利要求4所述化合物的晶型,其特征在于,晶型H的X-射线粉末衍射图谱至少包含位于2θ为21.7±0.2°、24.2±0.2°、11.4±0.2°中的一处或多处衍射峰,优选包含其中两条,更优选包含三条;任选的,进一步还可以包含位于2θ为22.9±0.2°、23.8±0.2°、14.7±0.2°、12.9±0.2°、26.4±0.2°中的至少一条,优选包含其中2条、3条、4条或5条;例如,21.7±0.2°、24.2±0.2°;24.2±0.2°、11.4±0.2°;21.7±0.2°、24.2±0.2°、11.4±0.2°;24.2±0.2°、11.4±0.2°、22.9±0.2°;21.7±0.2°、24.2±0.2°、11.4±0.2°、22.9±0.2°;24.2±0.2°、11.4±0.2°、22.9±0.2°、23.8±0.2°;21.7±0.2°、24.2±0.2°、11.4±0.2°、22.9±0.2°、23.8±0.2°;24.2±0.2°、11.4±0.2°、22.9±0.2°、23.8±0.2°、14.7±0.2°;晶型N的X-射线粉末衍射图谱至少包含位于2θ为6.7±0.2°、8.5±0.2°、9.0±0.2°中的一处或多处衍射峰,优选包含其中两条,更优选包含三条;任选的,进一步还可以包含位于2θ为18.7±0.2°、21.8±0.2°、12.3±0.2°、12.7±0.2°、14.5±0.2°中的至少一条,优选包含其中2条、3条、4条或5条;例如,6.7±0.2°、8.5±0.2°;9.0±0.2°、18.7±0.2°;6.7±0.2°、8.5±0.2°、9.0±0.2°;9.0±0.2°、18.7±0.2°、21.8±0.2°;6.7±0.2°、8.5±0.2°、9.0±0.2°、18.7±0.2°;9.0±0.2°、18.7±0.2°、21.8±0.2°、12.3±0.2°;6.7±0.2°、8.5±0.2°、9.0±0.2°、18.7±0.2°、21.8±0.2°;9.0±0.2°、18.7±0.2°、21.8±0.2°、12.3±0.2°、12.7±0.2°;晶型O的X-射线粉末衍射图谱至少包含位于2θ为5.0±0.2°、6.2±0.2°、7.2±0.2°中的一处或多处衍射峰,优选包含其中两条,更优选包含三条;任选的,进一步还可以包含位于2θ为8.7±0.2°、12.9±0.2°、17.3±0.2°、17.9±0.2°、20.4±0.2°中的至少一条,优选包含其中2条、3条、4条或5条;例如,5.0±0.2°、6.2±0.2°;6.2±0.2°、7.2±0.2°;5.0±0.2°、6.2±0.2°、7.2±0.2°;6.2±0.2°、7.2±0.2°、8.7±0.2°;5.0±0.2°、6.2±0.2°、7.2±0.2°、8.7±0.2°;6.2±0.2°、7.2±0.2°、8.7±0.2°、12.9±0.2°;5.0±0.2°、6.2±0.2°、7.2±0.2°、8.7±0.2°、12.9±0.2°;6.2±0.2°、7.2±0.2°、8.7±0.2°、12.9±0.2°、17.3±0.2°;晶型I的X-射线粉末衍射图谱至少包含位于2θ为20.8±0.2°、13.7±0.2°、12.7±0.2°中的一处或多处衍射峰,优选包含其中两条,更优选包含三条;任选的,进一步还可以包含位于2θ为14.4±0.2°、17.2±0.2°、11.3±0.2°、20.2±0.2°、25.1±0.2° 中的至少一条,优选包含其中2条、3条、4条或5条;例如,20.8±0.2°、13.7±0.2°;13.7±0.2°、12.7±0.2°;20.8±0.2°、13.7±0.2°、12.7±0.2°;13.7±0.2°、12.7±0.2°、14.4±0.2°;20.8±0.2°、13.7±0.2°、12.7±0.2°、14.4±0.2°;13.7±0.2°、12.7±0.2°、14.4±0.2°、17.2±0.2°;20.8±0.2°、13.7±0.2°、12.7±0.2°、14.4±0.2°、17.2±0.2°;13.7±0.2°、12.7±0.2°、14.4±0.2°、17.2±0.2°、11.3±0.2°。
- 根据权利要求4所述化合物的晶型,其特征在于:晶型H的X-射线粉末衍射图谱任选还包含位于2θ为21.7±0.2°、24.2±0.2°、11.4±0.2°、22.9±0.2°、23.8±0.2°、14.7±0.2°、12.9±0.2°、26.4±0.2°、8.0±0.2°、10.8±0.2°处具有衍射峰中的一处或多处衍射峰;优选至少包含其中任意2-3处,或者4-5处,或者6-7处;进一步优选,包含其中任意2处、3处、4处、5处、6处、7处;例如,21.7±0.2°、24.2±0.2°、11.4±0.2°、22.9±0.2°、23.8±0.2°、14.7±0.2°;24.2±0.2°、11.4±0.2°、22.9±0.2°、23.8±0.2°、14.7±0.2°、12.9±0.2°;24.2±0.2°、11.4±0.2°、22.9±0.2°、23.8±0.2°、14.7±0.2°、12.9±0.2°、26.4±0.2°;11.4±0.2°、22.9±0.2°、23.8±0.2°、14.7±0.2°、12.9±0.2°、26.4±0.2°、8.0±0.2°;21.7±0.2°、24.2±0.2°、11.4±0.2°、22.9±0.2°、23.8±0.2°、14.7±0.2°、12.9±0.2°、26.4±0.2°;24.2±0.2°、11.4±0.2°、22.9±0.2°、23.8±0.2°、14.7±0.2°、12.9±0.2°、26.4±0.2°、8.0±0.2°;晶型N的X-射线粉末衍射图谱任选还包含位于2θ为6.7±0.2°、8.5±0.2°、9.0±0.2°、18.7±0.2°、21.8±0.2°、12.3±0.2°、12.7±0.2°、14.5±0.2°、15.0±0.2°、22.3±0.2°处具有衍射峰中的一处或多处衍射峰;优选至少包含其中任意2-3处,或者4-5处,或者6-7处;进一步优选,包含其中任意2处、3处、4处、5处、6处、7处;例如,6.7±0.2°、8.5±0.2°、9.0±0.2°、18.7±0.2°、21.8±0.2°、12.3±0.2°;9.0±0.2°、18.7±0.2°、21.8±0.2°、12.3±0.2°、12.7±0.2°、14.5±0.2°;9.0±0.2°、18.7±0.2°、21.8±0.2°、12.3±0.2°、12.7±0.2°、14.5±0.2°、15.0±0.2°;18.7±0.2°、21.8±0.2°、12.3±0.2°、12.7±0.2°、14.5±0.2°、15.0±0.2°、22.3±0.2°;6.7±0.2°、8.5±0.2°、9.0±0.2°、18.7±0.2°、21.8±0.2°、12.3±0.2°、12.7±0.2°、14.5±0.2°;9.0±0.2°、18.7±0.2°、21.8±0.2°、12.3±0.2°、12.7±0.2°、14.5±0.2°、15.0±0.2°、 22.3±0.2°;晶型O的X-射线粉末衍射图谱任选还包含位于2θ为5.0±0.2°、6.1±0.2°、7.2±0.2°、8.7±0.2°、12.9±0.2°、17.3±0.2°、17.9±0.2°、20.4±0.2°、14.4±0.2°、12.4±0.2°处具有衍射峰中的一处或多处衍射峰;优选至少包含其中任意2-3处,或者4-5处,或者6-7处;进一步优选,包含其中任意2处、3处、4处、5处、6处、7处;例如,5.0±0.2°、6.2±0.2°、7.2±0.2°、8.7±0.2°、12.9±0.2°、17.3±0.2°;6.2±0.2°、7.2±0.2°、8.7±0.2°、12.9±0.2°、17.3±0.2°、17.9±0.2°;7.2±0.2°、8.7±0.2°、12.9±0.2°、17.3±0.2°、17.9±0.2°、20.4±0.2°、14.4±0.2°;8.7±0.2°、12.9±0.2°、17.3±0.2°、17.9±0.2°、20.4±0.2°、14.4±0.2°、12.4±0.2°;5.0±0.2°、6.2±0.2°、7.2±0.2°、8.7±0.2°、12.9±0.2°、17.3±0.2°、17.9±0.2°、20.4±0.2°;6.2±0.2°、7.2±0.2°、8.7±0.2°、12.9±0.2°、17.3±0.2°、17.9±0.2°、20.4±0.2°、14.4±0.2°;晶型I的X-射线粉末衍射图谱任选还包含位于2θ为20.8±0.2°、13.7±0.2°、12.7±0.2°、14.4±0.2°、17.2±0.2°、11.3±0.2°、20.2±0.2°、25.1±0.2°、22.5±0.2°处具有衍射峰中的一处或多处衍射峰;优选至少包含其中任意2-3处,或者4-5处,或者6-7处;进一步优选,包含其中任意2处、3处、4处、5处、6处、7处;例如,20.8±0.2°、13.7±0.2°、12.7±0.2°、14.4±0.2°、17.2±0.2°、11.3±0.2°;13.7±0.2°、12.7±0.2°、14.4±0.2°、17.2±0.2°、11.3±0.2°、20.2±0.2°;13.7±0.2°、12.7±0.2°、14.4±0.2°、17.2±0.2°、11.3±0.2°、20.2±0.2°、25.1±0.2°;12.7±0.2°、14.4±0.2°、17.2±0.2°、11.3±0.2°、20.2±0.2°、25.1±0.2°、22.5±0.2°;20.8±0.2°、13.7±0.2°、12.7±0.2°、14.4±0.2°、17.2±0.2°、11.3±0.2°、20.2±0.2°、25.1±0.2°;13.7±0.2°、12.7±0.2°、14.4±0.2°、17.2±0.2°、11.3±0.2°、20.2±0.2°、25.1±0.2°、22.5±0.2°。
- 根据权利要求4所述化合物的晶型,其特征在于:晶型H的X-射线粉末衍射图谱包含位于2θ为21.7±0.2°、24.2±0.2°、11.4±0.2°、22.9±0.2°、23.8±0.2°、14.7±0.2°、12.9±0.2°、26.4±0.2°、8.0±0.2°、10.8±0.2°、24.9±0.2°、12.0±0.2°、32.5±0.2°、31.3±0.2°、17.0±0.2°中的一处或多处衍射峰,优选的,包含其中任选的4处、5处、6处、8处或10处有衍射峰;例如,21.7±0.2°、22.9±0.2°、23.8±0.2°、14.7±0.2°;24.2±0.2°、23.8±0.2°、14.7±0.2°、12.9±0.2°;11.4±0.2°、12.9±0.2°、26.4±0.2°、8.0±0.2°、10.8±0.2°;22.9±0.2°、8.0±0.2°、10.8±0.2°、24.9±0.2°、32.5±0.2°;11.4±0.2°、22.9±0.2°、23.8±0.2°、14.7±0.2°、12.9±0.2°、26.4±0.2°;22.9±0.2°、23.8±0.2°、14.7±0.2°、12.9±0.2°、26.4±0.2°、8.0±0.2°;21.7±0.2°、22.9±0.2°、23.8±0.2°、14.7±0.2°、12.9±0.2°、26.4±0.2°、8.0±0.2°、10.8±0.2°;24.2±0.2°、23.8±0.2°、14.7±0.2°、12.9±0.2°、26.4±0.2°、8.0±0.2°、10.8±0.2°、24.9±0.2°;11.4±0.2°、22.9±0.2°、23.8±0.2°、14.7±0.2°、12.9±0.2°、26.4±0.2°、8.0±0.2°、10.8±0.2°、24.9±0.2°、12.0±0.2°;21.7±0.2°、23.8±0.2°、14.7±0.2°、12.9±0.2°、26.4±0.2°、8.0±0.2°、10.8±0.2°、24.9±0.2°、12.0±0.2°、32.5±0.2°;晶型N的X-射线粉末衍射图谱包含位于2θ为6.7±0.2°、8.5±0.2°、9.0±0.2°、18.7±0.2°、21.8±0.2°、12.3±0.2°、12.7±0.2°、14.5±0.2°、15.0±0.2°、22.3±0.2°、18.5±0.2°、24.6±0.2°、18.0±0.2°、23.7±0.2°、17.8±0.2°中的一处或多处衍射峰,优选的,包含其中任选的4处、5处、6处、8处或10处有衍射峰;例如,6.7±0.2°、18.7±0.2°、21.8±0.2°、12.3±0.2°;8.5±0.2°、21.8±0.2°、12.3±0.2°、12.7±0.2°;6.7±0.2°、18.7±0.2°、21.8±0.2°、12.3±0.2°、12.7±0.2°、14.5±0.2°;8.5±0.2°、21.8±0.2°、12.3±0.2°、12.7±0.2°、14.5±0.2°、15.0±0.2°;6.7±0.2°、18.7±0.2°、21.8±0.2°、12.3±0.2°、12.7±0.2°、14.5±0.2°、15.0±0.2°、22.3±0.2°;8.5±0.2°、21.8±0.2°、12.3±0.2°、12.7±0.2°、14.5±0.2°、15.0±0.2°、22.3±0.2°、18.5±0.2°;6.7±0.2°、18.7±0.2°、21.8±0.2°、12.3±0.2°、12.7±0.2°、14.5±0.2°、15.0±0.2°、22.3±0.2°、18.5±0.2°、24.6±0.2°;8.5±0.2°、21.9±0.2°、12.3±0.2°、12.7±0.2°、14.5±0.2°、15.0±0.2°、22.3±0.2°、18.5±0.2°、24.6±0.2°、18.0±0.2°;晶型O的X-射线粉末衍射图谱包含位于2θ为5.0±0.2°、6.1±0.2°、7.2±0.2°、8.7±0.2°、12.9±0.2°、17.3±0.2°、17.9±0.2°、20.4±0.2°、14.4±0.2°、12.4±0.2°、19.7±0.2°、18.7±0.2°、24.9±0.2°、20.1±0.2°、24.9±0.2°中的一处或多处衍射峰,优选的,包含其中任选的4处、5处、6处、8处或10处有衍射峰;例如,5.0±0.2°、8.7±0.2°、12.9±0.2°、17.3±0.2°;6.1±0.2°、12.9±0.2°、17.3±0.2°、17.9±0.2°;5.0±0.2°、8.7±0.2°、12.9±0.2°、17.3±0.2°、17.9±0.2°、20.4±0.2°;6.1±0.2°、12.9±0.2°、17.3±0.2°、17.9±0.2°、20.4±0.2°、14.4±0.2°;5.0±0.2°、8.7±0.2°、12.9±0.2°、17.3±0.2°、17.9±0.2°、20.4±0.2°、14.4±0.2°、12.4±0.2°;6.1±0.2°、12.9±0.2°、17.3±0.2°、17.9±0.2°、20.4±0.2°、14.4±0.2°、12.4±0.2°、19.7±0.2°;5.0±0.2°、8.7±0.2°、12.9±0.2°、17.3±0.2°、17.9±0.2°、20.4±0.2°、14.4±0.2°、12.4±0.2°、19.7±0.2°、18.7±0.2°;6.1±0.2°、12.9±0.2°、17.3±0.2°、17.9±0.2°、20.4±0.2°、14.4±0.2°、12.4±0.2°、19.7±0.2°、18.7±0.2°、24.9±0.2°;晶型I的X-射线粉末衍射图谱包含位于2θ为20.8±0.2°、13.7±0.2°、12.7±0.2°、14.4±0.2°、17.2±0.2°、11.3±0.2°、20.2±0.2°、25.1±0.2°、22.5±0.2°、14.6±0.2°、22.2±0.2°、26.0±0.2°、23.4±0.2°、17.6±0.2°、8.5±0.2°中的一处或多处衍射峰,优选的,包含其中任选的4处、5处、6处、8处或10处有衍射峰;例如,20.8±0.2°、14.4±0.2°、17.2±0.2°、11.3±0.2°;13.7±0.2°、17.2±0.2°、11.3±0.2°、20.2±0.2°;12.7±0.2°、11.3±0.2°、20.2±0.2°、25.1±0.2°、22.5±0.2°;20.8±0.2°、20.2±0.2°、25.1±0.2°、22.5±0.2°、14.6±0.2°;12.7±0.2°、14.4±0.2°、17.2±0.2°、11.3±0.2°、20.2±0.2°、25.1±0.2°;20.8±0.2°、17.2±0.2°、11.3±0.2°、20.2±0.2°、25.1±0.2°、22.5±0.2°;13.7±0.2°、14.4±0.2°、17.2±0.2°、11.3±0.2°、20.2±0.2°、25.1±0.2°、22.5±0.2°、14.6±0.2°;12.7±0.2°、17.2±0.2°、11.3±0.2°、20.2±0.2°、25.1±0.2°、22.5±0.2°、14.6±0.2°、22.2±0.2°;14.4±0.2°、17.2±0.2°、11.3±0.2°、20.2±0.2°、25.1±0.2°、22.5±0.2°、14.6±0.2°、22.2±0.2°、26.0±0.2°、8.5±0.2°;17.2±0.2°、11.3±0.2°、20.2±0.2°、25.1±0.2°、22.5±0.2°、14.6±0.2°、22.2±0.2°、26.0±0.2°、23.4±0.2°、17.6±0.2°。
- 根据权利要求1-7中任一项所述化合物的晶型,其特征在于,晶型H的X-射线粉末衍射图谱如图1所示;晶型N的X-射线粉末衍射图谱如图4所示;晶型O的X-射线粉末衍射图谱如图7所示,晶型I的X-射线粉末衍射图谱如图9所示。
- 根据权利要求1-7中任一项所述化合物的晶型,其特征在于,晶型H、晶型N、晶型O和晶型I的X-射线粉末衍射图谱中相对峰强度为前十强的衍射峰位置分别与图1、图4、图7和图9对应位置衍射峰的2θ误差为±0.2°~±0.5°,优 选±0.2°~±0.3°,最优选±0.2°。
- 根据权利要求1-7中任一项所述化合物的晶型,其特征在于,晶型H具有如图2所示的DSC图谱;或者具有如图3所示的TGA图谱;晶型N具有如图5所示的DSC图谱,或者具有如图6所示的TGA图谱;;晶型O具有如图8所示的DSC图谱;晶型I具有如图10所示的DSC图谱。
- 根据权利要求1-10中任一项所述化合物的晶型,其特征在于,晶型为无水物或水合物;当晶型为水合物时,水的个数为0.2-3,优选0.2、0.5、1、1.5、2、2.5或3,更优选0.5、1、2或3;优选地,晶型为无水物。
- 一种制备权利要求1-11任意一项所述化合物的晶型的方法,具体包括如下步骤:1)称取适量的自由碱,用良溶剂加热溶解;2)向以上所得溶液中滴加不良溶剂;3)将以上混悬液冷却,去除上清液,剩余固体干燥得到目标产物;其中:所述的良性溶剂选自甲醇、乙醇、丙酮、仲戊醇、正丁醇、正辛醇、正己醇、乙酸乙酯、乙腈、乙醇、88%丙酮、四氢呋喃、二氯甲烷、1,4-二氧六环、苯、甲苯、异丙醇、正丁醇、异丁醇、N,N-二甲基甲酰胺、N,N-二甲基乙酰胺、正丙醇、叔丁醇、2-丁酮或3-戊酮;优选甲醇、乙醇、丙酮、仲戊醇、正丁醇、正辛醇或正己醇;所述的不良溶剂选自庚烷、水、甲基叔丁基醚、甲苯或异丙醚。
- 一种制备权利要求1-11任意一项所述化合物的晶型的方法,具体包括如下步骤:1)称取适量的自由碱,用不良溶剂混悬;2)将混悬液振摇;3)将混悬液快速离心,去除上清液,剩余固体干燥得到目标产物;其中:所述的不良性溶剂选自丙酮、乙酸乙酯、醋酸异丙酯、乙腈、乙醇、88%丙酮、四氢呋喃、2-甲基四氢呋喃、二氯甲烷、1,4-二氧六环、苯、甲苯、异丙醇、正丁醇、异丁醇、N,N-二甲基甲酰胺、N,N-二甲基乙酰胺、正丙醇、叔丁醇、2-丁酮或3-戊酮、甲基叔丁基醚、水;优选丙酮、乙酸乙酯、醋酸异丙酯、乙腈、乙醇、88%丙酮、四氢呋喃、2-甲基四氢呋喃、二氯甲烷、1,4-二氧六环、甲苯、 异丙醇、2-丁酮、3-戊酮、甲基叔丁基醚或水。
- 一种药物组合物,其含有治疗有效量的权利要求1-11中任一项所述化合物的晶型以及一种或多种药学上可接受的载体或赋形剂。
- 根据权利要求1-11任一项所述化合物的晶型以及权利要求14所述的药物组合物在制备MEK抑制剂、EGFR抑制剂及其联用相关药物中的应用。
- 根据权利要求1-11任一项所述化合物的晶型,以及权利要求14所述的药物组合物在制备治疗癌症相关疾病中的应用;其中所述癌症选自乳腺癌、宫颈癌、结肠癌、肺癌、胃癌、直肠癌、胰腺癌、脑癌、肝癌、神经胶质瘤、神经胶母细胞瘤、白血病、淋巴瘤或骨髓瘤;优选非小细胞肺癌。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202180055271.5A CN116234556A (zh) | 2020-12-18 | 2021-12-15 | 一种芳基磷氧化物类衍生物自由碱的晶型及其制备方法和应用 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011505690 | 2020-12-18 | ||
CN202011510500.1 | 2020-12-18 | ||
CN202011510500 | 2020-12-18 | ||
CN202011505690.8 | 2020-12-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022127807A1 true WO2022127807A1 (zh) | 2022-06-23 |
Family
ID=82060064
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/138219 WO2022127807A1 (zh) | 2020-12-18 | 2021-12-15 | 一种芳基磷氧化物类衍生物自由碱的晶型及其制备方法和应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN116234556A (zh) |
WO (1) | WO2022127807A1 (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012051587A1 (en) * | 2010-10-14 | 2012-04-19 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in egfr-driven cancers |
CN107108559A (zh) * | 2014-10-21 | 2017-08-29 | 阿瑞雅德制药公司 | 5‑氯‑n4‑[2‑(二甲基磷酰基)苯基]‑n2‑{2‑甲氧基‑4‑[4‑(4‑甲基哌嗪‑1‑基)哌啶‑1‑基]嘧啶‑2,4‑二胺的晶形 |
WO2019015655A1 (zh) * | 2017-07-19 | 2019-01-24 | 正大天晴药业集团股份有限公司 | 作为egfr激酶抑制剂的芳基磷氧化合物 |
WO2020253860A1 (zh) * | 2019-06-21 | 2020-12-24 | 江苏豪森药业集团有限公司 | 芳基磷氧化物类衍生物抑制剂、其制备方法和应用 |
-
2021
- 2021-12-15 CN CN202180055271.5A patent/CN116234556A/zh active Pending
- 2021-12-15 WO PCT/CN2021/138219 patent/WO2022127807A1/zh active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012051587A1 (en) * | 2010-10-14 | 2012-04-19 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in egfr-driven cancers |
CN107108559A (zh) * | 2014-10-21 | 2017-08-29 | 阿瑞雅德制药公司 | 5‑氯‑n4‑[2‑(二甲基磷酰基)苯基]‑n2‑{2‑甲氧基‑4‑[4‑(4‑甲基哌嗪‑1‑基)哌啶‑1‑基]嘧啶‑2,4‑二胺的晶形 |
WO2019015655A1 (zh) * | 2017-07-19 | 2019-01-24 | 正大天晴药业集团股份有限公司 | 作为egfr激酶抑制剂的芳基磷氧化合物 |
WO2020253860A1 (zh) * | 2019-06-21 | 2020-12-24 | 江苏豪森药业集团有限公司 | 芳基磷氧化物类衍生物抑制剂、其制备方法和应用 |
WO2020253862A1 (zh) * | 2019-06-21 | 2020-12-24 | 上海翰森生物医药科技有限公司 | 含氮芳基磷氧化物类衍生物、其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN116234556A (zh) | 2023-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112469713B (zh) | 芳基磷氧化物类衍生物抑制剂、其制备方法和应用 | |
CN112225724B (zh) | 苯并咪唑类化合物激酶抑制剂及其制备方法和应用 | |
CN112368283B (zh) | 含二并环类衍生物抑制剂、其制备方法和应用 | |
CN112552294B (zh) | 含哌嗪杂环类衍生物抑制剂、其制备方法和应用 | |
ES2742409T3 (es) | Inhibidores de quinasa de pirazolilquinoxalina | |
TWI740288B (zh) | 含氮雜芳類衍生物調節劑、其製備方法和應用 | |
CN111295384A (zh) | 双环类衍生物抑制剂、其制备方法和应用 | |
WO2017071516A1 (zh) | 一种蛋白激酶抑制剂及其制备方法和医药用途 | |
JP2018524350A (ja) | TBK/IKKε阻害剤化合物及びその用途 | |
WO2013016999A1 (zh) | 杂芳基并嘧啶类衍生物、其制备方法和用途 | |
WO2021197452A1 (zh) | 含氮杂芳类衍生物自由碱的晶型 | |
JP2022119852A (ja) | キナゾリン化合物並びにその調製方法、使用及び医薬組成物 | |
CN112292378A (zh) | 含吲哚类衍生物抑制剂、其制备方法和应用 | |
KR20240051987A (ko) | 질소-함유 헤테로사이클릭 유도체 억제제, 이의 제조 방법 및 이의 용도 | |
KR20190021345A (ko) | Egfr 저해제로 제공되는 아닐린 피리미딘 화합물의 결정 | |
WO2022100738A1 (zh) | 含二并环类衍生物抑制剂自由碱的晶型及其制备方法和应用 | |
WO2022127807A1 (zh) | 一种芳基磷氧化物类衍生物自由碱的晶型及其制备方法和应用 | |
CN111601804B (zh) | 含氮杂芳类衍生物调节剂、其制备方法和应用 | |
CN115960117B (zh) | 含硫并环类衍生物抑制剂、其制备方法和应用 | |
WO2022161447A1 (zh) | 二甲酰胺类化合物、其制备方法及其在医药上的应用 | |
KR20240046408A (ko) | 단백질 키나아제 저해 활성을 갖는 피리미딘 유도체 및 이를 포함하는 치료용 약학 조성물 | |
CN113717202A (zh) | 杂芳类衍生物的自由碱晶型及其制备方法 | |
CN114644654A (zh) | 芳基磷氧化衍生物、酸式盐或其晶型及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21905734 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21905734 Country of ref document: EP Kind code of ref document: A1 |